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Abstract 
 
The most advanced stage of diabetic retinopathy, proliferative diabetic 
retinopathy, is characterised by retinal neovascularization due to wide spread 
retinal ischemia. While laser photocoagulation has remained the gold standard 
treatment for decades, anti-vascular endothelial growth factor agents are now 
increasingly used to treat proliferative diabetic retinopathy. Although evidence 
supports the use of anti-vascular endothelial growth factor agents, there are 
several limitations to this treatment that suggest alternative therapies should be 
explored. 
 
Poorly controlled complement activation is now associated with many 
pathologies, and recent evidence implicates complement dysregulation in the 
pathogenesis of several neovascular ocular diseases, including diabetic 
retinopathy. Although evidence that complement activation may contribute to 
vascular pathology is promising, crosstalk between the complement system and 
neovascularisation remains largely unclear. Taking a step back to understand 
the role of complement components in diabetic retinopathy would not only 
provide a more in-depth knowledge of the cellular and molecular mechanisms 
involved in disease pathogenesis, but it could also highlight novel therapeutic 
targets for DR and other vasoproliferative diseases in the eye.    
 
Therefore, the objectives of the studies presented in this thesis were to test to 
test the hypothesis that complement has a novel function in angiogenesis which 
is separate from its characterised role as an immune surveillance system within 
the ocular environment. This work is specifically focused on exploring the role of 
the central component of the alternative complement pathway, complement 
factor B in regulating retinal angiogenesis.  
 
Initially, CFB expression was characterised using rodent models and human 
patient samples. In the retina of STZ-induced diabetic mice there was no 
difference in CFB expression between buffer-injected controls and STZ-induced 
diabetic mice. Similarly, characterisation of systemic CFB levels in human 
vii 
 
patient serum samples revealed no differences between control and diabetic 
patients at different stages of retinopathy. However, analysis of ocular CFB 
levels in human aqueous samples, revealed a higher expression in diabetic 
patients with retinopathy compared to diabetic patients without. The well-
established mouse model of oxygen induced retinopathy was carried out to 
study CFB expression in pathologic vessel formation. RT-qPCR analysis 
demonstrated that CFB was significantly upregulated in mice retina subject to 
oxygen-induced retinopathy.  
 
To establish the impact of CFB on retinal vascular cell function and 
angiogenesis, in vitro and ex vivo angiogenesis assays were carried out. 
Results demonstrate that CFB was able to promote human retinal endothelial 
cell viability, proliferation, tube formation, Transwell migration, and aortic ring 
sprouting, thus indicating a pro-angiogenic role of CFB.  
 
Finally, to elucidate the mechanism through which CFB exerts its pro-
angiogenic function the relationship between CFB and the VEGF signalling 
system was investigated using in vitro cultures of human retinal endothelial 
cells. Observations from these preliminary mechanistic studies revealed that 
CFB mediates VEGF gene expression, and VEGFR2 gene and protein 
expression. And that the pro-angiogenic function of CFB is upstream of, and 
acts through the VEGF signalling pathway. 
  
Several reports have implicated complement and complement related proteins 
in the development of DR. However, few studies have investigated the more 
precise role played by CFB and the mechanism(s) by which complement 
mediates its tissue damaging effects. Collectively, results from this study clearly 
indicate a pro-angiogenic role of CFB in DR associated neovascularisation.  
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1. Introduction 
 
Diabetes mellitus (DM) is a metabolic disease that has seen a dramatic 
increase over the past century, and with approximately 350 million people 
affected worldwide it is now considered to be a global epidemic1,2: by 2035 this 
number is projected to increase to 600 million3. It can be defined as “a state in 
which homeostasis of carbohydrate and lipid metabolism is improperly 
regulated by insulin”4 and when sustained for a prolonged period this 
homeostatic imbalance ultimately leads to chronic hyperglycaemia5. 
Exacerbated by risk factors including genetics, hypertension and diet, chronic 
hyperglycaemia then acts through several downstream metabolic pathways to 
initiate vascular dysfunction6. 
Vascular complications arising from diabetes the major causes of morbidity and 
mortality seen in diabetic patients7,8, and they can be broadly categorised into 
macro- or microvascular diseases. Diabetes associated dysfunction affecting 
large arteries supplying the heart, the brain and lower extremities are major 
causes of myocardial infarction, stroke and lower limb amputation9. On the 
other hand, microvascular abnormalities can affect the retina (retinopathy), 
kidneys (nephropathy) and peripheral nerves (neuropathy)9,10.  
Of the three major manifestations of microvascular diseases, diabetic 
retinopathy (DR) is the most common, with an overall prevalence of over 40% in 
diabetic patients11. It is a major cause of visual impairment and blindness in 
working age adults worldwide, representing a substantial burden to patients, 
their families, health-care systems, and national economies2.  
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1.1  Our Vascular System 
 
Blood vessels line the entire circulatory system and play a central role in 
mediating physiology and pathogenesis. The vascular network is an elaborate 
transport system to supply oxygen and essential nutrients to tissues, and to 
facilitate the removal of metabolic waste products12. This process begins at the 
heart that pumps blood into hierarchical, organised vascular branches that span 
across multiple orders of magnitude (µM to cm)13,14. The macrovasculature 
(including the arterial, venous, and lymphatic systems) regulates bulk oxygen 
delivery to accommodate systemic metabolic demands15,16. On the other hand, 
the microvasculature network (including capillaries, pre-capillary arterioles, 
post-capillary venules and collecting venules) regulates local perfusion and 
conducts blood-tissue exchange of macromolecules15,17(please refer to Figure 
1). 
 
1.2 Anatomy of Blood Vessels 
 
Studies of vessel architecture have reported similarities in the basic wall 
structure of most blood vessels18,19. The innermost luminal wall, also known as 
the tunica intima, is comprised of a single layer of endothelial cells (EC)s, that 
align themselves in parallel to the blood flow. This layer, also known as the 
endothelium, is highly metabolically active and critically regulates vessel 
homeostasis by governing the expression of a multitude of signalling molecules 
that regulate vessel permeability, vascular tone, extramural cell growth and 
migration, inflammatory responses and haemostatic function18,20,21. Endothelial 
phenotypes vary between species, organs, vascular bed, and spatial and 
temporal distribution17. ECs demonstrate remarkable heterogeneity in cell 
morphology, function, gene expression, and antigen composition to serve 
specialised functions based on the physiological needs in the local 
microenvironment22,23. For example, the ECs found in the retinal 
microcirculation are non-fenestrated and tightly associated to form the blood-
3 
 
 
 
retinal barrier that restricts paracellular and transcellular movement of solutes to 
maintain retinal homeostasis and proper retinal function. On the contrary, the 
glomerular endothelium is highly fenestrated to regulate high flux filtration of 
fluid and small solutes15,24. The endothelial layer is the only common cellular 
component of capillaries, the simplest vascular structures with the smallest 
diameter25.  Ensheathing the endothelium is the tunica media layer which 
contains mural cells (smooth muscle cells, pericytes, and fibroblasts) sharing a 
common basement membrane with the ECs26,27. In the macrovascular 
circulation layers of vascular smooth muscle cells (vSMC)s wrap around 
macrovascular ECs to provide mechanical support and to regulate vascular 
tone and blood flow28. Instead of vSMCs, a discontinuous coat of pericytes 
(PC)s surround the microvascular ECs29. The PC:EC ratios, ranging from 1:1 
and 1:10, differs across different tissue beds, often found to be enriched at the 
EC-EC junctions and branch points. Just like ECs, the perivascular cells also 
feature distinct morphology, protein expression profile and functional plasticity30. 
For instance, mesangial cells are specialised renal pericytes that participate in 
ultrafiltration at the glomerulus, whereas hepatic stellate cells are specialised 
hepatic pericytes with additional fat-storing capacities31. 
 
Lastly, large calibre arteries and veins are wrapped in an additional layer known 
as the outer tunica adventitia which contains a collagen-rich ECM and 
interacting cell types including quiescent fibroblasts, nerve cells, resident 
macrophages, T-lymphocytes, B-lymphocytes, mast cells, and dendritic 
cells31,32. Besides providing mechanical support to the blood vessel, it serves as 
a biological compartment facilitating the retrieval, integration, storage and 
release of key regulators that are critical for blood vessel activation and 
homeostasis33. Moreover, recent studies also suggested that this outermost 
layer of the blood vessel also functions as a niche for resident vascular 
progenitor cells32. 
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Figure 1: Schematic representation of the basic structure of blood vessels. Blood vessels 
are organised as capillaries, arterioles and venioles, or arteries and veins. Capillaries are the 
most abundant blood vessels in our body. They consist of ECs surrounded by pericytes 
embedded within the EC basement membrane. Arterioles and venules SMCs that are able to 
contract and regulate blood flow. Besides the endothelium and mural cell layers, arteries and 
veins contain an additional layer of connective tissue with a mixture of different cell types. 
(Adapted from Nature: Scientific Reports, volume 8, pages 1-13 (11th July 2018)34 
https://creativecommons.org/licenses/by/4.0/)  
 
1.3  Blood Vessel Formation 
 
Blood vessel formation is a highly complex and tightly regulated process that 
results in the establishment of a vasculature that supports vital systems of the 
body. The cardiovascular system is the first organ system to form during 
embryonic development35 however at the earliest stage of vertebrate 
embryogenesis the embryos develop in the absence of a functional vascular 
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network with nutrients and waste products being exchanged by passive 
diffusion36. From the third week of gestation a functional vascular network 
begins to form to ensure an adequate supply of oxygen, nutrients and growth 
factors, and enable efficient removal of waste products from growing embryos37. 
During this time de novo blood vessel formation occurs through the 
differentiation of mesenchymal cells into ECs in a process termed 
vasculogenesis38 (please refer to Figure 2 for a schematic representation of 
vasculogenesis). Mesodermal progenitor cells in the mesodermal compartment 
of the developing embryo give rise to groups of homogenous cells termed 
hemangioblasts or blood islands. During proliferation and differentiation, cells in 
the centre of these blood islands give rise to hemopoietic stem cells (HSCs) and 
cells on the periphery give rise to endothelial progenitor cells (EPCs)39. As 
blood islands merge, the HSCs develop into blood cells and the EPCs form a 
primitive vascular plexus of small capillaries. Once a primitive vascular network 
is formed it then expands by angiogenesis and subsequently matures into a 
system of stable vessels40. 
 
 
 
Figure 2: Schematic representation of Vasculogenesis. Vasculogenesis is the de novo 
formation of the first capillaries. Aggregations of cells called blood islands form in the embryonic 
yolk sac. They contain a homogenous collection of cells called hemangioblasts that develop into 
hemopoietic stem cells (HSCs) and endothelial progenitor cells (EPCs). Blood islands merge: 
HSCs develop into blood cells and EPCs develop into a primitive capillary plexus. 
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1.4 Angiogenesis 
 
Angiogenesis is the growth of blood vessels from the existing vasculature. It 
occurs throughout life in both health and disease. Mature vessels are 
quiescent in nature and only transit into an activated state during specific 
growth periods, or in response to tissue injury28. Once a primitive vascular 
network is formed via vasculogenesis, it progressively expands and remodels 
via angiogenesis giving rise to a mature, highly organised system of stable 
blood vessels. This process can be split into two distinct processes; sprouting 
and non-sprouting (intussusceptive) angiogenesis (please refer to Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Schematic representation of angiogenesis and stabilisation. A, Sprouting 
angiogenesis. ECs sprout from the parent vessel by proliferation and migration, extending into 
the surrounding matrix. ECs proliferate to elongate the sprout and eventually fuse with others to 
form a closed loop, allowing for the initiation of blood flow. B, Intussusceptive angiogenesis. 
New blood vessels are created by splitting of an existing blood vessel. ECs on opposite sides of 
a capillary protrude into the lumen until they form contacts. These contacts form an EC bilayer 
which is then reorganised so that it becomes perforated at the centre. After angiogenesis 
stabilisation occurs whereby pericytes a are recruited to stabilise the neo-vessel so that it 
becomes fully functional. 
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1.4.1 . Intussusceptive Angiogenesis 	
A variant of angiogenesis is intussusceptive angiogenesis whereby vessels are 
divided into two via the formation of intraluminal pillars and splitting of the 
lumen41. Briefly, ECs situated on opposite sides of a capillary protrude into the 
lumen until they form contacts, also known as intraluminal pillars. These 
contacts, strengthened by the formation of inter-endothelial junctions, form an 
EC bilayer which is then reorganised in such a way that it becomes perforated 
at the centre. Finally, ECs retract and the newly formed pillar is invaded by 
fibroblasts and pericytes which lay down collagen fibrils, causing the pillar to 
increase in size. Unlike sprouting angiogenesis EC proliferation is not a critical 
part of this process41; initially it only requires reorganisation of existing ECs. As 
a result, intussusception is a fast and efficient process. Since intussusception is 
a reorganisation of existing cells it allows for a large increase in the number of 
capillaries without the need for a corresponding increase in the number of ECs. 
This is especially important in the developing embryo as there are not enough 
resources to create a rich microvasculature with new cells each time a vessel 
develops. In addition to forming new capillary structures, intussusceptive growth 
plays a major role in branching geometry and vascular pruning of larger 
vessels42,43. The first in vivo documentation of intussusceptive microvascular 
growth was demonstrated by video microscopy in a chick chorioallantoic 
membrane. Since then this process has been detected in other organs, tissue 
repair processes and also in tumour angiogenesis. 
 
1.4.2 .  Sprouting Angiogenesis 
 
The term angiogenesis was first coined by John Hunter in 1787 44,45. It is 
commonly used to describe the process of vascular growth, but in the strictest 
sense it refers to the growth of new blood vessels from pre-existing 
vasculature46. It results in new vessels composed of ECs that branch out from a 
parent vessel by proliferation and migration, extending into the surrounding 
matrix39. In response to stimulatory signals, ECs become activated and vascular 
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permeability increases which allows for the invasion of plasma proteins that lay 
down an ECM framework. Matrix metaloproteinases (MMPs) are also induced 
to degrade the basement membrane by proteolytic degradation allowing 
pericytes to liberate themselves from the vessel wall47. Once the path has been 
cleared, proliferating ECs migrate onto this provisional ECM and form an 
endothelial sprout48. To build a perfused tube a single EC (tip cell) leads the 
sprout, whilst subsidiary ECs (stalk cells) proliferate to elongate the sprout and 
establish a lumen49. To allow for the initiation of blood flow, tip cells at the 
leading edge of endothelial sprouts fuse with one another forming a closed 
loop50. Finally, for a blood vessel to become fully functional it is stabilised by 
pericytes, which in the final stages of angiogenesis are recruited to the neo-
vessel, laying down a basement membrane and thus reinforcing vascular 
structure51 (please refer to Figure 4 for a schematic representation of sprouting 
angiogenesis). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Schematic representation of sprouting angiogenesis. Sprouting angiogensis 
begins with 1 ED activation upon exposure to an angiogenic stimulus, 2 EC sprouting initiation 
mediated by basement membrane degradation and ECM remodelling, followed by 3 EC 
proliferation and directed migration leading to vascular outgrowth and stlk extension. The 
nascent vessel undergoes 4 lumen formation and anastomosis before finally undergoing 5 
maturation and stabilisation by mural cells. (Adapted from Journal of Cellular and Molecular 
Medicine, volume 18, pages 1491-1508 (2nd September 2014)52 
https://creativecommons.org/licenses/by/4.0/) 
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1.4.3 Regulating Angiogenesis 
 
To put simply, vascular development can be broken down into the following 
processes; formation, stabilisation, branching, remodelling and maturation. In 
order to develop without a glitch these processes are tightly regulated by a fine 
balance of molecular mechanisms, and perturbation of this balance can lead to 
excessive or insufficient angiogenesis. Abnormal blood vessel growth, whether 
it be too much or too little is now recognised as a common denominator 
underlying many disease states53. The importance of angiogenesis in health 
and disease has prompted extensive investigations to identify the multitude of 
molecular regulators that are fundamentally important in this process (please 
refer to Table 1 for examples of key regulators and inhibitors of angiogenesis). 
With rapid advancements in the cellular and molecular biology of angiogenesis, 
many of these angiogenic agents are now rigorously examined for their 
biological activities, clinical efficacies and safety to translation into therapeutic 
benefits54.  
 
Table 1: A table outlining the of the Key Regulators of Angiogenesis (Adapted from 
Postgraduate Medical Journal, volume 81, pages 236-242 (5th April 2005)45)  
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1.4.4 Vascular Endothelial Growth Factor 
 
The VEGF family of growth factors is the most well-recognised family of pro-
angiogenic regulators for their pivotal role in endothelial functions. In mammals, 
the family consists of five members; VEGF-A – VEGF-D and placental growth 
factor (PlGF). VEGF-A, the prototypical ligand, was originally discovered as 
vascular permeability factor (VPF) in the late 1980’s55 and in 1989 is was 
characterised and sequenced by different groups of investigators as an 
endothelial growth factor and renamed as VEGF56. In humans VEGF-A is 
encoded by a single gene with eight exons and seven introns, which can be 
alternatively spliced into as least nine major variants including VEGF121, 
VEGF145,VEGF148, VEGF162, VEGF165, VEGF183, VEGF189, and 
VEGF20657.These variants differ in their bioavailability and interaction with VEGF 
receptors. leading to distinct effects in angiogenesis58,59.VEGF165 is regarded as 
the most predominant and biologically potent isoform of VEGF in promoting 
angiogenesis and EC permeability60,61.   
 
VEGF family members transduce their signal intercellularly by binding to 
membrane-bound tyrosine kinase receptors, VEGF receptor (VEGFR-) 1 to 3. 
VEGFR-1 and VEGFR-2 are mainly expressed on ECs, although other cell 
types can also express these receptors62. The biological activities of VEGF-A 
are controlled mainly by the receptor VEGFR-263 .The binding of VEGF to 
VEGFR-2 induces downstream receptor dimerization and auto-phosphorylation 
of specific tyrosine residues within the dimeric complex64,65. Subsequently, 
activation of specific intracellular signalling transducers eventually up-regulate 
target genes that facilitate EC proliferation, migration, adhesion, lumenisation, 
and survival64,66.  
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1.5 The Retina 
1.5.1 Basic Anatomy 
 
The retina is an extension of the forebrain. It is consisted of a dense layer of 
specialised cell bodies separated by layers of neurites (please refer to Figure 5 
for a schematic representation of the retinal structure).  
 
 
Figure 5: Schematic representation outlining the cellular circuitry of the retina and the retinal 
blood vessels. Light detected by the retina is absorbed by photoreceptors, converted to 
electrical signals, and transmitted through the retinal layers via an intricate network of neuronal 
cells, made up largely of bipolar and ganglion cells. The signals converge at the optic disc and 
are conveyed to the brain for further processing by the optic nerve. Retinal blood vessels line 
the inner surface of the retina. Three capillary plexuses are embedded among retinal neurons: 
the superficial layer lies within the nerve fibre layer (NFL) with branches extending into the 
ganglion cell layer (GCL), while the intermediate and deep capillary plexuses align along each 
sides of the inner nuclear layer (INL). (Adapted from Progress in Retinal and Eye Research, 
volume 5, pages 1-40 (23 June 2015)67 and Frontiers in Physiology, volume 9, pages 1-14 (13 
July 2018)68 https://creativecommons.org/licenses/by/4.0/). 
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It functions to absorb photons of light entering the eye through the cornea and 
iris, translating these into biochemical and electrical signals which ultimately 
trigger nerve impulses that are sent to various visual centres of the brain 
through the fibres of the optic nerve.  The vitreous side of the retina is referred 
to as the ‘inner’ layer, while the side of the retina closer to the sclera is referred 
as the ‘outer layer.  
 
The macula, defined by the area that contains the yellow pigment xanthophyll69, 
is a small but important area in the centre of the retina. The fovea, found at the 
centre of the macula, is a highly specialised region responsible for visual 
acuity69. It contains the highest density of cone receptors (reaching more than 
200,000 mm2)70 and its most obvious feature is a small depression known as 
the foveal pit, in which the inner retinal layers are displaced to allow direct 
illumination of the photoreceptors. The fovea is also comprised of an area 
lacking a vascular supply, this region is called the foveal avascular zone 
(FAZ)71. Since incoming light has to pass through the entire retina before it 
reaches the photoreceptors cellular elements can cause retinal light scattering, 
which consequently reduces visual sensitivity and acuity, and decreases the 
quality and brightness of the visual image72. The unique characteristics of the 
fovea help reduce the transparency of the retina which improves visual acuity 
by minimising retinal light scattering72,73. 
 
Retinal cells can be grouped into three general types; photoreceptor cells, 
neural cells, and glial cells. Moving from the outer to inner retina, the two 
specialised photoreceptor cells (rods and cones) lie outermost in the retina 
forming the outer nuclear layer (ONL). They are composed of a membranous 
disk containing a photoreceptive pigment which absorbs photons from incoming 
light leading to electrical polarisation, which initiates a sensory cascade that 
stimulates the succeeding neurons of the retina, allowing a neural signal to be 
fed to the brain via the optic nerve in a process known as visual photo-
transduction74.  
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Neural cells of the retina include bipolar, ganglion, horizontal and amacrine 
cells. Bipolar cells form synoptic contacts with the photoreceptors75. They are 
arranged between photoreceptor cells and ganglion cells in the inner nuclear 
layer (INL), receiving their information from photoreceptors and relaying this 
information  to the ganglion cell layer (GCL) for further processing75. Horizontal 
and amacrine cells are found in the outer and inner retina respectively, and they 
help modulate signals along this ‘vertical’ pathway (from photoreceptor to 
bipolar cells)76. The final output neurons of the retina are ganglion cells in the 
GCL, where all visual information converges. They transmit information through 
the optic nerve into the brain’s visual centre for vision perception.  
 
The three main types of glial cells in the mammalian retina are Müller cells, 
astrocytes, and resident microglia77. They provide structural support and help 
maintain retinal homeostasis by providing metabolic support to retinal neurons 
through releasing neurotrophic factors and phagocytosing neuronal debris78. 
The principal glial cells, Müller cells, are homogenously distributed throughout 
the retina; they have their cell bodies within the INL and span across the entire 
thickness of the retina. They support neuroretinal architecture  and provide 
nourishment to all the constituent cells79. Muller cells also help redistribute 
metabolic waste of the photoreceptor activity77. Astrocytes, named after their 
stellate morphology are located almost exclusively in the innermost GCL80. The 
presence and distribution of retinal astrocytes is correlated with the presence 
and distribution of retinal blood vessels81: vascularised areas of the retina 
contain high numbers of astrocytes whereas avascular regions contain no 
astrocytes77. As the main producers of vascular endothelial growth factor 
(VEGF) during normal and pathological vascularisation82, they are strongly 
implicated in the proper development and functioning of the retinal 
vasculature83. As with Muller cells, astrocytes mediate the survival of retinal 
cells through the release neurotrophic factors. They also provide anti-oxidative 
support, aid in the formation and removal of synapses and are involved in the 
maintenance of the blood retinal barrier (BRB)84. However, in the presence of 
pathogenic stimuli, astrocytes up-regulate their expression of various genes 
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encoding cytokines, chemokines and elements of the complement cascade, 
thereby compromising the integrity of the BRB85.When activated, astrocytes are 
also able to cause activation of the third class of glial cells, the microglia86. 
Microglia represent the tissue macrophage population of the central nervous 
system (CNS)67. They are the only haematopoietic cells within the CNS. During 
development these cells enter from the bloodstream, develop from myeloid 
progenitors and differentiate into microglia87. As a result, they maintain 
numerous cellular antigens present in macrophages and monocytes87,88.  In the 
healthy retina, microglia are described as ‘resting’ or ‘ramified’. They have 
extensively branched processes and act as surveillant cells that continuously 
monitor the surrounding tissue. When the retina becomes diseased or damaged 
microglial cells become activated and their morphology is significantly different 
to those found in healthy tissue. Activated microglia have enlarged cell bodies, 
shortened processes, and increased expression of myeloid markers87. 
Microglial are the resident inflammatory cells in the retina. On activation they 
respond by secreting cytokines, growth factors and neurotrophic factors89. They 
can be stimulated into a macrophagic function and engage in phagocytosis of 
degenerating retinal neurons. In addition, they can also express molecules that 
are associated with an ability to stimulate T cells with antigen presentation87,90. 
 
1.5.2 Retinal Vascularisation 
 
The adult retina is a highly metabolic tissue with the highest oxygen 
consumption per unit weight of any human tissue91. To meet these high 
metabolic demands without obstructing light transmission, the retinal circulation 
is highly specialised92. It originates from two sources, the retinal and choroidal 
vessels, both of which arise from the ophthalmic artery93. The choroidal 
vasculature, between the RPE and sclera, supplies oxygen and nutrients to the 
RPE and the photoreceptors. The inner retinal cells however, receive nutrients 
and oxygen from the central retinal artery (CRA) which receives 20-30% of the 
ocular blood flow. The CRA  enters the eye at the optic nerve head94 where it 
branches into two major trunks, the superior and inferior arteries. These then 
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divide further to form the nasal and temporal branches that supply the four 
quadrants of the retina. As the large arteries extend within the retina toward the 
periphery they continue to bifurcate, forming arteries with progressively smaller 
diameters that provide a blood supply to the inner retinal layers. These smaller 
arterioles give rise to two types of capillary systems: horizontal branches that 
supply the GCL and deep branches that enter the INL. Venous outflow from the 
retina begins with drainage from the capillary network by venules and veins, 
which run from the peripheral retina towards the optic nerve head. They 
coalesce into the central retinal vein, and exit the eye parallel and counter-
current to the central retinal artery with the optic nerve95. 
 
1.5.3 Immune Privilege 
 
The human body is protected from the invasion and damage of pathogens by a 
highly evolved and complex immune response. However, these destructive 
responses not only target invading pathogens but also attack host tissues, 
which impose devastating consequences. To maintain optical stability, the 
retina is protected by a sophisticated system that allows it to have immune 
privilege meaning the body’s normal inflammatory immune response is limited. 
This system is made up of physical barriers, an inhibitory microenvironment 
composed of cell-bound and soluble factors, and tolerance-promoting antigen-
presenting cells (APCs)96.  
 
Firstly, the retina is protected by two barriers that help to maintain a highly 
regulated chemical environment. The outer blood-retina barrier (oBRB) is 
achieved by the RPE cell layer and acts as a filter to regulate the movement of 
solutes and nutrients from the choroid to the sub-retinal space97,98. The inner 
blood-retina barrier (iBRB) comprises the retinal vasculature and is formed by 
the endothelial cells (ECs) that line the lumen of retinal blood vessels99. Both 
the oBRB and iBRB owe their functionality to the tight junctions that are located 
on the basolateral side between RPE cells and ECs, respectively100. Tight 
junctions are transmembrane and cytosolic proteins that create a highly 
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selective barrier, allowing exchange of respiratory gases, amino acids, salts and 
sugars, but preventing circulating cells, macromolecules and pathogens from 
permeating the retinal parenchyma101. In a process known as immunological 
ignorance, the BRB segregates retinal antigens within the intraocular 
compartment thereby avoiding T cell activation and creating a functional 
absence of interactions between the immune system and retinal antigens102. 
Secondly, the retina lacks a lymphatic system, so endogenous insults are 
unlikely to be detected by circulating or choroidal/extraocular immune 
cells101,103. Finally, the retina possesses an immune regulatory system that is 
carried out by cells in the local microenvironment. These cells can inhibit the 
activity of myeloid cells by binding to their ligands via the expression of various 
cell-bound membrane receptors. In this manner activated cells that might 
otherwise attack and destroy retinal tissue are neutralised, and the retina is 
spared injury. In addition, retinal cells also possess mechanisms to induce the 
death of infiltrating immune cells104,105. Soluble factors secreted into the retina is 
another immunosuppressive mechanism that inhibits the activity of immune-
competent cells. Transforming growth factor -β (TGF-β) for example, is a potent 
suppressor of the activation of T cells, natural killer cells and macrophages106. 
Other factors include calcitonin gene-related peptide (CGRP) and α-
melanocyte-stimulating hormone (α-MSH), which act on activated macrophages 
and prevent them from secreting pro-inflammatory cytokines106.  
 
1.6 Diabetic Retinopathy 
 
Broadly speaking, diabetes mellitus (DM) is a class of metabolic diseases 
characterised by chronic hyperglycaemia107. Epidemiologically, DM exists as a 
major public health problem that has reached an epidemic globally108,109. It has 
been projected that the number of patients with DM is estimated to increase 
from 382 million in 2013 to 592 million by 2035110. In addition to the alarming 
magnitude of DM, around 50% of patients with diabetes are undiagnosed 111 
and these patients are likely to have a faster degree of progression because of 
the delay in diagnosis and treatment111.  
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DM has a poignant role in the development of diabetic microvascular 
complications including diabetic nephropathy, neuropathy and retinopathy112. 
DR, the most common microvascular complication of DM, is a major cause of 
vision loss in working-age population worldwide. The overall prevalence of DR 
in adults with DM is greater than 40%, with approximately 7% developing 
advanced stage, vision threatening proliferative diabetic retinopathy (PDR)113. 
The prevalence of DR increases with prolonged duration of diabetes114 and with 
recent improvements in reducing diabetes-related macrovascular mortality more 
patients live long enough to develop DR115: over 50% of patients who have had 
DM for over 25 years will develop DR116. As the global prevalence of DM 
continues to increase, the number of DR patients is expected to increase from 
37.3 million in 2010 to 56.3 million by 2030117, bringing with it substantial 
economic loss to patients, families, health-care systems and national 
economies.  
 
1.6.1 The Development and Progression of Diabetic 
Retinopathy 
 
DR is a progressive disease of the retina characterised by a complex 
pathogenesis involving multiple cell types, molecules, and growth factors118. 
The defining features of DR include thickening of the basement membrane 
shared between ECs and pericytes, pericyte loss, EC hyperpermeability, 
microaneurysm and local tissue ischemia which triggers abnormal vessel 
formation in the eye ultimately leading to visual impairment and blindness. The 
development of DR is slow and can be categorised into stages: retinal damage 
without any visible microvascular abnormalities; non-proliferative retinal 
microvascular changes referred to as non-proliferative diabetic retinopathy 
(NPDR); advanced proliferative DR (PDR) (please refer to Figure 6 and Figure 
7). 
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1.6.2 Retinal Damage Without Visible Abnormalities 
 
Traditionally DR has been viewed as a microcirculatory disease of the retina, 
however more recently it is now considered to be a more complex complication 
of diabetes in which neurodegeneration plays a role118. Neuroretinal damage 
leads to diminished retinal functions such as the loss of chromatic discrimination 
and contrast sensitivity, delayed dark adaptation, and abnormal visual 
fields119,120. Rather than an early event of DR progression neurodegeneration 
was believed to be a late manifestation, however these alterations have been 
observed to occur in patients without or with only minimal DR, i.e. early in 
disease progression before vascular pathology is detected in ophthalmic 
examination121-124. As a result it is now believed to predate and also participate 
in the development of microcirculatory  abnormalities that occur in DR125.  
 
The two hallmark features of retinal neurodegeneration are neural apoptosis 
and glial activation126. Neural apoptosis is first detected in retinal ganglion cells 
(RGCs) located in the inner retina, and consequently their loss results in a 
reduction in thickness of the GCL127. Neural apoptosis is accompanied by glial 
cell dysfunction, referred to as glial activation or reactive gliosis. Glial activation 
is the general response to injury and inflammatory stimuli in glial cells, and 
causes neuronal damage via early phagocytosis of normal neurons, production 
of neurotoxins and induction of apoptotic changes128. No consensus has been 
reached as to which of these elements (apoptosis or glial activation) is the first 
to occur. Nevertheless, these two mechanisms are critical in maintaining 
neuronal integrity which is essential for maintaining the normal functioning of 
the retina129.  
 
1.6.3 Non-Proliferative Diabetic Retinopathy 
 
The earliest vascular change observed in the retina is capillary degeneration, 
which is characterised by BM thickening, endothelial injury leading to disruption 
of tight junctions, and pericyte loss. Pericytes are specialised peri-vascular 
19 
 
 
 
support cells that exist in close proximity to ECs, at an almost 1:1 ratio in the 
retina130. They elongate and wrap around the endothelium, sharing a basement 
membrane131. Pericytes fulfil important functions including, regulation of 
vascular diameter and capillary blood flow, vessel stabilisation and maintenance 
of the BRB132. In addition, pericytes release TGF-β which acts on neighbouring 
ECs, inhibiting their proliferation and maintaining them in a quiescent state133. 
Pericytes are therefore essential components of the microvessel and are crucial 
for normal EC function, vessel stability and blood flow regulation134.The death of 
vascular retinal pericytes in DR results in the formation of ‘ghost capillaries’. 
Without the protection of pericytes, ECs become activated and proliferative 
leading to the development of microaneurysm and vessel dilation. They 
eventually rupture to form haemorrhages deep within the retina. Because of 
their dot-like appearance, they are sometimes referred to as “dot-and-blot” 
haemorrhages. Microaneurysms and dot intraretinal haemorrhages are the first 
clinically detectable abnormalities seen in DR135. Loss of pericytes also affects 
the integrity of the BRB, allowing the passage of intravascular fluid containing 
proteins, lipids, and inflammatory mediators into the interstitial space. This fluid 
leaves behind yellow deposits composed of extracellular lipid by-products that 
are referred to as hard exudates. Diabetic macular oedema (DME) is another 
consequence of these abnormalities and is caused by the leakage of plasma 
from the small blood vessels into the macula. During NPDR the retinal 
endothelium also becomes activated, inducing the release of pro-inflammatory 
cytokines leading to early and persistent inflammatory condition in the retinal 
microenvironment. This promotes leukocyte activation, leukocyte adhesion to 
the vascular endothelium136 and further BRB breakdown, contributing to the 
obstruction of retinal capillaries137. The microvascular BM is a thin sheet of ECM 
with an intricate architecture that serves as part of the barrier to control vascular 
permeability. It provides a mechanical framework on which cells reside, a 
substrate for adhesion and inter-cellular communication, and a selective barrier 
to filtration138. In DR, the BM becomes thickened because of increased 
synthesis and reduced degradation of its components (type IV collagen, laminin, 
fibronectin, heparan sulphate proteoglycans)137. These structural and 
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compositional alterations to the BM impaired oxygen and nutrient delivery to 
pericytes contributing to pericyte dropout139.   
 
As the severity of NPDR progresses, gradual non-perfusion of the retinal 
vascular bed increases, which ultimately results in regions of retinal ischemia. 
As demonstrated by fundoscopic examination, eyes with severe NPDR show 
‘cotton wool’ spots, indicating a large area of retinal ischaemia or infarction136. 
Intraretinal microvascular abnormalities (IRMA) are also observed in severe 
NPDR, which are characterised by dilate vessels that are tortuous and irregular 
in calibre136.  
 
1.6.4 Proliferative Diabetic Retinopathy 
 
The most advanced stage of DR, PDR, is characterised by aberrant 
angiogenesis. In the eye, highly vascular structures and completely avascular 
structures lie in close proximity to each other140 (a feature most obviously 
depicted in the fovea), therefore tight regulation of vascular growth and 
quiescence is crucial to the maintenance of healthy retinal tissue and visual 
acuity140,141. Vascular growth occurs mainly during embryonic development and 
is almost non-existent in the adult eye140, therefore the formation of new blood 
vessels in the retina represents cases where this delicate balance has been 
disturbed142. The main pathogenetic factor involved in PDR is chronic hypoxia, 
which is a potent inducer of tissue angiogenesis. The hypoxic environment 
results in an over-expression of growth factors, cytokines, chemokines and 
adhesion molecules, which together constitute a complex inflammatory 
response that results in aberrant, pathological angiogenesis (please refer to 
section 1.4.2. for a more detailed description of the angiogenic process). 
Pathological retinal angiogenesis generates chaotically orientated and 
physiologically deficient vessels that are fragile and leaky, and are unable to 
perfuse the ischemic tissue, which further exaggerates the ischemic burden of 
the affected retina leading to vicious cycle of tissue hypoxia and 
neovascularization. Furthermore, these new vessels are prone to bleeding and 
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tend to grow into the vitreous body. With age the vitreous begins to shrink, 
pulling on these fragile vessels and causing them to tear, which ultimately 
results in vitreous haemorrhage. Sometimes, these new vessels may become 
enveloped by a thick and dense fibrovascular tissue causing tractional retinal 
detachment. In the advanced stage of DR retinal detachment and vitreous 
haemorrhage represent the major causes of visual impairment and sudden 
vision loss. 
 
 
 
 
Figure 6: Retinal vasculature in normal and diabetic eyes. In normal, healthy eyes pericytes 
are present around blood vessels helping to maintain ECs in their quiescent state, and tight 
junctions maintain the integrity of the BRB. The balance of pro- and ant-angiogenic cues 
remains in equilibrium. Under diabetic conditions retinal blood vessels can be characterised by 
significant pericyte drop out, compromised BRB because of impaired tight junctions, immune 
cell infiltration and extravasation of red blood cells. The angiogenic equilibrium is tipped in 
favour of neovascular formation producing neo-vessels that are fragile and ‘leaky’ (Adapted 
from Eye, volume 32, pages 483-486 (March 2018)132. 
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Figure 7: Clinical signs of DR in a fundoscopic examination. A, Mild NPDR; 
microaneurysms form in the blood vessels bursting to form haemorrhages. B, Moderate NPDR; 
changes become more severe with the addition of cotton wool spot formation. C, PDR; 
neovascularisation forms at the optic disc and hard exudates begin to form. D, Diabetic macular 
oedema; vascular leakage occurs, lipid contents accumulate in the macula and hard exudates 
form. (Adapted from Nature Reviews Disease Primers, Volume 2, Pages 1-16 (17 March 
2016)136 ) 
 
1.7 Prevention of Diabetic Retinopathy 
 
There are a numerous risk factors associated with DR and of these reported 
risk factors the duration of diabetes, hyperglycaemia and hypertension are 
considered the most important for DR progression143. For patients diagnosed 
with diabetes, effective management of these modifiable risk factors is an 
important method to prevent the progression of DR144. 
 
 
1.7.1 Prevention by Glycaemic Control 
 
Hyperglycaemia is one of the risk factors for DR. Results from two large scale 
clinical trials, The Diabetes Control and Complications Trial (DCCT) for type 1 
diabetes145, and The United Kingdom Prospective Diabetes Trial (UKPDS) for 
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type 2 diabetes146, indicate that intensive glycemic control is successful at 
delaying initiation and progression of DR. Over a 7-year period the DCCT 
investigated intensive glycaemic control vs. conventional treatment with diet 
control, in two type 1 diabetic patient cohorts. The primary intervention cohort 
recruited patients with no existing DR, whereas the secondary intervention 
cohort recruited patients with pre-existing mild DR. The DCCT reported that 
intensive therapy to maintain HbA1c at 7% (the HbA1c levels are approximately 
9% in patients with type 1 diabetes) reduced the onset of new DR by 76% in 
comparison to patients who underwent conventional treatment. Moreover, the 
progression of existing DR in the secondary intervention cohort, was reduced by 
50%, highlighting the importance of achieving glycaemic control early, 
preferably before the onset of DR. In the UKPDS study glycaemic control was 
investigated in patients with type 2 diabetes. Over a 12-year period the 
glycaemic control group (HbA1c 7%) demonstrated a 21% reduction in the risk 
for DR in comparison to the conventional treatment group (HbA1c 7.9%). The 
importance of glycaemic management as early as possible during diabetes has 
been further emphasised by results of the Epidemiology of Diabetes 
Intervention and Complications (EDIC) study. This observational follow-up of 
the DCCT cohort of patients was observed that the group undergoing glycaemic 
control continued to exhibit a significantly lower incidence of further progression 
of their DR severity stage in comparison to the group undergoing conventional 
treatment147. These robust clinical results indicate the long-term impact of 
intensive glycaemic control, highlighting the importance of glycaemia 
management as early as possible during diabetes.  
  
1.7.2 Prevention by Blood Pressure Control 
 
Blood pressure is another risk factor that can be monitored to help prevent and 
manage DR. In addition to reducing shear damage to blood vessels resulting 
from hypertension, blood pressure control can reduce damage to ECs, blood 
vessels and surrounding tissues by preventing hypoperfusion148. As with 
glycaemic control, the clinical evidence for the beneficial effect of controlling 
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blood pressure on DR development and progression is convincing. In the 
UKPDS trail on type 2 diabetic patients, a tight blood pressure control group 
were administered either beta blockers or angiotensin-converting enzyme 
(ACE) to maintain blood pressure at a level <150/85 mm Hg, whereas the blood 
pressure of a less tight control group was maintained at a level <180/105 mm 
Hg. Following the 7-year study, the tight control group showed a 34% reduction 
in the risk of DR progression, a 47% reduction in vision loss, and a 35% 
reduction in the need for laser treatment146. However, unlike glycaemic control, 
the benefits of blood pressure regulation are lost without ongoing and long-term 
control.  
 
1.8 Management of Proliferative Diabetic Retinopathy 
 
Interventions using intraocular anti-VEGF agents, panretinal laser 
photocoagulation (PRP), and vitrectomy can help reduce vision loss resulting 
from PDR. 
1.8.1 Laser Photocoagulation 
 
Since two landmark trials in the 1980s, The Diabetic Retinopathy Study (DRS) 
and The Early Treatment Diabetic Retinopathy Study (ETDRS), laser therapy 
has been the gold standard treatment for PDR and DME. The DRS 
demonstrated a reduced risk of severe vision loss in patients with severe NPDR 
or PDR, from 33% to 13.9% at 5 years following PRP149. Similarly, the EDTRS 
demonstrated a 24% to 12% reduction in the risk of vision loss in patients with 
clinically significant DME150.  
 
The primary goal of laser therapy is to preserve patients’ useful vision and 
prevent blindness; reversal of vision loss is uncommon. Treatment by laser for 
PDR by PRP involves applying many evenly spaced laser spots (typically 1200 
to 1600, approximately 500 µM in size) to the peripheral retina, focally 
destroying out photoreceptors and RPE. The cells absorb the light and the 
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resultant heat causes destruction of the outer retina. Treatment for DME differs 
in that a gentle laser applied to the macula is used to target leaking 
microaneurysms directly. Although the mechanism of action is not fully 
understood, one hypothesis is that PRP alleviates hypoxia by improving oxygen 
supply to areas of the inner retina that had become oxygen-deprived151. This 
occurs because not only are the choriocapillaris physically closer to the inner 
retina allowing for diffusion of oxygen from the choroid, but also because the 
highly metabolically active rods and cones are no longer present to absorb 
oxygen from the choriocapillaris in the area of the burns. As a result, the 
improved retinal oxygenation reduces neovascularisation and oedema 
formation by reducing the production of hypoxia driven VEGF.  
 
However, despite widespread use, laser photocoagulation is associated with 
significant risk due to its destructive nature. Laser photocoagulation burns and 
destroys part of the retina which can result in visual symptoms related to the 
loss of function of the ‘burned’ part of the retina151. This can include loss of 
central vision, reduced night vision, decreased ability to focus and induction of a 
blind spot. In addition, a proportion of patients continue to develop active 
neovascularisation and vision loss 152,153. 
 
1.8.2 Management: Vitrectomy 
 
In 1970 the first successful vitrectomy was performed on a diabetic eye with 
persistent vitreous haemorrhage. Traditionally, non-clearing vitreous 
haemorrhage was the main indication for vitrectomy in the diabetic eye. 
However, advances in surgical techniques and surgical instruments mean that 
vitrectomy is now also used for the management of retinal detachments and 
fibrovascular proliferation.  With the vitreous body removed there is better 
access to the retina allowing for a variety of repairs, including the removal of 
scar tissue to release tractional forces that pull on the retina, removal of 
opacities such as non-clearing vitreous haemorrhage, laser repair of retinal 
detachments and to remove the scaffolding into which the neovascularisation 
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may grow. Since anti-VEGF therapies have become more efficient, safer and 
more accessible, proliferative neovascularisation and DME are treated less 
frequently with vitrectomy. Visual outcomes following vitrectomy are better in 
comparison to the natural course of disease progression, and if initial treatment 
is successful then long-term stability following surgery is good. However 
preventative measures such as improved control of glucose levels and timely 
application of laser treatment are more efficacious than vitrectomy154.  
 
1.8.3 Anti VEGF-Agents 
 
The VEGF-VEGFR system is one of the most predominant pathways involved 
in the later stages (DME and PDR) of DR progression. Therefore, most 
antiangiogenic agents used in clinics for the treatment of DME and PDR with 
evidence of clinical efficacy currently act by inhibiting VEGF. Unlike laser PRP, 
anti-VEGF agents have been shown to improve visual acuity and even ocular 
tissue structure in some cases155. Currently there are three commonly used 
agents for the treatment of DME and as an adjunct therapy for PDR, which all 
work by the inhibiting VEGF. 
 
Bevacizumab (Avastin®) is a full-length humanised antibody targeting all 
isoforms of VEGF-A. It was initially approved by Food and Drug Administration 
(FDA) for treatment of metastatic colorectal cancers in February 2004156 and it 
has since been approved for the treatment of other solid tumours (non-epithelial 
lung, breast, ovarian and renal cancers) and glioblastomas157. It is not approved 
for any ocular indication however ophthalmologists quickly determined that 
bevacizumab was also efficacious for the treatment for the diseases with ocular 
neovascularisation and started to use it ‘off label’ 158. Ranibizumab is the first 
approved anti-VEGF agent for ocular diseases and itis a recombinant antibody 
fragment (Fab) of the humanised anti-VEGF antibody bevacizumab that binds 
all isoforms of VEGF-A. After multiple trials, ranibizumab was approved by the 
FDA in 2017 for all stages of diabetic retinopathy. Finally, aflibercept is a 
recombinant fusion protein that has been constructed by fusing specific 
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domains from human VEGF-R1 and VEGF-R2 with the Fab fragment of human 
IgG1. It binds VEGF-A, VEGFB and PIGF to prevent their activation of VEGF-R, 
and it has been shown to bind VEGF with greater affinity than other anti-VEGF 
agents. 
 
Despite its clear efficacy, a substantial number of patients are intrinsically 
refractory to anti-VEGF treatment or may develop resistance over time. It is not 
surprising since many angiogenic factors jointly contribute to new blood vessel 
formation28. Indeed, VEGF inhibition in the eye was reported to cause 
compensatory activation of alternative angiogenic pathways, such as 
Hepatocyte Growth Factor (HGF)159 and  erythropoietin160. Furthermore, 
considering the important neuroprotective effect of VEGF161 and its role in 
physiological neovascularization162, long term treatment with  VEGF blockades 
may result in local and systemic side effects163-165.   
 
1.9 The Complement System 
 
1.9.1 Complement Activation 
 
The mammalian immune system is a complex choreography of biochemical 
processes that detect and eliminate pathogens that can cause harm to the host; 
no small task given the impressive number of pathogens and host processes 
that are able to cause diseases. One of the most important defence 
mechanisms of the human body is the complement system. Despite being 
discovered in the late 1880s, the complement system evolved over 700 million 
years ago166 and is an integral part of the innate immune system that acts as a 
first-line defence to protect the host from invading pathogens and abnormal self-
derived components. It is comprised of an army of over 30 different proteins that 
are mainly synthesised by the liver and circulate in the blood as inactive 
precursors167. The identification of a pathogenic surface initiates a proteolytic 
cascade that leads to three main effector mechanisms: (i) the generation of 
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potent pro-inflammatory mediators (anaphylatoxins), (ii) opsonisation (‘coating’) 
of the pathogenic surface by complement opsonins (e.g. C3b), and (iii) targeted 
lysis of the pathogenic surface through the assembly of membrane-penetrating 
pores known as the membrane attack complex (MAC)168.  
 
In the early stages, the complement cascade can be driven by three distinct 
pathways (classical, CP; alternative, AP; and lectin, LP). Each pathway of 
complement activation employs different recognition molecules and initiating 
serine proteases, however the three pathways all converge at the level of C3 to 
generate the same set of effector molecules169 (please refer Figure 8 to for a 
schematic representation of complement activation). These reactions are known 
as the ‘early’ events of complement activation, and consist of triggered-enzyme 
cascades in which inactive complement proteins are cleaved to yield two 
fragments, the larger of which is an active serine protease. The active serine 
protease is retained at the pathogen surface which ensures the next 
complement protein in the pathway is also cleaved and activated at the 
pathogen surface. The small peptide fragment (known as an anaphylatoxin) on 
the other hand, is released from the site of the reaction to act as a potent 
inflammatory mediator, targeting a broad spectrum of immune and non-immune 
cells170. Mechanisms such as this one, where the activation of a small number 
of complement proteins at the start of the pathway is hugely amplified by each 
successive step, results in a cascade that rapidly generates a large complement 
response. 
 
 
29 
 
 
 
 
 
Figure 8: Schematic representation of the three pathways of complement activation. 
Activation of C3, the central component of complement, may take place via three pathways: (1) 
classical, (2) lectin or (3) alternative pathway. The three pathways of complement activation. 
The CP is initiated by IgM or IgG antibody clusters that are associated with a bound antigen. 
The CP begins with a large protein complex, C1, which is comprised of three subunits; C1q, C1r 
and C1s. When the globular heads of the C1q subunit bind to two or more antibodies, C1r is 
enzymatically activated, which in turn cleaves and activates C1s. Activated C1s potentiates the 
action of the next protein in the cascade, C4, cleaving it into C4a and C4b. This cleavage 
exposes a thioester bond, allowing for the covalent deposition of C4b on surfaces in the 
immediate vicinity of the activation sites. Complement protein C2 can then complex with surface 
bound C4b, which allows for cleavage by C1s to generate C2a and the CP C3 convertase 
C4b2b. This convertase can bind and cleave C3 to initiate amplification by forming C3b, which 
complexes back with C4b2b to form the classical pathway C5 convertase C4b2b3b. The C5 
convertase initiates the formation of C5b and the later steps of complement activation. The LP 
is functionally similar to the CCP but is initiated by mannose-binding lectin (MBL). MBL acts as a 
pattern recognition molecule that predominantly recognises carbohydrate patterns. MBL is 
found in a complex with MBL-associated proteases (MASPs); MASP-1, MASP-2 and MASP-3. 
Binding of MBL to its surface target leads to the activation of Masp-2 which cleaves both C4 and 
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C2, generating the same C3 convertase as in the classical pathway. The AP is activated when a 
small fraction of circulating C3 molecules are hydrolysed to form the initial AP C3 convertase, 
C3(H2O)Bb, in the presence of Factors B and D, leading to additional C3 cleavage and eventual 
formation of the AP C3 convertase (C3bBb) and AP C5 convertase (C3bBbC3b). All three 
pathways culminate in the formation of the convertases, which in turn generate the major 
effectors of the complement system: anaphylatoxins (C4a/C3a/C5a), the membrane attack 
complex (MAC), and opsonins (e.g., C3b). Anaphylatoxins are potent proinflammatory 
molecules derived from the cleavage of C4, C3, and C5. The MAC is a terminal assembly of 
complement components C5b through C9, which can directly lyse targeted surfaces. C3b 
induces phagocytosis of opsonized targets and also serves to amplify complement activation 
through the AP. (Adapted from Cell Research, volume 20, pages 34-50, (15th December 
2009)168). 
 
The CP begins with a large protein complex, C1, which is comprised of three 
subunits; C1q, C1r and C1s. Initiation of the classical pathway occurs when 
C1q, binds to the Fc region of complement-fixing antibodies attached to 
pathogenic surfaces, activating C1r and C1s. Subsequently, activated C1s 
cleaves C4 and C2 into larger (C4b, C2a) and smaller (C4a, C2b) fragments. 
The larger fragments associate on pathogenic surfaces to form the complex 
C4bC2a, which gains the ability to cleave C3 and is termed the C3 
convertase171. Generation of the C3 convertase cleaves C3 into the 
anaphylatoxin C3a and the opsonin C3b, the point at which all complement 
activation cascades converge. The LP is functionally similar to the CP but is 
initiated by the serum protein mannose-binding lectin (MBL). MBL acts as a 
pattern recognition molecule that binds to carbohydrate structures on the 
surfaces of  bacteria or viruses172. MBL is found in a complex with MBL-
associated proteases (MASPs)-1, -2, and -3 which are functionally and 
structurally similar to C1s and C1r173. Binding of MBL to its target leads to the 
activation of the associated MASP-2, cleavage of C2 and C4, and ultimately 
generation of the same C3 convertase as in the classical pathway168. The AP is 
mechanistically distinct from the CP and LP; activation of the AP occurs in an 
antibody-independent manner171. It is initiated by the low-level, spontaneous 
hydrolysis of C3 to form C3(H2O) in a process known as ‘tick-over’174. CFB 
binds to C3(H20) and this complex is cleaved by the complement factor D 
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(CFD), generating Ba and Bb fragments. The Bb fragment remains associated 
with the complex, forming the initial AP C3(H20)Bb-convertase, which can 
cleave additional C3 molecules to generate C3b. Once produced by these 
means C3b initiates a positive feedback loop, associating with CFB and 
generating more C3-convertase (please refer to Figure 9 for a schematic 
representation of the AP of complement activation).   
 
 
 
Figure 9: Schematic representation of the alternative pathway of complement activation. 
It is initiated by the low-level, spontaneous hydrolysis of C3 to form C3(H2O) C3(H20) binds to 
CFB, and this complex is cleaved by CFD, generating Ba and Bb. The Bb fragment remains 
associated with the complex, forming the initial AP C3(H20)Bb-convertase, which can cleave 
additional C3 molecules to generate C3b. Once produced by these means C3b initiates a 
positive feedback loop, associating with CFB and generating more C3-convertase. C3b 
complexes with the C3-convertase to form the AP c5 convertase (C3bBbc3b).  
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1.9.2 Effectors of the Complement System 
 
Primarily, as an important branch of first-line defence, complement protects the 
host from invading pathogens and abnormal self-derived components. This can 
be achieved through three main mechanisms: (i) direct target lysis after 
incorporation of the MAC into the cell membrane of the invading pathogen, (ii) 
alerting and attracting immune cells through by the generation of potent 
proinflammatory anaphylatoxins, and (iii) opsonisation by complement activation 
products and engagement of complement receptors on phagocytic cells, such 
as macrophages and neutrophils. The MAC with its lytic pore is probably the 
best recognised of these effectors174. MAC assembly begins with cleavage of 
C5 into C5a and C5b by a C5 convertase: this cleavage is the final step in the 
‘early stage’ of complement activation, and the first step in the terminal 
pathway175. C5b cleavage exposes a binding site for C6, and the subsequent 
C5bC6 binds reversibly to the targeted surfaces and sequentially recruits C7, 
creating C5b-7. C5b7 is integrated into the phospholipid membrane bilayer on 
the target pathogen. This induces the membrane insertion of C8α and C8β, 
forming unstable pores. Finally, C9 binds to C8α and initiates polymerization of 
multiple C9 molecules to form stable inserted pores of approximately 10nm in 
diameter168. Formation of the fully formed MAC pore leads to targeted lysis of 
the surface upon which it has assembled176.  
 
Since certain pathogens have evolved mechanisms that enable them to evade 
the destructive potential of MAC, it is crucial for complement to engage and 
recruit other components of the immune system through the generation of 
potent pro-inflammatory anaphylatoxins (C3a, C4a and C5a). They are 
constantly released during activation and amplification triggering pro-
inflammatory signalling177. Their functions include many hallmark 
proinflammatory activities, such as increases in vascular permeability, smooth 
muscle contraction, leukocyte recruitment, as well as promoting the production 
and release of other inflammatory mediators (e.g. histamine).  
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The third and final major effector arm of activated complement lies in the ability 
of phagocytic cells to recognize, ingest, and eliminate cells coated with 
opsonins (C3b and C4b). Opsonins are the smaller cleavage fragments 
produced by complement activation that remain deposited on the target surface. 
They act as molecular beacons, interacting with receptors on macrophages, 
monocytes and neutrophils to enable phagocytosis of the target cell178. 
 
1.9.3 Regulation of the Complement System 
 
Primarily, as an important branch of first-line defence, complement protects the 
host from invading pathogens and abnormal self-derived components. Despite 
this, activated complement can be a double-edged sword that not only helps 
defend the host against pathogens, but also has the potential to inflict damage 
to self-tissues. To protect from the destructive effects of complement-mediated 
damage the host is endowed with rigorous complement regulatory proteins 
(CRegs) that allow for tight regulation of complement activation. In fact, 
because of its potent pro-inflammatory and destructive capabilities, nearly half 
of the complement proteins serve in regulation179. (Please refer to Table 2 for a 
list of the key membrane bound and soluble CRegs) 
 
Table 2: A table outlining the key membrane bound and soluble complement regulatory 
proteins. 
Membrane Bound 
Regulator Function 
Decay Accelerating Factor (DAF, 
CD55) 
CD55 inhibits the assembly of new C3 
convertases and shorten the half-life of 
preformed convertases, therefore limiting their 
ability to participate in further complement 
activation.  
Membrane Cofactor Protein 
(MCP, CD46) 
CD46 acts as a co-factor for the proteolytic 
activity of CFI, helping with non-specific C4b 
degradation 
Complement Receptor 1 (CR1, 
CD35) 
CR1 acts as a co-factor for the proteolytic 
activity of CFI. This helps with non-specific C3b 
and C4b degradation180. CRI also has decay-
accelerating activity to prevent classical, lectin, 
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and alternative pathway C3 convertase 
formation.  
Membrane Inhibitor of Reactive 
Lysis (MIRL, CD59) 
CD59 inhibits the assembly lytic MAC by 
preventing insertion of the final component C9 
into lipid bilayer of the target membrane 181 
Soluble Bound 
C1 Inhibitor (C1INH) C1INH regulates activation of the classical 
pathway by binding and inactivating C1r and 
C1s, leading to dissociation of the C1 
complex167 
C4 binding Protein (C4BP) C4BP acts as a cofactor for the proteolytic 
activity of CFI, to help prevent non-specific C4b 
degradation. also has decay-accelerating 
activity to prevent classical and lectin pathway 
C3 convertase formation and leads to the 
catabolism of C4b to its degradation products. 
Complement factor H (CFH) Factor H achieves host-specific protection by 
binding polyanions, such as sialic acid and 
heparin, which make up an essential component 
of eukaryotic, but not prokaryotic, cell surfaces. 
The functional consequence of this mechanism 
is that Factor H is preferentially targeted to host 
surfaces. Here it acts as a cofactor for the 
proteolytic activity of CFI and in addition, exerts 
decay-accelerating activities to prevent 
alternative pathway C3 convertase formation. 
Complement Factor I (CFI) CFI cleaves the opsonins, C3b and C4b, into 
inactive fragments180. 
 
 
1.9.4 Complement and Retinal Diseases 
 
Traditionally, complement has been primarily viewed as a first line of defence 
against microbial intruders, quickly tagging and eliminating them and buying the 
adaptive immune response time to pick up momentum. There is now a well-
established picture of how complement acts as an immune surveillance system 
to discriminate among healthy host tissue, cellular debris, apoptotic cells and 
foreign intruders. Underlying the proper functioning of the complement system 
is a finely balanced, intricate network of effectors, receptors and regulators, and 
any trigger that tips this delicate balance between complement activation and 
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regulation can induce self-attack177. There is now a new perception of 
complement that reaches far beyond the elimination of pathogens182. Numerous 
studies have elaborated on the pathogenic role of complement during immune, 
inflammatory, neurodegenerative, ischemic and age-related diseases183, and it 
is now widely accepted that the presence and activation of complement plays a 
crucial role in the pathogenesis of a large number of diseases, inclusive of 
retinal diseases such as age-related macular degeneration (AMD) and DR184. 
The subsequent chapters of this review will be focused of the AP in retinal 
diseases, and more specifically the role of Complement Factor B.  
 
1.9.4.1 Complement and Age-Related Macular Degeneration 
 
Age-related macular degeneration (AMD) is the progressive degeneration of the 
macula (central part of the retina). It accounts for 8.7% of blindness worldwide 
and is the leading cause of irreversible vision loss in the aging population in the 
Western world185. With an increasing aging population worldwide its prevalence 
its only expected to rise: an estimated 288 million people will be affected by 
AMD by 2040185. Despite not being the focus of this study, it is worth to briefly 
visit the role of complement in AMD: AMD and DR both share the same 
characteristic feature in that they are both driven by inflammation and aberrant 
angiogenesis and therefore complement involvement in AMD may have cross-
over with, and provide insights into the DR pathogenesis. The early stage of 
AMD is characterised by the formation of extracellular deposits, known as 
drusen, between the RPE and underlying Bruch’s membrane. Late AMD is 
broadly classified into two advanced clinical forms, a ‘dry’ form with geographic 
atrophy (GA) characterised by loss of RPE and outer retinal cells, or a ‘wet’ 
form, otherwise known as neovascular AMD (nAMD), characterised by 
abnormal choroidal neovascularisation (CNV) that extends into the retina 
generating immature blood vessels that leak and haemorrhage.  
 
There have been considerable advances in the unravelling of the biological 
bases of AMD, from which have emerged several lines of evidence implicating 
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activation of the complement cascade, especially the AP, in AMD pathogenesis. 
Firstly, the major stressors for AMD development, such as aging, smoking, and 
oxidative stress, have been linked to overactivation of the complement 
system186. As mentioned above, drusen are the first signs of early AMD. The 
observation that drusen contains proteins of the complement system was first 
made by two independent groups in France and the Netherlands, and then later 
confirmed by the Hageman group in the U.S. who conducted extensive 
immunohistochemical studies187-189. These findings on the molecular 
composition of drusen implicate local activation of the alternative pathway. In 
addition, increased levels of various complement components, including C3a, 
C3b and CFB, have been detected in the plasma from AMD patients190-193.  
 
Secondly, genetic studies have revealed highly significant statistical 
associations between AMD and genetic variants that affect different aspects of 
the AP. These variations in genes encoding complement proteins suggest that 
certain individuals may be genetically predisposed to AMD because of local or 
systemic aberration of the AP. In 2005, several studies were simultaneously 
published identifying and confirming variation in the complement factor H (CFH 
gene)194-197. These genetic studies were then extended by the observation that 
polymorphisms in other complement genes, notably those coding for CFB are 
also associated with AMD198-200.  
 
Lastly, a strong argument in support of the involvement of the AP in AMD 
comes from in vitro and in vivo experimental data. In a study aimed at 
elucidating how complement is regulated in the retina, one group reported that 
CFH, a negative regulator of the AP, is constitutively expressed by RPE cells 
and that RPE cells are a significant local source of CFH, which is negatively 
regulated by inflammation201. To further investigate the retinal complement 
regulatory system, they followed on from this by investigating the production 
and regulation of the central AP activator, CFB. Similarly, they found that CFB is 
also produced locally in the retina by RPE cells, however unlike CFH, CFB is 
positively regulated by inflammation202. These results suggest that under 
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inflammatory conditions, like those that manifest in both AMD and DR, the local 
production of CFB by RPE cells is increased, resulting in elevated levels of CFB 
within the retina. The exact biological consequence of elevated CFB is yet to be 
elucidated, however this data implies a link between the pro-inflammatory 
pathologies seen in both AMD and DR, and increased CFB levels.  
 
Another approach used to study the role of complement in retinal health is to 
evaluate and compare the retinal phenotype of mice carrying mutations or 
deletions of specific complement genes. In one study, the authors characterised 
the retinas of mice carrying null mutations in the genes of three central 
components of the AP, Cfb-/-, Cfh-/-, and Cfd-/-203. In addition, they also 
examined the phenotype of the Cfb-/-/Cfh-/- double knockout mouse retina. The 
retinae were examined at 12 months to identify signs of retinal abnormalities. 
They reported that in the first year of life there were no gross anatomical 
differences in retinal morphology between the genotypes with regard to retinal 
thickness and number of photoreceptors. Retinal vessel morphology and 
density was also examined by immunostaining retinal flatmounts. Across all 
genotypes, the retinal vascular plexus was morphologically comparable to that 
of wildtype mice including no withering vessels or other vascular abnormalities. 
This suggests that under physiological conditions the retina is stable and 
healthy in the absence of a functional alternative pathway203. However, this 
study was carried out in the absence of a pathological challenge or 
environmental stressor, and therefore provides limited insight into how 
complement contributes to vascular pathology under disease conditions. There 
are several studies however, that have utilised the mouse model of laser-
induced choroidal neovascularisation (CNV) to mimic vascular pathology seen 
in AMD and explore the role of complement in choroidal angiogenesis. 
Choroidal neovascularisation (CNV) is the hallmark of neovascular AMD 
(nAMD) and one of the ways to induce CNV in mice is to rupture the Bruch’s 
membrane with laser photocoagulation. One group who utilised siRNA directed 
against CFB in C57BL/6 mice, demonstrated a significant reduction in CNV 
compared to their wild-type controls204. However, this data using siRNA must be 
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interpreted with caution because it has been reported that that siRNA can 
supress angiogenesis and CNV independent of the target gene205. Other 
studies have used a combination of CNV and complete gene knock-out of CFB 
in mice to determine which complement pathway is essential for CNV 
development. They reported that following laser photocoagulation, CFB -/- mice 
developed smaller CNV lesions and as a result better-preserved retinal 
function206,207. 
 
1.9.4.2 Complement and Diabetic Retinopathy 
 
DR has a complex pathophysiology characterised by progressive degeneration 
of the retinal vasculature136. Disease pathology begins with the loss of 
pericytes,  hypertrophy of the basement membrane, inflammation, and 
BRB136,208,209. This is followed by loss of capillaries that become acellular and 
nonperfused along with both vascular and neural cell apoptosis209. The 
destruction of retinal vessels leads to ischemia followed by expression of 
angiogenic growth factors culminating in proliferative neovascularisation and 
eventually vision loss210,211. Being an immune-privileged organ the retina has its 
own unique immune regulatory mechanisms and immune defence mechanisms, 
which when alerted by any kind of noxious signal, starts a cascade of 
inflammatory events as an adaptive response to restore the homeostatic 
balance212-214. These mechanisms not only reduce the risk of infection, but also 
prevent inappropriate immune responses, consequently reducing the risk of 
inflammation-mediated retinal damage214. Low-level activation of the innate 
immune mechanisms, specifically the complement system, is required for the 
homeostatic tissue husbandry necessary for long-term maintenance of the 
functional and structural integrity of the adult retina215. However, this protective 
mechanism can have a detrimental impact if the insults persist for a sustained 
period of time, leading to irreversible functional loss212.  
 
In comparison to AMD, genetic evidence for the involvement of complement in 
DR is minimal, however the role of genetic factors in the development of DR 
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was explored in a 2013 study. This group investigated a possible association of 
CFH and CFB complement genes in type 2 diabetic patients. By generating tag-
single nucleotide polymorphisms (tSNPs) in CFH and CFB, they compared the 
allelic and genotypic frequencies of a CFH variant and four CFB variants, in 
type 2 diabetic patients with and without retinopathy. They observed a 
significant decrease in the frequencies of the A allele and the AA genotype for 
the CFH variant (rs800292) in patients with DR compared to diabetic controls. 
On the other hand, the study revealed a significant increase in the frequencies 
of the A allele and AA genotype for one of the CFB variants (rs1049709) in 
patients with DR compared to diabetic controls. The results from this study 
suggest that the mutation in CFH, a regulator of the AP, provides protection 
against DR whereas a mutation in CFB, an activator of the AP, increases the 
risk of developing DR216. Although these findings further strengthen the concept 
that the complement system, particularly the AP, is associated with the 
pathogenesis of DR, this study does not explore the biological function of the 
mutations and consequently the pathogenic significance of the CFH and CFB 
polymorphisms remains unclear. The variant in CFB represents a synonymous 
substitution whereby one base is substituted for another in the exon of the 
gene. With the mutation situated in the exon of the gene the coded amino acid 
will not be affected, so the increased risk of developing DR with the CFB 
mutation is likely to be because the mutation cause changes in CFB gene 
transcription or changes in tissue specificity of CFB gene expression. However, 
determining the biological roles of these polymorphisms in DR would require 
further investigation. 
 
Over the past decade, a body of clinical evidence has emerged that supports a 
link between the AP and the pathogenesis of DR. Firstly, increased 
glycosylation that occurs in DM has been implicated in the inactivation of 
important complement regulatory proteins, such as CD59, which normally serve 
to prevent self-cells from being targeted by MAC217. Evidence comes from the 
observation that membrane bound inhibitors of complement, CD55 and CD59, 
expression is significantly depressed or impaired due in part to non-enzymatic 
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glycation218,219. Several proteomic studies have been carried out to analyse the 
protein profiles of human vitreous samples from patients with DR. In these 
studies, vitreous fluid obtained from diabetic patients undergoing vitreoretinal 
surgery was analysed for protein composition. Results reported that 
complement factors C3, CFI, CFB, C4, C4b, C2 CFD and CFH were detected in 
the vitreous of patients with PDR89,220-226. However, there are two confounding 
factors that mean data reported in these studies should be interpreted with 
caution. Firstly, vitreous haemorrhage, which often occurs in patients with PDR, 
can produce a large influx of serum proteins227. Secondly, the disruption of the 
blood-retina barrier that occurs in DR also produces an increase in proteins in 
the vitreous body227. Both these factors may preclude the usefulness of the 
vitreous fluid when studying intraocular production of a particular protein, since 
elevated intravitreal levels of a particular protein does not necessarily indicate 
an increase in intraocular production, and might simply reflect a non-specific 
increase in protein levels due diffusion. Immunohistochemistry methods have 
also reported that activation of the AP system is involved in the pathogenesis of 
DR. In one study, using a panel of antibodies directed against candidate 
markers of complement activation, investigators examined the presence of 
activated complement in donor eyes affected by DR found extensive staining for 
the terminal complex MAC228. In the same study, no positive staining was found 
for C1, C4 or MBL which suggests that the classical and lectin pathways did not 
participate in complement activation, and the AP of activation seems most 
likely228. Although findings in this study implicating the AP in DR bare some 
relevance, it is worth to note a couple of limitations associated with this study. 
Firstly, only the posterior poles of diabetic eyes were available for study 
because in most cases the retinas were detached, and as a result complement 
activation could only be examined in the choriocapillaries not in the retinal 
vasculature. Secondly, extensive complement deposition was observed in some 
diabetic patients without severe retinopathy228.   
 
Another argument for the involvement of the AP in DR, in particular CFB, comes 
from in vivo experimental data. However, results are somewhat conflicting to 
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studies in AMD. The mouse model of oxygen-induced retinopathy (OIR) is used 
to mimic vascular pathology seen in DR, however unlike the mouse model of 
CNV for AMD, it seems fewer studies have been carried out using OIR to study 
complement in retinal angiogenesis. The OIR model is a well-defined model 
associated with late-stage destructive neovascularisation and inflammation. The 
first phase of OIR involves exposure of mouse pups to hyperoxia, resulting in 
inhibition of normal retinal vessel growth and dropout of pre-existing 
vasculature, leaving a centrally avascular retina229. The second stage of OIR is 
initiated when mouse pups are placed back into a normal oxygen environment. 
The initial loss of retinal vasculature, coupled with the increasing metabolic 
demands of the developing retina, leads to local hypoxia and the up-regulation 
of angiogenic growth factors. As a consequence, there is an overcompensating 
vasoproliferative response with the formation of disorganized and leaky 
neovascular tufts230. In 2014 one group who used this model to investigate how 
the AP regulates pathological angiogenesis in the retina reported a link between 
CFB and retinal vascular pathology following OIR. In order to characterise the 
role of the AP in pathological retinal neovascularisation the authors induced OIR 
in CFB deficient mice. They found that OIR treatment in CFB -/- mice resulted in 
a significant increase in neovascularisation compared with control mice. Since 
VEGF plays a pivotal role in driving neovessel formation in the OIR model, in 
seeking to explain the enhanced neovessel formation in CFB-/- mice, the 
authors first compared VEGF expression between control and CFB-/- retina 
subjected to OIR. Interestingly the expression levels of VEGF and its type II 
receptor, VEGFR2, were not affected in the retina of CFB-/- mice subjected to 
OIR.  Another explanation for the increased neovascularisation seen in CFB-/- 
mice could be enhanced neovessel proliferation. Although the VEGF data 
suggested no change in growth stimulation it is not a direct reflection of 
proliferation, so to directly determine this the authors quantitated the amount of 
EC proliferation by intraperitoneal injection of EdU (a thymidine analogue that 
intercalates into the DNA of proliferating cells). Consistent with the observation 
of unchanged VEGF expression, the rate of neovessel proliferation remained 
unchanged in CFB -/- mice following OIR compared to their control 
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counterparts. In addition, an increase in CFB gene expression following OIR 
treatment in the retina of wildtype mice and co-localisation of CFB with neo-
vessels was reported231; both these observations implicate  CFB in driving 
vascular pathology. This led to the idea that the increase in neovascularisation 
in CFB-/- mice was not a result of higher levels of VEGF or neovessel 
proliferation, but rather because of a decrease in the removal of neovessels 
over time. The authors later showed a significant reduction in apoptotic cells in 
retinal neovessels of OIR treated CFB -/- mice which suggests that CFB may 
have a protective role in the development of neovascularisation and exerts its 
function through mediating cell apoptosis.   
 
1.10  Summary 
 
DR is a major microvascular complication of DM. It can be broadly classified 
into two stages: NPDR and PDR. Vascular changes in NPDR include vascular 
basement membrane thickening, the loss of pericytes and the formation of 
microaneurysms. These progressive functional and structural alterations of 
retinal vasculature result in capillary degeneration and retinal ischemia, which 
subsequently trigger an adverse compensatory neovascularisation response: 
the hallmark of PDR. These newly formed blood vessels are fragile and more 
liable to bleed. Total or partial vision loss can occur when abnormal blood 
vessels breach the inner limiting membrane of the retina and grow into the 
vitreous causing vitreous haemorrhage, retinal detachment and eventually 
vision loss232. For many decades, laser photocoagulation has been the gold 
standard treatment for PDR and although effective at preserving central visual 
acuity, patients often suffer the loss of peripheral vision233 234,235. Recent 
advances in elucidating the molecular mechanisms of angiogenesis have led to 
the development of potentially disease-modifying treatments for PDR236. 
Pharmacological agents that inhibit VEGF, a key causative factor associated 
with PDR pathologies, are now increasingly used as adjuvant treatment to laser 
photocoagulation. Despite being highly effective at inhibiting neovascularization 
and preventing further vision loss, anti-VEGF treatment is not able to relieve 
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ischemic stress caused by vascular degeneration, and so neovascularization is 
likely to reoccur once the treatment is stopped. Consequently, long-term 
repetitive treatment is necessary, and not only does this place a significant 
burden upon healthcare systems, chronic VEGF suppression also raises 
concerns regarding potential adverse effects due to the loss of its important 
neuro- trophic and protective role237,238. Furthermore, around 50% of patients 
are not responsive to ant-VEGF treatment or develop resistance over time, 
which is not surprising as angiogenesis is regulated by multiple angiogenic 
pathways28. Targeting VEGF may also lead to compensatory activation of 
alternative angiogenic pathways. Therefore, effective management of PDR 
remains a significant unmet medical worldwide. Consequently, the development 
of new therapies capable of preventing or slowing the onset and progression of 
DR remains a priority239 and this underpins the need for continuing efforts to 
fully elucidate the mechanisms involved in the pathogenesis of DR. Although 
DR has long been considered a vascular disease, evidence shows that poorly 
controlled complement activation, in particular the AP, is associated vascular 
pathologies in the eye240. Investigating the role of the complement in retinal 
angiogenesis could provide a better insight into the cellular and molecular 
mechanisms underlying DR, which may facilitate the development of alternative 
or complementary treatment to current anti-VEGF therapeutics. 
 
1.11  Aims and Objectives 
 
Genetic, clinical and experimental based evidence, including that obtained from 
studies on AMD, strongly implicates the AP of complement, in particular CFB, in 
the development of DR. Unfortunately, the exact pathogenic significance of this 
association remains unclear. As a result, investigating the biological function of 
CFB within the retina will help link complement activation to specific molecular 
events in order to determine the pathologic effects of complement activity in DR. 
Therefore, the overarching aim of this project is to explore the role of one of the 
key components of the AP, CFB, in DR. We hypothesise that CFB plays a 
causative role in DR by promoting diabetes-associated retinal 
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neovascularisation. In order to satisfy this aim, the specific objectives are 
threefold: 
 
1) To characterise the expression level of CFB in rodent models of PDR, 
and human PDR patient samples. 
2) To investigate the role of CFB in retinal vascular endothelial cell 
behaviour and angiogenesis. 
3) To elucidate the mechanism through which CFB contributes to vascular 
pathology in DR. 
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2 Materials and Methods 
2.1 Human Patient Samples 
 
Aqueous humor samples were collected from patients referred to Tan Tock 
Seng Hospital, Singapore for vitreoretinal surgery to treat PDR. Samples were 
obtained from patients who provided written-informed consent. The study was in 
accordance with the Declaration of Helsinki for Human Research, and with 
guidelines from the Health Sciences Authority of Singapore. Study protocols for 
allocation and biochemical analysis of specimens were approved by the 
SingHealth Centralised Institutional Review Board. 
2.2 Animal Husbandry 
 
All procedures were performed according to the Responsible Care and Use of 
Laboratory Animals (RCULA) guidelines and approved by the Institutional 
Animal Care and Use Committees (IACUC) in Nanyang Technological 
University, Singapore. Mice were maintained at the designated animal facility 
under a 12-hour dark-light cycle at 23°C± 2°C and given standard mouse chow 
and water ad libitum. 
2.3 STZ Diabetic Mouse Model 
 
Diabetes was induced by subcutaneous injection of 50 mg/kg Streptozotocin 
(STZ) for five consecutive days241. 6-week male mice were weighed and 
subjected for basal fasting blood glucose (FBG) test using a point-of care 
glucometer following a 16-h starvation period. Mice with body weight >20g and 
FBG <100mg/dl or >250mg/dl were used for the induction of diabetes. Mice 
were then starved for 6-h each day before being subjected to intraperitoneal 
(IP) injection of 50mg/kg of freshly prepared STZ solution for 5 consecutive 
days. The STZ solution was freshly prepared just before injection by 
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reconstituting STZ powder into 0.1 M citrate buffer (please refer to Appendix 
Table 6 for composition of the sodium citrate buffer) at pH 4.5. Mice were 
subjected to measurement of FBG  4- and 8-week post-injection. Mice with FBG 
levels ³250mg/dl at both time points were considered diabetic. Mice that did not 
development hyperglycemia at 4-weeks post-induction were subject to a second 
cycle of STZ-injection. Those with FBG levels of ³250mg/dl at both the 4- and 
8-week post-injection time-points were included in downstream studies.  
 
2.4 Oxygen-Induced Retinopathy (OIR) Mouse Model 
 
Nursing mothers and neonatal mice were kept at room air from birth through to 
postnatal day (P)7. At P7 mouse litters were placed in a 75% oxygen chamber 
for 5 days until P12. The mice were then returned to room air until at P12 until 
P17. Retina were harvested for RNA and protein isolation (please refer 
Figure 10 for a schematic representation of the OIR mouse model) 
 
 
 
Figure 10: Schematic of the mouse model of OIR. From P7 to P12 mice are exposed to 75% 
oxygen for 5 days, which inhibits retinal vessel growth and causes significant vessel loss, 
leading to a central zone of vaso-obliteration. At P12, when the mice are returned to room air, 
the central avascular retina becomes hypoxic, triggering pathological neovascular growth, which 
reaches its maximum severity at P17. Between P17 and P25 neovascularisation begins to 
regress. (Adapted from Nature Protocols, Volume 4, Pages 1565-1573 (8th October 2009)242 ) 
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2.5 Protein Isolation from Retinal Tissue 
 
Eyes were enucleated by placing 45° forceps under the eyeball. Eyes were 
transferred to a 1.5 mL Eppendorf tube containing 1 mL 1X PBS and kept on ice 
until all remaining eyes had been harvested. Enucleated eyes were transferred 
to a 9 mm petri dish and submerged in 1X PBS. The retinae were dissected 
under using Leica M165 FC Stereo Microscope. Forceps were used to grip the 
optic nerve and gently rotate the eye such that the front (cornea and lens) were 
facing upwards. Whilst maintaining a grip on the eye an 18-gauge needle was 
used to make a small incision on the ora serrata, the serrated junction between 
the retina and ciliary body. Micro-dissection scissors were placed within the 
puncture and used to cut around the circumference of the ora serrata as the eye 
was gently rotated using the forceps gripping the optic nerve. After finishing the 
cut, the cornea, iris, and lens could be removed, leaving behind the posterior 
section of the eye. Two pairs of straight micro-forceps were then used to free 
the retina by peeling it away from the eyecup (RPE/Choroid). To do so, one pair 
of forceps was used to grip tightly between the eyecup and the retina. A second 
pair of forceps was placed loosely between the eyecup and the retina. The first 
pair of forceps were slowly pulled such that it caused the second pair of forceps 
to slide along the eye, detaching the retina from the eyecup (the action is similar 
to grasping a piece of paper between the thumb and forefinger of one hand and 
gently pulling it through the grasp with the other hand). Once the retinae had 
been separated from the eyecup they were transferred into a new 1.5 mL 
eppendorf tube, snap-frozen in liquid nitrogen and stored at -80°C. 
 
Retina were homogenised before adding 30 µL of cold RIPA lysis buffer (please 
refer to Appendix Table 6 for RIPA buffer composition). Samples were 
incubated on ice for 10 minutes before being snap-frozen in liquid nitrogen, 
thawed in a water bath and vortexed for 10 seconds. This freeze-thaw cycle 
was repeated three times before samples were centrifuged at 13,000 RPM for 
10 minutes to remove cell debris. The supernatant for each sample was 
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transferred into a new 1.5 mL and protein concentration was determined by 
Bradford Assay.    
 
2.6 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
 
After calculating protein concentration using the Bradford assay, samples were 
diluted in laemmli loading buffer (please refer to Appendix Table 6 for laemlli 
buffer composition) so that an equal amount of protein for each sample was 
loaded onto the gel. Each sample was prepared in 20µL volume and denatured 
by incubating at 100°C for 5 minutes. All samples, including a molecular weight 
marker, were loaded into the wells of a 10% SDS-PAGE gel (please refer to 
Appendix Tabe 22 for SDS-PAGE gel composition). The gel was placed into a 
Mini Trans-Blot® Cell (Appendix Table 3)  and topped up with running buffer 
before securing the lid and ensuring the terminals were correctly aligned (red to 
red and black to black). The gel was run at 80 V for 30 minutes to allow 
samples to pass through the stacking gel. After which the voltage was 
increased to 110 V for 2 hours (or until the loading dye had run off the end of 
the gel).  
 
2.7 Western Blotting: Wet Transfer 
 
Following electrophoresis, proteins were blotted onto a polyvinylidene fluoride 
(PVDF) membrane (Appendix Table 4) using a wet blotting system. Sponges 
and filter paper were soaked in transfer buffer before being assembled in 
gel/membrane sandwich in the blotting cassette as follows; sponge, 2 x filter 
paper, PVDF membrane (pre-soaked in methanol), 2 x filter paper. A roller was 
used to remove any bubbles between layers. The blotting cassette was 
clamped tightly together and placed into a Mini Trans-Blot® Cell along with an 
ice pack. The tank was topped up with transfer buffer (please refer to Appendix 
Table 6 for transfer buffer composition) to the fill level and the lid secured, 
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ensuring the terminals were correctly aligned. The transfer was run at 90V for 
90 minutes. Once complete, the blotting cassette was disassembled, and the 
membrane was removed for target protein detection.  
 
2.8 Target Detection 
 
After transferring, the membrane was blocked in 5% milk solution for 1h at room 
temperature under gentle agitation. The membrane was washed 3 X 15 minutes 
in TBS-T followed by overnight incubation at 4°C with primary antibody (Table 
10) diluted in 5% BSA (please refer to Appendix Table 6 for 5% milk solution, 
5% BSA blocking buffer, and TBS-T composition). Gentle agitation was applied 
to ensure homogenous covering of the membrane by antibody containing 
blocking buffer. The following morning, the membrane was washed 3 X 15 
minutes in TBS-T to remove residual primary antibody and then incubated with 
blocking buffer containing appropriate Horse Radish Peroxidase (HRP) 
conjugated secondary antibody (Appendix, Table 11) for 2h at room 
temperature. After incubation the membrane was washed with TBS-T 3-4 times 
for 2h at room temperature with gentle agitation to remove residual secondary 
antibody. 
 
Chemiluminescence was used to visualize targets of interest. Firstly, excess 
TBS-T was removed from the membrane by blotting gently on a paper towel. 
Equal volumes of solution A (fixation agent) and solution B (development agent) 
of SuperSignal™ West Pico PLUS Substrate (Appendix, Table 3) were mixed 
together and applied directly onto the membrane. The membrane was then 
placed between two plastic sheets inside a developing cassette with protein 
side facing upwards. All subsequent steps were carried out in a dark room. The 
light sensitive X-Ray film was removed from its packaging, cut to size and 
placed over the membrane. The cassette lid was closed, and the film exposed 
to the membrane. After exposure the film was developed.  
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2.9 Western Blot Stripping 
 
To re-probe the membrane for the detection of other protein targets, the 
membrane was first washed three times in TBS-T to remove the staining. The 
primary and secondary antibodies were removed by incubating the membrane 
in stripping buffer for 10 minutes at room temperature under gentle agitation, 
washed under running tap water to remove stripping buffer followed by blocking 
in 5% (w/v) fat free milk solution in TBS-T for 1h at room temperature. After the 
membrane was probed with new primary antibody and as described above.  
 
2.10  RNA Isolation from Retinal Tissue 
 
Retina were dissected as previously described (please refer to methods section 
2.5). To isolate RNA from retinal tissue 500 µL RNAzol®RT was added directly 
to each dissected retina in a 1.5 mL eppendorf tube and homogenised using a 
23 and 26G needle. 200 µL of RNAase free dH2O was added to the tissue 
homogenate. The resulting mixture was shaken vigorously for 15 seconds, 
incubated at room temperature for 10 minutes before centrifuging at 12,000G 
for 15 minutes. Following centrifugation, DNA, proteins, and most 
polysaccharides form a semisolid pellet at the bottom of the tube, whereas the 
RNA remains soluble in the supernatant. Approximately 550 µL of the 
supernatant (75% of the total supernatant volume) was transferred to a new 
tube leaving a layer of the supernatant above the DNA/protein pellet. To 
precipitate the RNA, 200 µL of 75% of ethanol was added to the supernatant 
and samples were stored at -20°C overnight. The following day, samples were 
centrifuged at 12,000g for 8 minutes, after which the RNA precipitate formed a 
white pellet at the bottom of the tube. The pellet was washed a further 2-3 times 
using 75% ethanol and centrifuging at 8,000g for 3 minutes. After the final 
wash, the RNA pellet was air-dried for 5 minutes and then dissolved in 20 µL of 
RNAase free dH2O. Extracted mRNA was quantified using a NanoDrop ND-
1000 Spectrophotometer. Purity was determined using 260/280 and 260/230 
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ratios; only samples with values over 1.8 were used for gene expression 
studies. RNA samples were stored at -80ºC. 
 
2.11  Quantification of DNA and RNA by Spectroscopy 
 
DNA and RNA preparations were quantified using the NanoDrop™ 2000c. 
Following background correction with µL of dH2O, 1 µL of DNA was quantified 
by measuring the absorbance at 260nm. A conversion factor of 50 for DNA and 
40 for RNA for every unit of absorbance represents an estimated 50 µg/L and 
40 µg/ µL respectively. 
 
2.12  First Strand cDNA Synthesis 
 
First strand cDNA was synthesised from RNA using 5X qScript® cDNA 
SuperMix Kit. 1 µg of RNA was added into a RNase free 0.2 mL tube, along 
with 4 µL of 5X qScript® cDNA SuperMix and RNase free dH2O. The reaction 
volume per RNA template was 20 µL (refer to Table 17 for the composition of 
the qScript® cDNA SuperMix). 
 
2.13  SYBR® Green Real-Time PCR 
 
The cDNA was subject to quantitative real time polymerase chain reaction (RT-
qPCR). Each reaction was performed in a 20 µL volume containing cDNA, 
forward and reverse primers, nuclease free dH2O and iTaq™ Universal Synergy 
Brands (SYBR®) Green Supermix. Reactions were performed in experimental 
duplicates and read from a 96-well plate. All RT-qPCR components were 
thawed on ice. A master-mix for each target gene was prepared by combining 
forward and reverse primers (please refer to Appendix Table 18 and Table 19 
for primer sequences), nuclease free dH2O and SYBR® Green supermix in a 
1.5 mL eppendorf tube on ice (please refer to Appendix Table 20 for SYBR® 
reaction volume composition). The 96-well RT-qPCR plate was placed on ice 
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and 19 µL of the master-mix was added to the wells, followed by the addition of 
1 µL of sample cDNA. The 96-well plate was briefly centrifuged to ensure all 
components were collected at the bottom of each well. RT-qPCR was 
performed using Applied Biosystems StepOnePlus™ Real Time PCR System 
(please refer to Appendix Table 21 for RT-qPCR cycling conditions). 
Relative gene expression was quantified using the DDcT method to calculate 
fold change, normalising against the housekeeping gene β-actin, as described 
in the equation below. 
  
Relative Expression: 
2-∆∆cT 
Where: 
∆∆cT = ∆cTsample - ∆cTcontrol 
∆cT = cTgene of interest - ∆cThousekeeping gene 
 
 
2.14  Cell Culture Basics 
 
All cell culture was performed in sterile conditions in an Airstream® (ESCO) 
Class II biological safety cabinet. All materials and equipment to be used in the 
biological safety cabinets were either sterilised with 70% IMS or autoclaved. All 
cell culture plastic-ware was bought pre-sterilised. Any liquids were bought pre-
sterilised or were sterile filtered using a 0.22 µM filter in the biological safety 
cabinets. Cells were cultured in an incubator in humidified conditions at 37°C 
and 5% CO2. All cell culture media was pre-warmed in a 37°C water bath for 30 
minutes prior to cell culture.  
 
2.15  Thawing Cells 
 
Prior to thawing, a T25 tissue culture flask was coated with Quick Coating 
Solution for 5 minutes. Cryopreserved cells (1ml per cryovial) were defrosted 
rapidly in a 37°C water bath and transferred to a 15 mL universal tube 
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containing 9ml of appropriate cell growth media. The cell suspension was then 
placed into a centrifuge and spun at 1300 rpm for 5 minutes. After pelleting, the 
supernatant was removed and the cells re-suspended 5 mL appropriate cell 
growth media. The quick coat solution was removed from the T25 flask and the 
cell suspension was transferred from the 15 mL universal. Media was replaced 
the following day and every 2-3 days thereafter until cells were 80-90% 
confluent. 
 
2.16  Counting Cells 
 
To count the number of cells in a cell suspension, a glass haemocytometer was 
used. The hemocytometer and coverslip were cleaned with 70% ethanol prior to 
use. The coverslip was moistened with water to affix to the hemocytometer. 
Cells were re-suspended in 1ml of the appropriate culture medium. 10 µl of the 
cell suspension was pipetted into the haemocytometer tip at the edge of the 
chambers, allowing capillary action to draw the suspension from the pipette. 
The haemocytometer was viewed under an inverted microscope at 10x 
objective and phase contrast was used to visualise cells. A hand tally counter 
was used to count the total number of cells within a one set of 16 squares 
occupying a volume of 1 x 10-4 ml.  To avoid counting cells more than once, 
cells were only counted when they were set within a square or on the left-hand 
or top boundary line. Counting was repeated for the remaining 3 sets of 16 
squares to obtain an average cell number. The calculation outlined below was 
used to calculate the total number of cells per mL of cell suspension. 
 
Number of cells/mL: 
(X / D) * Y 
Where: 
X = Number of live cells counted 
D = Dilution Factor 
Y = 1mL/volume of 1 haemocytometer corner square 
 
e.g. (240 live cells/4 squares) *104 
= 6 *105 cells/mL  
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Calculation for cell seeding: 
(A/B) *N = Tc 
Where: 
A = Number of cells needed 
B = Number of cells counted/mL 
N = Number of wells/flasks to be seeded 
Tc = Total volume of cell suspension 
Tv – Tc = Tm 
Where: 
Tv = Total final volume of all wells/flasks 
Tm = Total respective media required 
 
2.17  Primary Cells: Culture and Sub-Cultivation 
 
Human Retinal Microvascular Endothelial Cells (HRECs) isolated from normal 
human retinal tissue were purchased as a cryopreserved stock of 5x105 cells 
per vial at passage 3. Upon thawing, HRECs were plated onto a T25 tissue 
culture flask coated with Quick Coating Solution and maintained in Endothelial 
Growth Medium (EGM-2™). EGM-2™ was made from a kit comprised of 
Endothelial Basal Media (EBM-2™) and Endothelial Growth Supplement Mix. 
To prepare the culture medium the contents of the supplement mix were added 
to 500 ml of EBM-2™ in a class II biological safety cabinet. In addition, 1% 
penicillin/streptomycin was added (please refer to Appendix Table 12 for the 
specification of EBM-2™ media composition). 
 
Cultures were grown at 37°C in 5% CO2 with media replaced every 2-3 days. 
Upon reaching 80-90% confluence cells were passaged to allow for cellular 
proliferation to expand the number of cells available for experimentation. To 
passage cells, media was removed from the T25 flask and washed once with 
2.5 mL of 1X phosphate buffered saline (PBS) to remove any residual serum 
proteins. Flasks were then incubated with 1 mL of trypsin EDTA at room 
temperature for 2-3 minutes. To counteract the action of trypsin 2.5 mL of EGM-
2™ was added and the cell suspension was transferred into a 15 mL universal 
tube. The cell suspension was centrifuged at 1300 rpm for 5 minutes before re-
suspending in 1 ml of culture medium. Cells were either plated at the desired 
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density for experiments or re-plated for continued cell culture. HRECs were split 
in the ratio of 1:3. HRECs were used until passage 12 in this study. 
 
2.18  Primary Cells: Cryopreservation 
 
When cells had reached 90% confluency, they were trypsinsed. Cells were 
resuspended in 1 mL of cell freezing media (please refer to Appendix Table 5 
for cell freezing medium details) and counted. Cells were re-suspended further 
to a concentration of 1X106 cells per mL The cell suspension was added to 1 
mL cryovials labelled with cell type, cell passage number, cell concentration and 
date of cryopreservation. Cryovials were cooled on ice for 10 minutes and then 
transferred to a freezing container that enabled cells to be cooled at a rate of -1 
°C per minute. The container was placed into a -80 °C freezer overnight before 
transferring the cryovials to a liquid nitrogen dewar for long-term storage.  
 
 
2.19  Freestyle 293-F Cells: Culture and Sub Cultivation 
Freestyle 293-F cells were purchased as a cryopreserved stock of   cells 
in 1 mL 90% Freestyle Expression Medium (FEM) and 10% DMSO. Prior to 
thawing, a 125 mL shaker flask was filled with 30 mL of pre-warmed freestyle 
293 culture media. Cryopreserved cells were removed from liquid nitrogen 
storage and defrosted rapidly in a 37°C water bath. Just before cells were 
completely thawed, the outside of the vial was decontaminated with 70% IMS 
and the entire contents of the cryovial was then and transferred directly to the 
125 mL shaker flask. Cells were incubated in a 37°C incubator containing a 
humidified atmosphere of 8% CO2 on an orbital shaker platform rotating at 125 
rpm. To allow oxygenation/aeration the cap of the flask was loosened a quarter 
turn from snug. 
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Cells were sub-cultured once the cell density had reached greater than 2-3 x 
106 cells/mL (typically 3 to 5 days). After determining the total cell number, the 
cell suspension was transferred aseptically from the 125 mL shaker flask into a 
50 mL universal tube and spun at 100 G for 5 minutes. Cells were resuspended 
in the appropriate volume of pre-warmed FEM to give a cell density of 3 x 105 
cells/ mL. Either 125- or 250-mL shaker flasks containing 30- or 50-mL total 
working volume of cell suspension, respectively were used. 
2.20  Freestyle 293-F Cells: Cryopreservation 
Freezing medium was prepared immediately before use. In a sterile 15 mL 
universal the following reagents were mixed together for every 1 mL of freezing 
medium needed: 0.9 mL FEM and 0.1 mL DMSO. The freezing medium was 
filter sterilised using a 0.22 µM filter unit and then placed on ice until use. Any 
remaining freezing medium was discarded after use.  
 
The Freestyle 293-F cells were counted to determine the total cell number. After 
determining the total cell number, the cell suspension was transferred 
aseptically from the 125 mL shaker flask into a 50 mL universal tube and spun 
at 100 G for 5 minutes. Cells were resuspended in the required volume of 
freezing medium to give a final cell density of 5-8 x 106 cells/mL. 1 mL of the 
cell suspension was aliquoted into a cryovial labelled with the cell type, cell 
passage number, cell concentration and date of cryopreservation. Cryovials 
were cooled on ice for 10 minutes, transferred to a freezing container and 
placed into a -80 °C freezer for at 24hours before transferring the cryovials to a 
liquid nitrogen dewar for long-term storage. 
 
2.21  Molecular Cloning of CFB Sequence 
 
The coding sequence human CFB (NM_001710.5) carrying a 6XHis tag at the 
3’ end and Kozak consensus sequence at the 5’ end was cloned into pcDNA3.1 
at the AFLII/XbaL sites to form pcDNA-CFB-His (please refer to Figure 11). 
57 
 
 
 
 
 
Figure 11: Schematic outline of the rhCFB cloning strategy. The coding sequence of human 
CFB (NM_001710.5) with a 6 X His tag at the 3’ end was cloned into pcDNA3.1 expression 
vector at the Afl II/ Xbal I sites to form pcDNA-rhCFB-His. 
 
2.22  Polymerase Chain Reaction (PCR) 
 
The coding sequence of human CFB (NM_001710.5) was amplified from 
sequence-verified cDNA clone MGC:1795 IMAGE:2959705 (Dharmacon), using 
Q5® High-Fidelity DNA Polymerase. All reaction components were assembled 
on ice in a 0.2mL PCR strip tube (please refer to Appendix Table 15 for the 
final PCR Mastermix composition). The reaction was gently mixed, followed by 
a pulse spin to collect all liquid to the bottom of the tube, before transferring the 
PCR tubes to the PCR machine for thermocycling (please refer to Appendix 
Table 16 for the PCR amplification thermocycling conditions).  
 
2.23  Agarose Gel Electrophoresis 
 
PCR products were separated and analysed for reaction quality by gel 
electrophoresis using a 1% agarose gel. 1% (w/v) agarose was prepared by 
mixing 1g agarose power in 100 mL 1 X TBE buffer and microwaving at full 
power for 2 minutes. The solution was cooled before adding 10 µL GelRed® 
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nucleic acid gel stain (Appendix Table 5)  to visualise DNA using ultraviolet 
(UV) light. Gels were poured into Sub® Cell GT electrophoresis chambers 
(Appendix, Table 3) and allowed to set before being placed into gel box and 
flooding with 1 X TBE buffer.  PCR samples were mixed with GelPilot ® DNA 
loading dye and loaded into the wells of the agarose gel. Samples were run 
next to GeneRuler 1 kb DNA ladder for approximate size calculation. Gels were 
run at 120V for 1.5 hour and then removed from the tank and placed onto a 
Dark Reader™ blue light transilluminator to visualise the bands of stained 
nucleic acid.   
 
2.24  PCR Product Purification 
 
PCR product was purified using QIAquick PCR purification kit (Appendix, 
Table 9) to remove unincorporated primers, left over dNTPs, salts, and other 
impurities from PCR amplicons. The method was carried out in accordance with 
the manufacturers protocol. DNA concentration was measured using the 
NanoDrop™ 2000c 
 
2.25  Restriction Digestion 
 
Restriction enzyme digestion of plasmid DNA (pcDNA3.1 vector and CFB 
insert) was performed with AFLII and XbaL restriction endonucleases 
(Appendix, Table 9) in FastDigest buffer (Appendix, Table 9) . Restriction 
enzyme digests were performed using the buffer system with time and 
temperature according to manufacturer’s instruction. Briefly, 20 units of enzyme 
was used in a reaction mixture containing the FastDigest buffer, 1 µg plasmid 
DNA, and incubated d at 37°C for 1-2 hours in a water bath. 
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2.26  Agarose Gel Purification 
 
The digested DNA product was separated in 0.8% agarose gel. The DNA 
fragment with appropriate size was excised from the gel using a clean scalpel. 
Purification proceeded using the QIAquick Gel Extraction Kit (Appendix, Table 
9) in accordance with the manufacturers protocol. DNA concentration was 
measured using the NanoDrop™ 2000c. 
 
2.27  Ligation 
 
DNA ligation was carried out in a 20 µL reaction volume by combining 50 ng 
vector DNA (pcDNA3.1) in a 3:1 molar ratio with insert DNA (CFB) and Quick 
Ligation™ Kit components in a microcentrifuge tube on ice (please refer to 
Appendix Table 14 for the Quick Ligation reaction components). The online 
NEBiocaluclator was used to calculate molar ratios.  The reaction was mixed by 
gentle pipetting before incubating at room temperature for 5 minutes. The 
ligation reaction mixture was chilled on ice before transforming into 50 µL of 
competent cells.     
 
2.28  Transformation 
 
Microbiological Luria-Bertani (LB) agar plates were used for growing bacterial 
cells. To make 200 mL (enough for approximately 20 plates), 7g of Agar powder 
(Appendix, Table 5) was added to 200 mL dH2O in a glass Duran. The mixture 
was shaken briefly to free the powder from the bottom of the bottle and remove 
major clumps, before autoclaving to sterilise. After autoclaving the mixture was 
cooled slightly (not below 45-50°C) and 25 µg/mL Chloramphenicol antibiotic 
(Appendix, Table 5) was added. Approximately 10 mL of LB agar was poured 
into each plate.  
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Bacterial strains were grown in LB medium (Appendix, Table 5)  with antibiotic 
selection from a single colony. Stocks of bacteria were stored at -80°C in 
cryovials in a minimum of 10% glycerol. For each transformation, 5 µL of the 
ligation reaction was mixed with 50 µL of chemically competent cells by gentle 
pipetting and incubated on ice for 30 minutes, followed by heat shock at 42°C 
for 30 seconds. The cells were allowed to recover in 950 µL of room 
temperature media (without antibiotic) and then incubated for 60 minutes at 
37°C with shaking at 250 rpm. Cells were plated on LB-agar plates containing 
25 µg/mL chloramphenicol antibiotic and incubated statically at 37°C overnight.  
 
2.29  Mini-Prep 
 
After overnight incubation, a single colony was picked up using a sterile pipette 
tip and cultured with 4 mL of LB media containing and cultured overnight at 
37°C on an orbital shaker at 190-225 rpm. The bacteria were pelleted and lysed 
for plasmid DNA isolation using QIAprep Spin Miniprep Kit (Appendix, Table 9) 
in accordance with manufactures protocol. The plasmid DNA was then 
adsorbed on a QIAprep membrane, washed then eluted with nuclease free 
H2O. The DNA was quantified using the NanoDrop™ 2000c.  
 
2.30  Freestyle 293-F Transfection 
 
Over-expression of CFB in Freestyle 293-F cells was achieved using a 
transient transfection method. Transfection experiments were performed in a 
30 mL volume with a total cell count of 3 x 107 cells. The day before 
transfection Freestyle 293-F cells were counted to determine the total cell 
number. After determining the total cell number, the cell suspension was 
transferred aseptically from the 125 mL shaker flask into a 50 mL universal 
tube and spun at 100 G for 5 minutes. Cells were resuspended in the required 
volume of pre-warmed FEM to give a final cell density of 6-7 x 105 cells/mL.  
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The following day, cells were counted again as described in to determine the 
total cell count and cell viability. For optimal transfection cells needed to be in 
a single cell suspension with viability of over 90%. The volume of cell 
suspension containing 3 x 107 cells was calculated and transferred into a new 
125 mL shaker flask. The volume was topped up to 30 mL with fresh pre-
warmed FEM. The shaker flask was incubated in a 37°C incubator containing 
a humidified atmosphere of 8% CO2 on an orbital shaker platform rotating at 
125 rpm whilst the transfection reagent mix was prepared. For the transfection 
of one 125 mL flask containing 3 x 107 cells in 30 mL FEM, 112.5 µL OptiMEM 
containing 37.5 µL of lipofectamine 2000 was added to 150 µL Opti-MEM® 
containing 37.5 µg of pCFB in a 1.5 mL eppendorf tube and incubated at room 
temperature for 20 minutes to allow the DNA-lipofectamine complexes to form. 
After incubation, the transfection reagent mix was added dropwise to the 125 
mL shaker flask prepared earlier. The shaker flask was incubated in a 37°C 
incubator containing a humidified atmosphere of 8% CO2 on an orbital shaker 
platform rotating at 125 rpm. Samples of conditioned media were harvested 
every 24h to check for recombinant protein expression.  
 
Approximately 72h after transfection, cells were counted to determine the total 
cell number. After determining the total cell number, the cell suspension was 
transferred aseptically from the 125 mL shaker flask into a 50 mL universal 
tube and spun at 100 G for 5 minutes. The conditioned media was collected 
into a new 50 mL universal and stored at -80°C until downstream protein 
purification was to be carried out.  
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2.31  Protein Purification 
 
2.31.1 Buffer Preparation 
0.1M Sodium Phosphate Buffer 
 
To prepare 50mL 1M stock solutions of NaH2PO4•H2O (monobasic) and 
Na2HPO4•H2O (dibasic), 6.9 g and 8.9 g were dissolved in dH2O respectively 
(Table 7). To prepare 500mL of 0.1M sodium phosphate buffer at pH 7.4 (from 
1M stock), 11.3 mL NaH2PO4 and 38.7 mL Na2HPO4 were diluted to 1L (final 
volume) with dH2O. 
 
Elution and Binding Buffers 
 
To prepare stock buffer 1 and stock buffer 2, buffer components were dissolved 
in 400 mL dH2O. The solutions were cooled at 4°C and the pH was adjusted to 
pH 7.4 before diluting to a final volume of 500mL with dH2O. Working 50 mL 
stocks of elution and binding buffers were prepared by mixing the correct 
volumes of stock buffer 1 and stock buffer 2 (Table 8). Elution and binding 
buffers were passed through a 0.22 µM filter before use.  
 
2.31.2 Protein Concentration 
 
Conditioned media collected from 239-F cells was thawed overnight on ice. 
After centrifuging at 100 G for 5 minutes, the supernatant was filtered using a 
0.22 µM filter before being concentrated using an Amicon® Pro Affinity 
concentrator spun at 4000 G for 30 minutes at 4°C. After each spin the flow-
through was discarded and the conditioned media in the reservoir was topped 
up. Conditioned media was concentrated to 100 X the starting volume.  
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2.31.3 Buffer Exchange 
 
After concentration, the conditioned media was equilibrated with binding buffer. 
The concentrated media was gently resuspended using a pipette and the 
reservoir was topped up with binding buffer before centrifuging at 4000 G for 30 
minutes or until the sample was concentrated to 10 X the starting volume. The 
flow through was discarded and the reservoir topped up to 10 mL with binding 
buffer. This step was repeated three times.  
 
2.31.4 Protein Binding 
 
Ni Sepharose high performance nickel-charged immobilised metal ion affinity 
chromatography (IMAC) resin was used to purify the rhCFB. 600 µL of Nickel 
beads were transferred to a 15 mL falcon tube, topped up to 5 mL with cold 
sterile PBS and centrifuged at 800 G for 5 minutes. This washing step was 
repeated twice with PBS and a final time with binding buffer. After buffer 
exchange the concentrated protein solution was gently re-suspended before 
being transferred to the 15 mL falcon with Ni beads. The tube was topped up to 
10 mL with binding buffer and incubated on the roller at 4°C overnight. 
 
2.31.5 Elution 
 
After overnight incubation the Ni beads were centrifuged at 800 G for 5 minutes. 
The supernatant was removed, and the beads were incubated with 10 mL cold 
binding buffer on the roller at 4°C for 10 minutes, before being centrifuged at 
800 G for five minutes. This washing step was repeated three times. After the 
final wash, Ni beads were incubated with 2 mL of elution buffer on the roller at 
4°C and incubated for 10 minutes before being spun at 800 G for 5 minutes. 
The eluent was collected, and the protein concentration was evaluated using 
Bradford reagent (180 µl 1  Bradford + 20 µl eluent) and checking for a colour 
change by eye. The elution steps were repeated until a colour change could no 
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longer be observed using the Bradford reagent. The eluent was then 
concentrated using Amicon Ultra 2 mL centrifugal filters. The membrane was 
washed first by adding 500 µL of cold PBS and spun at 4000 G for 
approximately 10 minutes (or until all of the PBS has passed through). After 
washing the membrane was spun at 4000 G for 10-15 minutes or until the 
sample was concentrated to 4 X the starting volume. The flow through was 
discarded and the reservoir topped up to 2 mL with eluent. This step was 
repeated, each time topping up the reservoir once the level of eluent drops, until 
the eluent was concentrated to approximately 500 µL. The the protein 
concentration was evaluated using Bradford reagent. 
 
2.31.6 Dialysis 
 
To remove imidazole from the concentrated protein solution dialysis was carried 
out using a 15 mL Scientific Slide-A-Lyzer MINI Dialysis Device. The Slide-A-
Lyzer MINI Dialysis Device was removed from the conical tube, being careful to 
not touch thee dialysis membrane so to avoid contamination. 14 mL of cold PBS 
buffer was added to the conical tube. 500 µL of the concentrated protein sample 
was added to the device, which was then placed slowly into the conical tube 
containing the buffer, making sure the membrane was in contact with the buffer 
and no air bubbles had been introduced. The conical tube was placed in the 
4°C cold room on an orbital shaker set at 200 rpm. The dialysis procedure was 
as follows: dialyze for 2h; change the dialysis buffer and dialyze overnight. After 
overnight dialysis, the device was removed from the conical tube and the 
sample collected using a pipette. The protein concentration of the sample was 
measured, and the protein purity was confirmed by InstantBlue™ protein stain 
solution (Concentrated protein was aliquot into smaller volumes in 1.5 mL 
eppendorf tubes, and stored at -80°C. 
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2.31.7 Protein Purity 
 
Gels were prepared and run as described (please refer to section 2.23). 
Following electrophoresis gels were removed from cassettes and transferred 
directly into the InstantBlue™ staining solution, making sure the gel was able to 
move freely within the solution to allow for diffusion. Protein bands were allowed 
to develop for 15 minutes at room temperature with gentle agitation.  
 
2.32  Primary Cell Transfection: Small Interfering RNA 
(siRNA) Silencing 
 
10 nM pooled CFB siRNA was briefly centrifuged to ensure that the pellet was 
collected at the bottom of the tube before resuspending in 100 µL of RNase-
free dH2O to obtain a stock solution with a concentration of 100 µM. The tube 
was securely sealed with and placed onto an orbital shaker for 30 minutes at 
room temperature. siRNA was briefly centrifuged again to ensure that the 
solution was collected at the bottom of the tube before being aliquoted into 
smaller 5 µL volumes to limit the number of freeze-thaw cycles. Resuspended 
siRNA was stored at -20°C. After thawing, storage at 4°C was suitable for up 
to 6 weeks.  
 
Knockdown of CFB in primary cells was achieved using a transient 
transfection method. HRECs were seeded in EGM-2™ overnight at a density 
of  2 X 105 cells per 6-well so that the following day they were approximately 
70-90% confluent before transfection. For transfection of one well, 150 µL 
OptiMEM® containing 6 µL of lipofectamine 3000 was added to 150 µL Opti-
MEM® containing 1µL of 100 µM stock CFB siRNA in a 1.5 mL eppendorf 
tube and incubated at room temperature for 20 minutes. 1.2 mL of fresh Opti-
MEM® was added to the 300 µL transfection reagent mix giving a final 
concentration of 66nM. HRECs were washed once with Opti-MEM® before 
adding the transfection mix. HRECs were incubated with the transfection mix 
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for 6h at 37°C and 5% CO2. After 6h, the transfection reagent mix was 
removed and replaced with 1.5 mL fresh EGM-2™.  Cells were incubated for a 
further 24h-48h before they were used for downstream experiments. CFB 
knockdown was confirmed by qRT-PCR.  
 
2.33  Primary Cell Transfection: CFB Over-expression 
 
Over-expression of CFB was achieved using a transient transfection method 
(please refer to section 2.21 for molecular cloning of CFB). HRECs were 
seeded in EGM-2™ overnight at a density of 2X105 cells per 6-well so that the 
following day they were approximately 70-90% confluent before transfection. 
For the transfection of one well, 150 µL OptiMEM® containing 2 µL of 
lipofectamine 3000 was added to 150 µL Opti-MEM® containing 1 µg of pCFB 
and 2 µL p3000 in a 1.5 mL eppendorf tube and incubated at room 
temperature for 20 minutes. After incubation 1.2 mL of fresh Opti-MEM® was 
added to the 300 µL transfection reagent mix. HRECs were washed once with 
Opti-MEM® before adding the transfection mix. HRECs were incubated with 
the transfection mix for 6h at 37°C and 5% CO2. After 6h, the transfection 
reagent mix was removed and replaced with 1.5 mL fresh EGM-2™. Cells 
were incubated for a further 24-48h before they were used for downstream 
experiments. CFB over-expression was confirmed by qRT-PCR. 
 
 
2.34  Growth factors and Inhibitor Treatments 
 
Recombinant human CFB (rhCFB) was expressed in FreeStyle™233-F cells 
and purified as described (please refer to section 2.31 for transfection protocol). 
For all in vitro and ex vivo assays rhCFB was used at a concentration of 100 
µg/mL. The multi-targeted tyrosine kinase inhibitor, Linifanib, was used in the 
Matrigel® network formation assay at a concentration of 5nM. 
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2.35  Cell Viability Assay 
 
Cell viability of cultured cells was evaluated over 2 days using the colorimetric 
MTS tetrazolium assay in a 96-well tissue culture plate. Prior to cell seeding, the 
number of individual wells required for the assay were calculated and each well 
was coated with 50 µL of Quick Coating Solution for 5 minutes. To evaluate 
HREC viability after rhCFB treatment, cells were seeded at 1000 cells per 96-
well in 100 µL EGM-2™ and cultured for 24 hours. After 24h culture cells were 
washed once with 1X PBS and cultured in EBM-2™ for 3h. Following this, EBM-
2™   media was aspirated from the wells and replaced with EGM-2™ containing 
either 100 µg/mL rhCFB or equivalent vehicle control. The day 0 time point was 
taken immediately after adding treatments. To evaluate HREC viability after 
CFB knockdown or over-expression, cells were transfected as described 
(please refer to section 2.32 and 2.33) and harvested after 48h. Cells were 
seeded at 1500 cells per 96-well in 100 µL EGM-2™ and cultured for 4h to 
allow cells to settle and adhere. After cells had adhered the EGM-2™ was 
aspirated, cells were rinsed once with 1X PBS and cultured for 3h in EBM-2™. 
Following this EBM-2™ was aspirated from the wells and replaced with EGM-
2™. The day 0 time point was taken immediately after adding fresh EGM-2™.  
 
Cell viability was measured at the following time points: day 0, day 1, and day 2. 
An equivalent group of EGM-2™ without any cells was included in parallel for 
use as a media blank. At each time point, 10 µL of MTS reagent was added into 
the corresponding wells and incubated for 2h at 37°C in 5% CO2. After 
incubation the absorbance of formazan product was measured using a plate 
reader at the wavelength of 490 nm. The final value was obtained by 
subtracting the absorbance reading of the media blank control. Each time point 
was measured in triplicate per group and control. 
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2.36  Cell Proliferation Assay 
 
Cell proliferation of cultured cells was evaluated by immunofluorescence 
staining of the nuclear marker Ki67. Cell proliferation was evaluated in a 48-well 
plate. Prior to cell seeding, the number of individual wells required for the assay 
was calculated and each well was coated with 500 µL of Quick Coating Solution 
for 5 minutes. To evaluate HREC proliferation after rhCFB treatment, cells were 
seeded at 10,000 cells per 48-well in 500 µL EGM-2™ and cultured for 24 
hours. Following this, fresh EGM-2™ containing either 100 µg/mL rhCFB or 
equivalent PBS control was added to the HRECs and cultured for 24h. To 
evaluate HREC viability after CFB knockdown or over-expression cells were 
transfected as described (please refer to section 2.32 and 2.33)  and harvested 
after 48h. Cells were seeded at 12,000 cells per 48-well in 500 µL EGM-2™ and 
Transfected HRECs were cultured for a further 24h.  
 
At the assay endpoint culture media was removed and cells were washed three 
times with sterile 1x PBS before fixation in 4% paraformaldehyde (PFA) for 15 
minutes. Once the cells had been fixed, subsequent work was carried out in 
non-sterile conditions on the laboratory bench. 4% PFA was aspirated from the 
wells and cells were washed three times with 1X PBS before being blocked and 
permeabilised in 1X blocking buffer (please refer to Appendix Table 6 for the 
composition of blocking 1 X buffer) for 45 minutes at room temperature. After 
blocking, cells were incubated with primary rabbit anti- Ki67 antibody (please 
refer to Appendix Table 10 for primary antibody details) diluted in 1x blocking 
buffer at 4°C overnight. After overnight incubation, cells were washed three 
times with 1x blocking buffer to remove excess primary antibody before 
incubating with Alexa Fluo® 594 conjugated goat anti-rabbit IgG secondary 
antibody (please refer to Appendix Table 11 for secondary antibody details) 
diluted in 1x blocking buffer, for 2h in the dark at room temperature. Excess 
secondary antibody was removed by washing three times with 1X PBS followed 
by incubation with DAPI dye diluted in 1x PBS, for 10 minutes in the dark at 
room temperature. A final three washes with 1x PBS was carried out before 
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imaging. Fluorescent images were captured using an Eclipse Ti-E Inverted 
Research Microscope (Nikon, Japan). Images were captured across five fields 
of view per well and the total number of cell nuclei and the total number of Ki-
67+ cell nuclei were manually counted. The cell proliferation rate was calculated 
as a percentage Ki-67+ cells. The average of the five fields of view was taken to 
give a final proliferation rate per well. 
 
2.37 MatrigelÒ Network Formation 
 
The day prior to conducting the tube formation assay, growth factor reduced 
Corning® Matrigel® Matrix was thawed overnight on ice at 4°C. 60ul of 
completely thawed Matrigel® was plated into each well of a pre-cooled 96-well 
plate and allowed to polymerise for 30 minutes at 37°C.  
 
To evaluate HREC network formation after rhCFB treatment, cells were seeded 
onto the polymerised Matrigel® at 12,000 cells per well of a 96-well plate in 100 
µL EGM-2™ medium containing either 100 µg/mL rhCFB or equivalent volume 
of PBS control and cultured overnight for 16 hours. To evaluate HREC tube 
formation after CFB knockdown or over-expression, cells were transfected as 
previously described (please refer to section 2.32 and 2.33) and harvested after 
48h before being seeded at 15,000 cells per well of a 96-well plate in 100 µL 
EGM-2™ medium and cultured overnight for 16 hours.  
 
After incubation, the vasculature was imaged using Eclipse Ti-E Inverted 
Research Microscope (Nikon, USA) at 4x magnification. Quantification of the 
vascular network was analysed using Image J (National Institute of Health, 
USA) for total number of junctions, total vessel length and total branching length 
per well. The values for each parameter were normalised to the control group 
(untreated control, scrambled control or pcDNA control) for statistical analysis.  
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2.38  Transwell Migration Assay 
 
HREC migration was evaluated using Transwell migration inserts. The day prior 
to conducting the migration assay, 8 µM Transwell® 24-Well Plate Inserts were 
coated with 1 mL Quick Coating Solution for 5 minutes and then allowed to dry 
thoroughly overnight.  
 
To evaluate HREC migration after rhCFB treatment, cells were seeded in a 6-
well plate in EGM-2™ at a density of 2x105 cells per well and cultured for 24h. 
The following day cells were rinsed once with 1x PBS and pre-treated with 
EBM-2™ containing either 100 µg/mL rhCFB or equivalent volume of PBS for 
24h. After pre-treatment, cells were harvested and seeded into the upper 
chamber of the 8 µM Transwell® inserts at a density of 30,000 cells per well of 
a 24-well plate in 200 µL EBM-2™. In the lower chamber of the inserts, EBM2 
containing 5% foetal bovine serum (FBS) was used as a chemoattractant.  
 
To evaluate HREC tube formation after CFB knockdown or over-expression 
cells were transfected as previously described (please refer to section 2.32 and 
2.33), and harvested after 48h. Cells were seeded into the upper chamber of 
the 8 µM Transwell® inserts at a density of 40,000 cells per 24-well in 200 µL 
EBM-2™. In the lower chamber of the l inserts, 600 µL EBM2 containing 5% 
FBS was used as a chemoattractant.  
 
After 4h of incubation media was removed from both the upper and lower 
chambers and inserts were washed three times in 1x PBS. To fix cells, 1 mL 1% 
PFA was added to each insert for 10 minutes followed by washing three times 
with 1x PBS. Cells were permeabilised with 0.2% Triton-X 100 for 10 minutes 
and non-migrated cells on the upper side of inserts were gently removed using 
cotton swabs. Inserts were washed a further three times with 1x PBS before 
migrated cells on the underside of the inserts were incubated with the nuclear 
stain DAPI, diluted in 1x PBS for 10 minutes in the dark at room temperature. A 
final three washes with 1x PBS was carried out to remove excess DAPI. Images 
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were captured across five fields of view per well using an Eclipse Ti-E Inverted 
Research Microscope (Nikon, USA). The total number of cell nuclei per field of 
view were counted manually using Image J (National Institutes of Health, USA). 
The five fields of view were averaged to give a total number of migrated cells 
per well.  
 
2.39  Aortic Ring Sprouting Assay 
 
All dissection instruments were sterilised before use and kept in 70% industrial 
methylated spirit (IMS) during the procedure to maintain sterility. The C57BL/6 
mouse strain was used for this assay. 
 
The thoracic aortas were dissected from wild type postnatal day 3 (P3) mouse 
pups. After surface-sterilising the mouse by spraying with 70% industrial IMS, it 
was lay back-down on a dissecting board with pins used to fix the legs in place. 
Dissection scissors were used to make a single cut in the ventral skin and blunt 
dissection was used to peel back the skin. To open the thoracic cavity 
dissection scissors were used to cut through and along the sternum, and 
around the ribcage. The heart and lungs were removed to expose the aorta 
which is visible as a fat-covered blood vessel tracking down along the spine. 
Forceps were used to grasp the anterior end of the aorta in one hand. Using a 
closed pair of sharp forceps in the other hand, the aorta was detached from the 
spinal column by blunt dissection. running the instrument between the aorta and 
spine all the way down toward the posterior end before the artery branches into 
the iliacs in the abdomen. Once the aorta was separated from the spine it was 
cut once near the abdominal branch and once near the anterior end and 
transferred into a petri dish containing aortic ring media (please refer to 
Appendix Table 13 for the composition of aortic ring media) Under the Leica 
M165 FC Stereo microscope dissection microscope all extraneous fat, tissue 
and branching vessels were removed with forceps and a scalpel. Using a 
scalpel, the aorta was then cut into rings approximately 0.5 mm in width and 
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transferred to a new petri dish containing ARM. On average, a total of 5-10 
rings can be obtained from each P3 aorta. 
 
Following dissection, the aortic ring explants were embedded in collagen. Type I 
collagen was prepared to a final concentration of 1mg/mL in ARM and the pH 
was adjusted to pH 7 by adding 1-N NaOH dropwise into the collagen solution. 
One aortic ring was embedded per well of a 96-well plate and 8-10 aortic rings 
were used per treatment group. For embedding, 60 µL of collagen was added to 
each well of a 96-well plate and aortic rings were carefully transferred from the 
petri dish using forceps, ensuring that they were completely submerged in the 
collagen, and placed so that the luminal axis was parallel to the bottom of the 
well. The plate was left undisturbed for 10-15 minutes at room temperature 
followed by incubation for 30 minutes at 37°C and 5% CO2 to ensure the 
collagen gel was fully polymerised. After incubation, 100 µL of ARM without 
treatment was added to all the aortic rings and they were cultured for 24h. The 
following day, media was carefully removed from the wells and replaced with 
ARM containing either 100 µg/mL rhCFB or equivalent volume of PBS. The 
media was changed every other day for 5-7 days.  
 
At the conclusion of the culture period, culture media was carefully removed, 
and the aortic rings were washed once with 200 µL 1X PBS before being fixed 
with 100 µL of 4% PFA for 20 minutes at room temperature. Aortic rings were 
then washed three times with 200 µL 1X PBS and submerged in 100 µL of 1% 
blocking buffer for 1 hour at room temperature. After blocking, aortic rings were 
incubated in 50 µL of 1% blocking buffer containing biotinylated primary anti-
GSL I-B4 Isolectin antibody to stain ECs, and primary rabbit-anti NG2-antibody 
to stain supporting cells overnight at 4°C in the dark (please refer to Appendix 
Table 10 for primary antibody details). After incubation, aortic rings were 
washed with 200 µL 1% blocking buffer three times to remove excess antibody, 
followed by incubation with 50 µL 1X PBS containing DAPI dye in the dark at 
room temperature. A final three washes with 1X PBS were carried out to 
remove excess DAPI. After immunofluorescence staining of aortic rings, they 
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were visualised under the Nikon Eclipse Ti Inverted Fluorescence Microscope. 
To quantify, starting from a specific point on the ring (e.g. the 12 o’clock 
position), each micro-vessel emerging from the main ring as a sprout and then 
individual branches arising from it as separate vessels, were counted. The 
focus was adjusted manually whilst moving around the ring to ensure that 
vessels sprouting in different planes were counted. Quantification was carried 
for the mean number of microvessels per ring. A mean of ≥8 aortic rings being 
analysed for each treatment. Representative images were captured and were 
processed In Adobe Photoshop to mask for presentation purposes.  
 
2.40  Fetal Metatarsal Sprouting Assay 
 
The fetal metatarsal sprouting assay was carried out as described243. The 
C57BL/6 mouse strain was used for this assay. Time-mating was performed to 
achieve an accurate prediction of the embryonic stages of the foetuses. In brief, 
a male and two other females were placed in the same cage. Thereafter, the 
females were examined for a copulatory plug every morning. The plugged 
female was transferred into a new cage and the gestation stage was considered 
to be E0.5. Embryos between E16.5 to E18 were sacrificed and metatarsal 
bones were dissected under a stereomicroscope and maintained in ice-cold 
dissection media (please refer to Appendix Table 13 for the composition of 
metatarsal dissection media). Individual metatarsals were mounted onto a 24-
well coated with 0.1% gelatin and left to adhere for 5 minutes. Next, 200 µL of 
metatarsal growth media was added to each mounted metatarsal (please refer 
to Table 13 for the composition of metatarsal growth media). The explants were 
incubated for 48 hours to allow for fibroblast migration out from the metatarsal 
bones. Any explants lacking fibroblast sprouting were classed as non-viable and 
were discounted from the assay. Those with visible fibroblast sprouting were 
subject to further treatments. The explants were treated with 300µL of fresh 
metatarsal growth media containing either 100 µg/mL rhCFB or equivalent 
volume of PBS. The media was changed every other day for 10-12 days. 
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At the conclusion of the culture period culture media was carefully removed, 
and the metatarsal explants were washed once with 200 µL 1X PBS before 
being fixed with 100 µL of 4% PFA for 20 minutes at room temperature. 
Metatarsal explants were then washed three times with 200 µL 1X PBS and 
submerged in 200 µL of 1X blocking buffer for 1 hour at room temperature. After 
blocking, metatarsal explants were incubated with primary rabbit anti-CD31 
antibody diluted in 1x blocking buffer at 4°C overnight (please refer to 
Appendix Table 10 for primary antibody details). After overnight incubation 
metatarsal explants were washed three times with 200 µL of 1X blocking buffer 
to remove excess primary antibody before incubating with Alexa Fluo® 594 
conjugated goat anti-rabbit IgG secondary antibody diluted in 1x blocking buffer, 
for 2h in the dark at room temperature (please refer to Appendix Table 11 for 
secondary antibody details). Excess secondary antibody was removed by 
washing three times with 1X PBS followed by incubation with DAPI dye diluted 
in 1x PBS, for 10 minutes in the dark at room temperature. A final three washes 
with 1x PBS was carried out before imaging. Explants were imaged directly in 
the 24-well plate using the Nikon Eclipse Ti Inverted Fluorescence Microscope. 
The raw images were processed in Adobe Photoshop CS4 to mask for 
quantification purposes. The total area of the masked image was normalised to 
the bone area to give the percentage of sprouting area.   
 
2.41  RNA Isolation from Cell Lines 
 
For RNA isolation, all pipetting was carried using filter pipette tips and all 
centrifugation steps were performed at 4°C. Cell culture media was removed, 
and cells were washed once with 1X PBS. After washing, 500 µl RNAzol®RT 
was added to each well and incubated for five minutes at room temperature to 
lyse the cells. Following incubation, the lysate was passed through a pipette 
several times and added to 200 µL of RNAase free dH2O in a 1.5 mL eppendorf 
tube. The resulting mixture was shaken vigorously for 15 seconds, incubated at 
room temperature for 10 minutes before centrifuging at 12,000G for 15 minutes. 
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Following centrifugation, DNA, proteins, and most polysaccharides form a 
semisolid pellet at the bottom of the tube, whereas the RNA remains soluble in 
the supernatant. Approximately 550 µL of the supernatant (75% of the total 
supernatant volume) was transferred to a new tube leaving a layer of the 
supernatant above the DNA/protein pellet. To precipitate the RNA, 200 µL of 
75% of ethanol was added to the supernatant and samples were stored at -
20°C overnight. The following day, samples were centrifuged at 12,000g for 8 
minutes, after which the RNA precipitate formed a white pellet at the bottom of 
the tube. The pellet was washed a further 2-3 times using 75% ethanol and 
centrifuging at 8,000g for 3 minutes. After the final wash, the RNA pellet was 
air-dried for 5 minutes and then dissolved in 20 µL of RNAase free dH2O. 
Extracted mRNA was quantified using a NanoDrop ND-1000 
Spectrophotometer. Purity was determined using 260/280 and 260/230 ratios; 
only samples with values over 1.8 were used for gene expression studies. RNA 
samples were stored at -80ºC. 
and the samples were then processed as described (please refer to section 
2.40). RNA concentration was determined using the NanoDrop™2000c. 
 
2.42  Biochemical Methods 
2.42.1 Protein Isolation from Cell Lysates 
 
Cell culture media was removed, and cells were washed once with 1X PBS 
before adding 25 µL of cold RIPA lysis buffer containing 1X protease inhibitor 
and 1X phosphatase inhibitor to each well of a 6-well plate. A cell scraper was 
used to dissociate the cells from the bottom of the well and samples were 
pipetted into 1.5 mL eppendorf tubes and incubated on ice for 10 minutes. After 
incubation, samples were snap-frozen in liquid nitrogen, thawed in a water bath 
and vortexed for 10 seconds. This freeze-thaw cycle was repeated three times 
before samples were centrifuged at 13,000 RPM for 10 minutes to remove cell 
debris. The supernatant for each sample was transferred into a new 1.5 mL and 
protein concentration was determined by Bradford Assay.    
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2.43  Statistical Analysis 
 
Statistical analysis was performed using GraphPad Prism software (GraphPad 
Software, Inc.). Results are depicted as mean ± standard deviation (SD). Prior 
to running any statistical analysis, the Shapiro-Wilk normality test was carried 
out. If data was found to have normal distribution, for experiments with n≥3, 
statistical analysis was performed using unpaired, two-tailed t-test, or one-way 
analysis of variance (ANOVA) followed by Turkey’s multiple comparisons test. If 
data was not normally distributed, for experiments with n≥3, statistical analysis 
was performed using the Mann-Whitney test. Differences were deemed 
statistically significant for p-values <0.05. For gene expression data where all 
control values are represented as 1, statistical significance was determined on 
raw delta-CT values by unpaired two-tailed students’ t-test.  
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3 Results 
3.1 Characterising the Expression of Complement Factor B 
Using Rodent Models and Human Patient Samples 
 
CFB, a 95-kDa serine protease, is the crucial catalytic element of the AP that 
acts as a C3 convertase in the presence of factor D. In addition to its role in 
activating the alternative pathway, previous studies have shown a link between 
the CFB and DR pathogenesis (please refer to chapter 1.9.4.) To begin with the 
expression of CFB was characterised using a chemically induced mouse model 
of diabetes, established by subcutaneous streptozotocin (STZ) injection. To 
investigate the association between CFB and diabetes, CFB gene and protein 
expression in the retina of STZ-induced diabetic mice was analysed by RT-
qPCR and western blot. No significant differences were observed in either CFB 
gene or CFB protein expression between the buffer-injected controls and STZ 
mice (Figure 12). Following on from this, CFB protein expression in the serum 
and aqueous humor of diabetic patients at various stages of DR progression 
was analysed by western blot. No significant differences were observed in 
serum samples from diabetic patients with no DR, NPDR and PDR as 
compared to the non-diabetic control group (Figure 13). In the aqueous 
samples, an up-regulation of CFB protein expression was observed in both 
diabetic patients with NPDR and PDR, respectively, when compared to diabetic 
patients with no DR (Figure 14). 
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Figure 12: CFB expression in the retina of STZ-induced diabetic mice. Diabetes was 
induced by Streptozotocin injection. The retinae were harvested for the analysis of CFB mRNA 
and protein expression. The changes in gene expression were calculated using fold change (-
2(∆∆cT). The changes in protein expression were detected by western blot A, RT-qPCR 
analysis of CFB transcript levels in the retina of STZ injected mice, represented as fold change 
normalised to wildtype buffer, B, Representative western blot of CFB protein levels in the retina 
of wildtype buffer and STZ injected mice, GAPDH was used as a loading control. C, 
Densitometry quantification of western blot. CFB was first normalised to the internal control 
GAPDH.  Quantification is represented as fold change normalised to wildtype buffer. Results 
represent the mean ± SD. Differences were not statistically significant as tested by Student’s t-
test: n ≥ 3 
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Figure 13: CFB expression in human patient serum samples. Human serum samples from 
patients with varying severity of DM and DR were analysed for CFB protein expression. The 
changes in protein expression were detected by western blot. A, Representative western blot of 
CFB. B-D Densitometry quantification of western blot. Quantification is represented as fold 
change normalised to control patient samples. Results represent the mean ± SD. Differences 
were not statistically significant as tested by Student’s t-test: n ≥ 3. 
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Figure 14: CFB expression in human patient aqueous samples. Human aqueous humor 
samples from patients with varying severity of DM and DR were analysed for CFB protein 
expression. The changes in protein expression were detected by western blot.  A, 
Representative western blot of CFB. B, Densitometry quantification of western blot. 
Quantification is represented as fold change normalised to DM no DR patient samples. No 
statistical test was performed: n =1 
 
 
To study the role of CFB in pathological neovascularisation, the well-established 
model of oxygen-induced retinopathy (OIR) was used. The OIR model of 
pathological neovascularization is used to mimic the clinical features of 
proliferative retinopathies230. Briefly, neonatal mice were exposed to hyperoxic 
(75%) conditions from postnatal day (P) 7-12. This abundance of oxygen 
prevents further vessel growth and causes already formed immature vessels to 
regress. From P12-17 the mice are returned to normoxic conditions (21%) and 
the avascular retina become hypoxic triggering exuberant 
neovascularization230,244. Using the OIR model, retinae were harvested at P12 
and P17 for RT-pPCR analysis of CFB gene expression. At P12 there was a 
significant reduction in CFB gene expression (*p< 0.05) in OIR retina when 
compared to retina in the normal oxygen control group. On the other hand, at 
P17 there is a significant increase in CFB expression (*p< 0.01) in OIR retina 
when compared to the normal oxygen control group (Figure 15).   
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Figure 15: CFB gene expression in the retina of OIR mice. C57BL/6 mice were subject to 
OIR to induce pathological neovascularisation. Retina were harvested at P12 and P17 for 
analysis of CFB mRNA expression. The changes in CFB gene expression were calculated 
using fold change (-2(∆∆cT). A, RT-qPCR analysis of CFB transcript levels in the retina of P12 
OIR mice, represented as fold change normalised to the normal oxygen control. B, RT-qPCR 
analysis of CFB transcript levels in the retina of P17 OIR mice, represented as fold change 
normalised to the normal oxygen control. Results represent the mean ± SD. Statistical 
significance was determined by unpaired two-tailed students’ t-test; n=³3, *:p< 0.05, **: p< 0.01. 
 
 
3.2 The Role of CFB in Regulating Retinal Angiogenesis 
 
The progression of DR is a complex process resulting from chronic and 
sustained hyperglycaemia, which culminates in a series of pathological events 
that result in vascular dysfunction and eventually blindness245. The formation of 
new blood vessels in the retina as a result of aberrant angiogenesis is a 
hallmark feature of the advanced stage of the disease, PDR. Retinal ECs are 
one of the primary cells involved in retinal angiogenesis: they line the blood 
vessels and are involved in each of the angiogenic processes; basement 
membrane disruption, migration, proliferation, stabilisation and maturation142. 
We set out to evaluate the angiogenic potential of CFB, by studying its impact 
on retinal EC behaviour using in vitro angiogenesis assays following 
recombinant CFB treatment, CFB over-expression and CFB knockdown. Firstly, 
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we attempted to demonstrate the pro-angiogenic effects of CFB using standard 
cell viability and proliferation assays, on an organ specific EC cell line, HRECs. 
The effect of CFB was assed using rhCFB treatment, CFB over-expression 
(pCFB) or CFB knockdown using siRNA (siCFB). For recombinant protein 
treatment cells were treated with 100µg/mL rhCFB and the effects of rhCFB 
were compared to the PBS control group. CFB has been reported to have an 
approximate plasma concentration of 200 µg/mL207 The pre-determined dose of 
rhCFB at 100 µg/mL was chosen based on this reported concentration. For CFB 
over-expression cells were transfected with 1µg pCFB or 1µg pcDNA control. 
Similarly, for CFB knowckdown cells were transfected with 1µg siCFB or 1µg 
siRNA. The effects of CFB over-expression and CFB knockdown were 
compared the pcDNA and siContol groups, respectively (for confirmation of 
successful knockdown and overexpression please refer to Figure 34 and 
Figure 35 in the supplementary figures for CFB mRNA expression following 
CFB knockdown and over-expression). 
 
HREC viability was evaluated using the colorimetric MTS assay. MTS assay 
indirectly measures the capacity of metabolically active healthy cells to convert 
the tetrazolium reagent into a coloured formazan end-product. The assay is a 
surrogate means to estimate the number of metabolically-viable ECs upon 
rhCFB treatment.  Given the treatment conditions, rhCFB significantly promoted 
the viability of HRECs. Compared with the untreated control, 100 µg/mL rhCFB 
significantly increased the viability of HREC on Day 1(*R<0.05) and Day 2 
(**R<0.0001) (Figure 16). Similarly, pCFB increased HREC viability on Day 
1(ns) and with a significant increase on Day 2 (****R<0.0001), in comparison to 
the pcDNA control group (Figure 17). Compared with siControl, siCFB 
significantly reduced HREC viability on Day 1 (**R<0.01) and Day 2(***R<0.001) 
(Figure 18).  
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Figure 16: rhCFB treatment promotes HREC viability. Primary HRECs were treated with 100 
µg/mL rhCFB or equivalent PBS control and functional change was measured as quantitative 
changes in cell viability on day 1 and day 2. A, HREC growth curve measured by MTS assay. B, 
Cell viability of HRECs on day 2. Results were presented as fold change normalised to PBS 
control. Results represent the mean ± SD. Statistical significance was determined using two-
way ANOVA followed by post-hoc Sidak’s multiple comparisons test; n=3, *: p< 0.05, 
****p<0.0001. 
 
 
 
  
Figure 17: CFB overexpression increases HREC viability. Primary HRECs were transfected 
with 1µg pCFB or 1µg pcDNA control and functional change was measured as quantitative 
changes in cell viability on day 1 and day 2.  A, HREC growth curve measured by MTS assay. 
B, Cell viability of HRECs on day 2. Results were presented as fold change normalised to 
pcDNA control. Results represent the mean ± SD.  Statistical significance was determined using 
two-way ANOVA followed by post-hoc Sidak’s multiple comparisons test; n=3, **: p< 0.0001. 
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Figure 18: 1 CFB silencing reduces HREC viability. Primary HRECs were transfected with 
66nM siCFB or 66nM siRNA control and functional change was measured as quantitative 
changes in cell viability on day 1 and day 2 A, HREC growth curve measured by MTS assay. B, 
Cell viability of HRECs on day 2. Results were presented as fold change normalised to siRNA 
control. Results represent the mean ± SD. Statistical significance was determined using two-
way ANOVA followed by post-hoc Sidak’s multiple comparisons test; n=3, **: p< 0.01, ****: p< 
0.0001 
 
Notably, the overall cell viability is regulated by a balance between the rate of 
cell proliferation and cell death. Hence, to improve our understanding in the 
CFB-regulated cell viability, it’s impact on cell proliferation was examined by 
staining HRECs with an antibody specific to Ki-67, a human nuclear protein that 
is strictly associated with cell proliferation. The total number of cell nuclei and 
the total number of Ki-67+ cell nuclei (please refer to the white arrows on Figure 
19, Figure 20 and Figure 21) were manually counted and the cell proliferation 
rate was calculated as a percentage Ki-67+ cells. Consistent with the 
observation in HREC viability, rhCFB treatment resulted in a significant increase 
in cell proliferation. Compared with the PBS control, treatment with 100 µg/mL 
rhCFB significantly increased the percentage of Ki67+ cells (**R<0.001) 
compared to the PBS control, (Figure 19). Similarly, pCFB significantly 
increased cell proliferation (**R<0.001) in comparison to the pcDNA control, 
(Figure 20). On the other hand, compared with siControl, siCFB significantly 
attenuated cell proliferation, (**R<0.05) (Figure 21).    
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Figure 19: Recombinant CFB treatment promotes HREC proliferation. Primary HRECs 
were treated with 100 µg/mL rhCFB or equivalent PBS control and functional change was 
measured as a change in cellular proliferation after 24h. Changes in cell proliferation was 
demonstrated using Ki-67 proliferation marker (green) localised in the cell nucleus (blue). A-B, 
Representative images of Ki-67 staining. Scale bar: 200 µM. C, Quantification of proliferating 
cells reported as the percentage of Ki-67+ nucleus. Results represent the mean ± SD of three 
experiments per treatment performed in duplicate (the symbols representing the technical 
repeats). Statistical significance was determined by unpaired, two-tailed students’ t-test; n=6, **: 
p< 0.01. 
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Figure 20: CFB overexpression promotes HREC proliferation. Primary HRECs were 
transfected with 1µg pCFB or 1µg pcDNA control and functional change was measured as a 
change in cellular proliferation after 24h. Changes in cell proliferation was demonstrated using 
Ki-67 proliferation marker (green) localised in the cell nucleus (blue). A-B, Representative 
images of Ki-67 staining. Scale bar: 200 µM. C, Quantification of proliferating cells reported as 
the percentage of Ki-67+ nucleus. Results represent the mean ± SD of three experiments per 
treatment performed in duplicate (the symbols representing the technical repeats). Statistical 
significance was determined by unpaired, two-tailed students’ t-test; n=6, **: p< 0.01. 
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Figure 21: CFB knockdown reduces HREC proliferation. Primary HRECs were transfected 
with 66nM siCFB or 66nM siRNA control and the functional change was measured as a change 
in cellular proliferation after 24h. Changes in cell proliferation was demonstrated using Ki-67 
proliferation marker (pink) localised in the cell nucleus (blue). A-B, Representative images of 
Ki-67 staining. Scale bar: 200 µM. C, Quantification of proliferating cells reported as the 
percentage of Ki-67+ nucleus. Results represent the mean ± SD of three experiments per 
treatment performed in duplicate (the symbols representing the technical repeats). Statistical 
significance was determined by unpaired, two-tailed students’ t-test; n=6, *: p< 0.05. 
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As mentioned, angiogenesis is a highly dynamic process. In response to local 
angiogenic cues, ECs degrade the basement membrane and migrate along 
chemical gradients established by angiogenic factors. The transwell migration 
assay, also known as the Boyden chamber assay, was chosen to evaluate 
CFB’s effect on HREC migration. Given the experimental setup (please refer to 
2.38) the directional migration was induced by the FBS gradient, in which cells 
migrated across a 0.8µM porous filter membrane, from the upper well 
(containing 0% FBS) to the bottom side of the well (containing 2% FBS). 
Following a five-hour incubation period the number of transmigrated DAPI+ cell 
nuclei were manually counted. Compared with the untreated control, treatment 
with 100 µg/mL rhCFB significantly increased HREC migration (****R<0.0001) 
(Figure 22). On the other hand, compared with siControl, siCFB significantly 
attenuated HREC migration, (****R<0.0001) (Figure 23).   
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Figure 22: Recombinant CFB treatment promotes HREC transwell migration. Primary 
HRECs were treated with 100 µg/mL rhCFB or equivalent PBS control and the functional 
change was measured as a change in cellular trans-migration after 5 hours. A-B, 
Representative images of migrated HRECs. Scale bar: 200 µM C, Quantification of migrated 
cells reported as the number of migrated DAPI+ cell nuclei. Results represent the mean ± SD of 
three experiments per treatment performed in triplicate (the symbols representing the technical 
repeats). Statistical significance was determined by unpaired, two-tailed students’ t-test; n=9, 
****: p< 0.0001. 
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Figure 23: CFB silencing reduces HREC transwell migration. Primary HRECs were 
transfected with 66nM siCFB or 66nM siRNA control and functional change was measured as 
changes in cellular trans-migration after 5 hours. A-B, Representative images of migrated 
HRECs after transfection with 66nM control siRNA or 66nM CFB siRNA. Scale bar: 200 µM.C, 
Quantification of migrated cells reported as the number of migrated DAPI+ cell nuclei. Results 
represent the mean ± SD of three experiments per treatment performed in triplicate (the 
symbols representing the technical repeats). Statistical significance was determined by 
unpaired, two-tailed students’ t-test; n=9, ****: p< 0.0001 
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The innate ability of ECs to spontaneously assemble into tubular structures is a 
critical step during sprouting angiogenesis. Growth factor-reduced MatrigelÒ is 
a specially formulated ECM that supports cells to form two-dimensional vascular 
networks. HRECs were seeded onto solidified GFR MatrigelÒ for 16 hours to 
form stable tubule-like structures. The extent of network formation was analysed 
using the Angiogenesis Analyzer plugin in Image J to quantify the number of 
junctions and total tubule length. Compared with the untreated control, 100 
µg/mL rhCFB was able to promote HREC network formation, as demonstrated 
by a significant in the number of junctions (****R<0.0001), and total tube length 
(****R<0.0001), respectively (Figure 24). Similarly, pCFB induced HREC 
network formation, with a significant increase in number of junctions 
(****R<0.0001), and total tube length (****R<0.0001), respectively (Figure 25). 
Compared with siControl, siCFB significantly attenuated HREC network 
formation with a reduction in number of junctions and total tube length, 
respectively (Figure 26). 
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Figure 24: Recombinant CFB treatment promotes HREC network formation. Primary 
HRECs were treated with 100 µg/mL rhCFB or equivalent PBS control and the functional 
changes were measured as changes in EC network formation after 16 hours incubation. A-B, 
Representative images of the Matrigel® network formation assay. Scale bar: 200 µM C-D, 
Quantification of HREC Matrigel® network formation reported as the total number of junctions 
and total tubule length. Results represent the mean ± SD of three experiments per treatment 
performed in triplicate (the symbols representing the technical repeats). Statistical significance 
was determined by unpaired, two-tailed students’ t-test; n=9, ****: p< 0.0001. 
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Figure 25: CFB overexpression promotes HREC network formation. Primary HRECs were 
transfected with 1µg pCFB or 1µg pcDNA and the functional changes were measured as 
changes in EC network formation after 16 hours incubation. A-B, Representative images of the 
Matrigel® network formation assay. Scale bar: 200 µM C-D, Quantification of HREC Matrigel® 
network formation reported as the total number of junctions and total tubule length. Results 
represent the mean ± SD of three experiments per treatment performed in triplicate (the 
symbols representing the technical repeats). Statistical significance was determined by 
unpaired, two-tailed students’ t-test; n=9, ****: p< 0.0001. 
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Figure 26: CFB silencing reduces HREC network formation. Primary HRECs were 
transfected with 66nM siCFB or 66nM siRNA control and the functional changes were 
measured as changes in EC network formation after 16 hours incubation. A-B, Representative 
images of the Matrigel® network formation assay. Scale bar: 200 µM C-D, Quantification of 
HREC Matrigel® network formation reported as the total number of junctions and total tubule 
length. Results represent the mean ± SD of three experiments per treatment performed in 
triplicate (the symbols representing the technical repeats). Statistical significance was 
determined by unpaired, two-tailed students’ t-test; n=9, ****: p< 0.0001. 
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Angiogenesis is a complex process involving multiple cell types and 
extracellular components246. Apart from ECs, perivascular cells, non-vascular 
cells, inflammatory cells, and ECM components also actively participate in the 
angiogenic process247,248. Hence, ex vivo angiogenesis assays provide unique 
opportunity to study the interplay of the multiple cell types subjected to the 
same microenvironment. Two different ex vivo angiogenesis assays were used 
to confirm the role of CFB in a more complex experimental setup. Both the fetal 
metatarsal and aortic ring assays were chosen to evaluate microvascular 
outgrowth, a phenomenon that models the physiologically angiogenic process in 
a more accurate way243. Dissected aortic ring explants were embedded in a 
collagen matrix and cultured in aortic ring media containing 100µg/mL rhCFB for 
an extended period of 7 days. Its impact on microvessel outgrowth was 
examined by staining explants with I-B4 Iseolectin, an antibody specific to ECs, 
and quantified by manually counting the number of microvessels that grew from 
each aortic ring explant.  Consistent with previous findings, rhCFB significantly 
promoted the number of microvessel sprouts per explant (****R<0.0001), in 
comparison to the PBS control (Figure 27).  In the fetal metatarsal assay, 
dissected metatarsal bones were embedded onto pre-coated plates and 
cultured in metatarsal growth media containing 100µg/mL rhCFB for an 
extended period of 12 days. Its impact on microvessel outgrowth was examined 
by staining explants with CD-31, an antibody specific to ECs, and quantified 
using Adobe Photoshop CS6 software to calculate the sprouting area per 
explant. As with the aortic ring assay, rhCFB significantly induced the sprouting 
area of the metatarsal explants (****R<0.0001), in comparison to the PBS 
control (Figure 28).  
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Figure 27: Recombinant CFB treatment promotes vessel outgrowth in the aortic ring 
explant assay.  Aortic ring explants were dissected, embedded into collagen and cultured in 
aortic ring media with the addition of 100µg/mL rhCFB for 7 days. The resultant microvessel 
outgrowth was stained with I-B4 Isolectin and quantified manually by counting the number of 
microvessels growing from each explant. A-B, Representative images of aortic ring microvessel 
outgrowth C, Quantification of microvesel outgrowth reported as the number of microvessels per 
explant. Results represent the mean ± SD of 15 explants per treatment. Statistical significance 
was determined by unpaired, two-tailed students’ t-test; n =15 PBS, n = 14, rhCFB ****: p< 
0.0001 
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Figure 28:  Recombinant CFB treatment promotes vessel outgrowth in the aortic ring 
explant assay. Metatarsal explants were dissected and mounted onto culture dishes and 
cultured in metatarsal growth media with the addition of 100µg/mL rhCFB for 12 days. The 
resultant microvessel outgrowth was stained with CD31 and quantified using Adobe Photoshop 
CS6 software. A-B, Representative images of metatarsal sprouting microvessel outgrowth C, 
Quantification of microvesel outgrowth reported as the percentage of sprouting area normalised 
to the metatarsal area. Results represent the mean ± SD of 15 explants per treatment. 
Statistical significance was determined by unpaired, two-tailed students’ t-test; n >14, ****: p< 
0.0001. 
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3.3 Investigating the relationship between Complement 
Factor B and VEGF-A and VEGFR2 
 
In the previous chapter, a pro-angiogenic effect of CFB in both cultured HRECs 
and ex vivo models of angiogenesis was established. To follow on from this we 
sought to find a plausible mechanism that integrated CFB into the angiogenic 
signalling network underlying PDR pathology. Retinal angiogenesis is a highly 
complex biological process that involves a delicate balance between angiogenic 
and anti-angiogenic factors, each regulated by multiple control systems141. 
Among the cytokines involved in pathological angiogenesis in the retina, VEGF 
serves as the most potent angiogenic stimulator141. A link between complement, 
angiogenesis and VEGF has been established in the pathogenesis of tumour 
angiogenesis, where activation of the AP was shown to stimulate cells to 
produce VEGF, which promoted angiogenesis of ECs249. Understandably the 
relevance of this study is questionable since its focus was the role of 
complement in cancer, and the impact of the AP on angiogenesis was 
examined in vitro using bone osteosarcoma epithelial cells. Having said that, 
angiogenesis is a characteristic feature of many pathologies, including both 
tumour growth and diabetic retinopathy, where it aberrantly contributes to 
disease progression. Some of the mechanisms that underlie pathological 
angiogenesis in the retina and tumour angiogenesis are similar, and 
consequently complement involvement in tumour angiogenesis may have 
cross-over with, and provide insights into DR pathogenesis. There are also a 
number of studies that report a link between complement components and 
VEGF in the context of AMD. In these studies, complement components are 
able to induce VEGF expression both in vitro and in vivo. However, it is 
important to note here that the complement components examined in these 
studies are C3a250, C5a250, and MAC251, and they could have different 
mechanisms of action to CFB. One group that focused specifically on CFB, 
used short hairpin RNA (shRNA) to knockdown CFB in rats. They reported a 
significant inhibition of the formation and development of CNV in vivo following 
CFB knockdown which was attributed to a reduction of VEGF expression in the 
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RPE and choroidal tissues252. In a separate study by a different group, CFB was 
knocked down in mice using siRNA. Similarly, they reported significant 
attenuation on the development of laser-induced CNV as well as reduced VEGF 
expression204. Although not directly relevant to this project, these studies bare 
more relevance than the aforementioned cancer study, because, as previously 
mentioned, AMD and DR share the same characteristic feature in that they are 
driven by aberrant angiogenesis, and it is possible that similar mechanisms may 
be involved in the pathophysiology of both AMD and DR. Given that proteins 
and receptors of the VEGF family are important drivers of pathological 
angiogenesis in PDR, the possibility that CFB contributes to dysregulation of the 
VEGF-VEGFR2 signalling cascade was considered. To query whether CFB 
regulates VEGF expression, and gain an understanding of the molecular 
mechanisms regulating the CFB mediated induction of angiogenesis in HRECs, 
RT-qPCR was used to identify the changes in gene transcripts associated with 
the gain-of-function or the loss-of-function of CFB using rhCFB treatment or 
CFB knockdown using siRNA (siCFB). For recombinant protein treatment cells 
were treated with 100µg/mL rhCFB and the effects of rhCFB were compared to 
the PBS control group. For CFB knowckdown cells were transfected with 66nM 
siCFB or 66nM siRNA. The effects of CFB knockdown were compared the 
siContol groups, respectively (for confirmation of successful knockdown please 
refer to Figure 35 in the supplementary figures for CFB mRNA expression 
following CFB knockdown). Compared with the untreated control, 100 µg/mL 
rhCFB significantly increased the gene expression of both VEGF-A (**p< 0.01) 
and VEGFR2 (**p< 0.01). In contrast, siCFB significantly decreased the gene 
expression of both VEGF-A (**p< 0.01) and VEGFR2 (*p< 0.05) compared with 
siControl (Figure 29).  
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Figure 29: Recombinant CFB treatment induces VEGF-A and VEGFR2 mRNA expression. 
Primary HRECs were treated with 100 µg/mL rhCFB and changes in VEGF and VEGFR2 
mRNA levels were analysed after 48 hours incubation. The changes in gene expression were 
calculated using fold change (-2(∆∆cT). A-B, RT-qPCR analysis of VEGF and VEGFR2 
transcript levels represented as fold change normalised to PBS control. Results represent the 
mean ± SD. Statistical significance was determined on raw delta-CT values by unpaired two-
tailed students’ t-test; n=3, **: p< 0.01. 
 
 
 
 
Figure 30: CFB silencing reduces VEGF-A and VEGFR2 mRNA expression. Primary 
HRECs were transfected with 66nM siCFB or 66nM siRNA control and changes in VEGF and 
VEGFR2 mRNA levels were analysed after 48 hours transfection. The changes in gene 
expression were calculated using fold change (-2(∆∆cT). A-B, RT-qPCR analysis of VEGF and 
VEGFR2 transcript levels represented as fold change normalised to siControl. Results 
represent the mean ± SD. Statistical significance was determined on raw delta-CT values by 
unpaired two-tailed students’ t-test; n=3, *: p<0.05, **: p< 0.01. 
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Having observed CFB mediated changes in VEGF-A and VEGFR2 gene 
expression, western blot analysis was used to identify the changes in protein 
expression associated with the loss-of-function of CFB. CFB knockdown was 
first confirmed (*p< 0.05). There were no significant changes in VEGF-A protein 
expression following CFB knockdown. However, in line with the observation of 
VEGFR2 gene expression, a significant decrease of VEGFR2 protein 
expression (*p< 0.05) was observed alongside the downregulation of CFB, 
when compared to siControl (Figure 31). 
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Figure 31: CFB silencing reduces VEGFR2 but not VEGF-A protein expression. Primary 
HRECs were transfected with 66nM siCFB or 66nM siRNA control and changes in VEGF and 
VEGFR2 protein expression were analysed after 48h of transfection. The changes in protein 
expression were detected by western blot. A, Representative western blot of CFB, VEGF, 
VEGFR2. GAPDH was used as a loading control. B-D, Densitometry quantification of western 
blot. CFB, VEGF and VEGFR2 were first normalised to the internal control GAPDH. 
Quantification is represented as fold change normalised to siControl. Data are expressed as 
mean ± SD. Statistical significance was determined by unpaired, two-tailed students’ t-test; n=3, 
*: p< 0.05. 
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Moving on, to further investigate if the CFB-regulated changes in VEGFR2 
protein expression has functional consequence on the angiogenic potential of 
HRECs, the Matrigel® network formation assay was conducted using HRECs 
treated with rhCFB treatment in the absence and presence of a VEGFR2 small 
molecule inhibitor Linifanib. (Please refer to Figure 36 in the supplementary 
figures for Linifanib concentration optimisation). Compared with the PBS 
control, 100 µg/mL rhCFB was able to promote HREC tube formation, indicated 
by a significant increase in number of junctions (****p< 0.0001) and total tube 
length (****p< 0.0001) (Figure 32). The presence of 5nM Linifanib attenuated 
HREC tube formation, observed by a significant decrease in number of 
junctions and total tube length for both the PBS (****p< 0.0001) and rhCFB 
group (****p< 0.0001).  
104 
 
 
 
 
105 
 
 
 
Figure 32: Linifanib attenuates CFB induced HREC network formation. Primary HRECs 
were treated with 100 µg/mL rhCFB or equivalent PBS control with the presence or absence of 
5nM VEGFR2 inhibitor, Linifanib. Functional changes were measured as changes in EC 
network formation after 16 hours incubation A-D, Representative images of Matrigel® network 
formation. E-F, Quantification of HREC Matrigel® network formation reported as the total 
number of junctions and total tubule length. Results represent the mean ± SD of three 
experiments per treatment performed in triplicate (the symbols representing the technical 
repeats). Statistical significance was determined by unpaired, two-tailed students’ t-test; n=9, 
****: p< 0.0001. 
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4 Discussion 
 
The function of the systemic complement system in innate immune defence has 
been extensively characterised; it is well known to perform homeostatic 
functions that include opsonisation for phagocytosis, formation of the terminal 
complex MAC, and recruitment of immune cells. As a crucial mediator of the 
innate immune response, the complement system has for a long time only been 
perceived as a front-line surveillance system in host defence. This still holds 
true; however, it is now becoming clear that the complement system also has 
functions that reach far beyond immune surveillance. The presence of 
complement proteins and a complement regulatory system in the retina is 
widely accepted101, and since the retina is an immune-privileged tissue, its local 
complement system is independent of the systemic complement components 
typically produced by the liver253. DR, characterised by pathological retinal 
angiogenesis is a major cause of irreversible vision loss worldwide and although 
the involvement of the complement components in the progression of DR has 
been recognised101 (please refer to section 1.9.4) there is still a great deal more 
to be uncovered. Previous studies addressing the influence of complement on 
retinal neovascularisation have revealed contradictory results. For instance, a 
pro-angiogenic function of CFB has been implicated in the model of laser-
induced CNV, which represents a model of angiogenesis during the wet form of 
AMD206,207,254. Moreover, CFH and CFB polymorphisms have been associated 
with neovascular AMD198,199,255. In contrast, another study reported that CFB -/- 
mice demonstrated significantly more neovascularisation following OIR 
treatment, and suggested that CFB has a protective role in DR  by aiding in the 
clearance of pathological neo-vessels231. It is clear that the mechanisms 
involved in the crosstalk between CFB and neovascularisation remains 
ambiguous, and as a result the main focus of this study was to investigate the 
involvement of CFB in the neovascular pathology of DR. 
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4.1 Characterising the Expression of Complement Factor B 
Using Rodent Models and Human Patient Samples 
 
Dysregulation of the complement system is now a recognised characteristic of 
patients with DR. However, DR is a multifactorial disease and isolating the 
specific contributions of individual complement proteins to disease pathology is 
not straightforward. One approach, adopted by Williams et al in 2016, to 
studying the role of the complement system in the maintenance of retinal health 
was to characterise the retinal phenotype of mice carrying deletions of specific 
complement genes. After 12 months, they reported that the retinal morphology 
and retinal vasculature did not appear different across the genotypes. Although 
these results suggest that under physiological conditions the retina is stable and 
healthy even with the absence of a functional AP, it doesn’t mean to say that 
these genotypes do not contribute to pathological retinal vascular changes. This 
study was carried out in the absence of a pathological challenge or 
environmental stressor, and therefore provides limited insight into how 
complement contributes to vascular pathology under the disease conditions that 
manifest in DR. This project aimed to address this by using human patient 
samples from diabetic patients with retinopathy, and rodent models that better 
mimic the pathology that manifests in DR.  
 
Most complement proteins and complement regulatory proteins are synthesised 
in the liver by hepatocytes and released into the blood for distribution256, 
therefore to begin with CFB expression was first examined in human patient 
serum samples at different stages of retinopathy. Unsurprisingly, there was no 
difference in human patient serum CFB levels between control and diabetic 
patients at different stages of retinopathy. A major problem associated with 
using serum to detect changes in protein expression is the fact that the 
detection of low abundant proteins is largely hidden by a vast amount of high 
abundant proteins such as albumin and IgGs and therefore it might be difficult 
to detect changes in CFB expression in serum above a high background.  
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The retina is segregated from the circulation by the BRB and is considered to 
be an immune privileged257. However, it is now well established that an 
extrahepatic system of complement biosynthesis exists within the retina to 
compensate for the restricted entry of bloodborne proteins normally excluded by 
the BRB.258  Since the retina is an immune privileged organ and is protected 
from exposure to systemic circulation, human patient serum samples are not a 
true representation of the retinal microenvironment and may not reflect changes 
in ocular CFB expression. As a result local concentrations are likely to be more 
indicative227. In terms of DM-induced microvascular complications, the shift from 
a healthy state to pathology can influence protein constituents and/or protein 
abundance in the ocular fluids. As a result, levels of proteins in the ocular fluids 
can be used to indicate the health status of blood vessels and/or tissue, and 
indirectly explore the pathophysiologic events that take place. The vitreous is 
the largest component structure of the eye. In its normal state, it is a clear 
gelatinous matrix between the lens and retina, that is primarily composed of 
water, collagen, glycosaminoglycans, and proteoglycans259. In addition to 
optical functions, the vitreous also contains a whole host of factors that can 
influence retinal physiology.89 The metabolic and functional  alterations that 
occur in DR can result in molecular changes in the vitreous. In turn, alterations 
of the vitreous exert pathological effects on the diabetic retina, resulting in a 
viscous cycle that contributes to disease progression260.  Consequently, 
vitreous samples obtained from diabetic patients undergoing vitreoretinal 
surgery are currently used to indirectly explore mediators involved in the 
development of DR227. Several proteomic studies have been261 carried out to 
analyse the protein profiles of human vitreous samples from patients with DR. In 
these studies, complement factors including CFB were found to be increased in 
the vitreous of patients with PDR226,261. Protein levels in the vitreous may be a 
better indication of retinal health status than other ocular due to the close 
proximity between the vitreous and retina262. However, surgical harvesting of 
vitreous fluid is associated with a risk of vitreous haemorrhage, retinal tears, 
and retinal detachment, and it is difficult to obtain vitreous samples for 
diagnostic or investigative purpose263. The aqueous humor (AH) is a 
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transparent extracellular fluid that is secreted by the non-pigmented ciliary body 
epithelium of the eye. The AH helps to maintain intraocular pressure and the 
globe shape of the eye, and supplies oxygen and nutrients to the avascular 
cornea and lens. In comparison to vitreous samples, obtaining aqueous 
samples is a far easier and less risky procedure. In the AH of human eyes, a 
number of growth factors have been detected, such as basic fibroblast growth 
factor (bFGF), epidermal growth factor (EGF), TGF-b, insulin-like growth factor 
(IGF)-1, platelet-derived growth factor (PDGF), VEGF, hepatocyte growth factor 
(HGF), and interleukin (IL)-6, the composition of which changes dramatically 
with different conditions264. Previous studies have linked elevated cytokine 
levels in aqueous humor to vitreous fluid levels and to the progression of DR265. 
Consequently, the AH may act as a powerful tool in understanding the 
pathophysiology of DR and serve as biomarkers for predicting the development 
of the disease266. In this regard AH samples obtained from diabetic patients 
undergoing vitreoretinal surgery were used to evaluate ocular CFB levels. CFB 
levels were higher in aqueous samples of diabetic patients with retinopathy. In 
theory, checking CFB expression both systemically in serum and locally in 
aqueous samples allows comparison between the two. This could help 
determine if any changes of CFB levels in the aqueous are a localised effect 
rather than a non-specific, additive effect due to serum diffusion. As no changes 
in CFB expression were detected in the human serum samples, this observed 
up-regulated expression of CFB in the aqueous samples from DR patients may 
be caused by local changes in the eye. However, it is worthy to note that this 
observation was based on 1 aqueous sample from each patient group and 
should be confirmed in a larger cohort of patients. 
 
Enhanced expression of complement components have also been observed in 
the retina of STZ-induced diabetic rats219,267. However, the expression of CFB at 
both RNA and protein levels remain unchanged in the retina of mice suffering 
from STZ-induced diabetes. This is likely due to the mild retinal vascular 
changes in these mice: inducing diabetes in this manner reproduces early 
symptoms of DR, such as loss of retinal pericytes and capillaries, BM thickening 
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and increased vascular permeability, however advanced proliferative changes 
characteristic of PDR do not develop268. The lack of pathological 
neovascularization in STZ mice may explain the flat CFB expression.  
  
The mouse OIR model is a well-established technique used to mimic 
pathological retinal neovascularisation seen in PDR. The OIR model consists of 
2 distinct phases. In the first phase, P7 through P12, mice are placed in a high-
oxygen environment that results in vasoobliteration of the developing 
vasculature. The second phase begins when the mice are returned to 
atmospheric oxygen at P12. The relatively low oxygen concentration causes the 
central avascular zone to become hypoxic, inducing the expression 
proangiogenic mediators such as VEGF. Although these pathways stimulate the 
growth of normal vessels, they also cause the formation of pathological vessels 
which sprout from the superficial retinal vasculature resembling the pathological 
neovascularization seen in humans with DR. In this study, it has been 
demonstrated that CFB mRNA expression correlated with the 
neovascularisation progression in OIR in a similar manner to that reported for 
VEGF269. In P12 mice when the high oxygen exposure supresses vascular 
growth and causes retinal vaso-obliteration, CFB gene expression is lower in 
the OIR retina compared to normal oxygen control. In P17 mice, upon return to 
normoxic conditions when the retina becomes hypoxic and there is aberrant 
angiogenesis, CFB gene expression is significantly increased. The 
correspondence of increased CFB expression to the phase in which 
neovascularisation occurs in the OIR model suggests an association of CFB 
with retinal neo-vessel formation. These results are supported by data from 
Sweigard et al who not only reported an increase in both CFB mRNA and 
protein expression following OIR, but who also demonstrated CFB deposition 
on retinal neo-vessels by immunofluorescence staining231. In addition, these 
results are also in line with a previous study in which authors reported an 
induction of CFB expression in the pathological retinal blood vessels of several 
mouse models that exhibit marked remodelling of the retinal vasculature270. By 
conducting genome-wide transcriptional analysis of retinal microvessel 
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fragments isolated from the retinal degeneration 1 (rd1) mouse very low-density 
lipoprotein receptor (VLDLR) knockout mouse (Vldlr-/-), the Grhl3ct/J curly tail 
mouse and appropriate wild-type controls, they found 62 genes that were 
differentially regulated but common to all three models. When ranked according 
to fold change, CFB was one of most significantly up-regulated genes across all 
three models.  
 
Despite there being no changes in human serum CFB levels or in the retina of 
STZ mice, higher CFB in aqueous samples of diabetic patients with retinopathy, 
alongside the increase of CFB expression in OIR retina, indicates a possible 
role of CFB in driving DR. It suggests that CFB might not only contribute to the 
innate defence mechanism of the AP but might also contribute to DR pathology 
through functional crosstalk with other cellular networks. Whilst this 
characterisation suggests CFB may contribute to DR, the function of this protein 
has yet to be determined.  
 
4.2 The Role of CFB in Regulating Retinal Angiogenesis  
 
Angiogenesis is a highly complex and tightly regulated process that results in 
the establishment of a vasculature that supports vital systems of the body. 
However, when misdirected, angiogenesis manifests in numerous pathologies 
including diabetic microvascular complications. A defining feature of PDR is the 
formation of destructive neovascularisation, and the balance between this new 
vessel formation and regression determines the progression to blindness231. 
Results discussed in the previous section suggest an association of CFB with 
neovascular formation and so to understand the more precise function of CFB, 
several in vitro and ex vivo angiogenesis assays were conducted.  
 
In vitro assays of angiogenesis are an indispensable tool to gain a better 
understanding of this process. They represent a rapid, defined and efficient 
experimental strategy to gain understanding of complex molecular events that 
occur during angiogenesis; they can be used for modelling pathological 
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conditions as well as provide a platform for the investigation of biochemical 
factors that have the potential to be used as therapeutic agents for the 
treatment of angiogenesis related diseases. An ideal assay would allow for the 
assessment of multiple parameters, providing reliable and reproducible results 
that can be related to those found in the clinic271. Currently, there is no ‘gold 
standard’ assay that accurately represents the process in its entirety and so to 
provide a comprehensive overview of the angiogenic process, the effect of CFB 
was evaluated in retinal-specific EC line using a number of in vitro and ex vivo 
assays. Results revealed a promoting effect of CFB on HREC survival, 
proliferation, migration, and the ability to assemble into tubular networks. 
Despite providing important observations regarding EC behaviour, in vitro 
assays are unable to fully recapitulate blood vessel formation in vivo. To 
overcome these limitations and supplement findings from the cell-based 
studies, two ex vivo assays were carried out: the aortic ring and fetal metatarsal 
explant assays. Consistent with observations from the in vitro studies, in both 
ex vivo assays, vessel outgrowth from explanted tissue was significantly 
increased after the addition of exogenous CFB. These assays provided a more 
physiologically relevant platform to study angiogenesis, since explants 
developed lumenised blood vessels with surrounding supporting cells in a 
timescale similar to that observed in vivo46.  
 
Although this data strongly implicates a pro-angiogenic effect of CFB, it is 
contradictory to a previous report by Sweigard et al. Despite reporting an 
increase in CFB gene and protein expression, and co-localisation of CFB on 
retinal neo-vessels following OIR, they found that OIR mice deficient in CFB 
had a significant increase in neovascularisation after exposure to OIR, in 
comparison to their wildtype counterparts231. They concluded that the increase 
in neovascularisation was not a consequence of increased stimulation but 
rather a result of reduced neo-vessel removal, and CFB a protective effect by 
facilitating with neo-vessel clearance. One reason for these conflicting 
observations could be down to the use of either in vitro or in vivo experimental 
settings to investigate the angiogenic potential of CFB. The main findings from 
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this study are based on in vitro experiments where the effect of CFB was 
explored in an isolated, and controlled manner using a single cell type. 
However, it is important to highlight that angiogenesis is a highly context 
dependent process and the response of different cell types to certain 
angiogenic stimuli can be significantly different.  It is possible that in vitro, CFB 
exerts a promoting effect on HRECs, but when translated in vivo, CFB acts on 
other retinal cell types that mediate its anti-angiogenic effects. In the context of 
DR, anti-angiogenesis may be the predominant action of CFB, overriding the 
promoting effect of CFB on HRECs alone. One particular study that supports 
this idea found that the anti-angiogenic effect of complement was in fact not 
mediated by endothelial cells, but rather by macrophages272. In addition, 
Sweigard et al conducted their study using knockout mice that had been 
generated by conventional gene disruption using homologous recombination. 
This means the knockout manifests itself in all cells of the organism. Since the 
retina possesses its own complement regulatory system and it has been 
reported that RPE cells are the major extrahepatical source of CFB in the 
retina, it WOULD be interesting to investigate the effect of inducing the CFB 
gene defect in a tissue specific manner. Tissue specific knockdown of CFB in 
the RPE means the mice would possess a normal complement system in all 
other tissues and so it is possible that the increase in neovasculairsation 
observed in the CFB deficient mice following OIR could be attenuated by 
depleting CFB only within the retina.  
 
In summary, results revealed that CFB can exert pro-angiogenic activity in 
cultured HRECs and in ex vivo models of angiogenesis. This novel function is 
distinct from CFB’s well-established role within the AP and indicates an 
association between systems and pathways that otherwise would be 
considered as unrelated and antithetical.  
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4.3. Investigating the relationship between Complement 
Factor B and VEGF-A and VEGFR2 
 
The previous chapter reported a pro-angiogenic effect of CFB in both cultured 
HRECs and in ex vivo models of angiogenesis, however the mechanisms 
underlying the regulation of angiogenesis by CFB remain to be elucidated. This 
leaves an important question unanswered: how does CFB exert this pro-
angiogenic function?  
 
The VEGF signalling pathway is one of the most potent angiogenic mediators 
and VEGF is well established as the main agent responsible for vascular 
leakage and angiogenesis in the diabetic retina273. Some VEGF makes its way 
to the retina from systemic sources and some is produced locally in the eye273: 
ECs, pericytes, Muller cells, microglia, astrocytes, RPE cells, and neurons have 
all been known to produce VEGF in retinal disease274. Additionally, VEGF has a 
well-established role in promoting neovascularisation in the OIR model275 and 
as demonstrated by this study, CFB mRNA expression correlated with the 
neovascularisation progression in a similar manner to that reported for VEGF269. 
Therefore, a plausible explanation for the pro-angiogenic effect of CFB could be 
because of increased VEGF signalling. Since increased VEGF signalling could 
not only be a consequence of increased ligand expression, but also due to 
increased receptor expression, the mRNA and protein expression of both 
VEGF-A and VEGFR2 by cultured HRECs was examined. The ability of 
exogenous CFB to increase VEGF-A and VEGFR2 mRNA expression in 
HRECs suggests that CFB is able to mediate both VEGF-A and VEGFR2 at the 
transcript level. The promoting effect of CFB observed in the in vitro 
angiogenesis assays may be driven by the increased mRNA expression of the 
VEGF signalling pathway components. This effect was confirmed by CFB 
silencing, where the opposite trend was observed and VEGF-A and VEGFR2 
mRNA expression was attenuated. The decrease in angiogenic potential of 
HRECs observed in the in vitro assays after CFB silencing, could be a result of 
reduced expression of VEGF-A and VEGFR2 mRNA. Looking at changes in 
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mRNA expression helps gives an indication of functional protein changes, 
however this is not necessarily always the case. So, to confirm this observation, 
the effect of CFB on VEGF-A and VEGFR2 protein expression in HRECs was 
also investigated. Despite the significant suppression of both VEGF-A and 
VEGFR2 at the mRNA level, VEGFR2 protein level but not VEGF-A was 
significantly reduced in HRECs subject to treatment with CFB siRNA. This could 
be due to different rates of translation of VEGF-A and VEGFR2, meaning the 
duration of the experiment was long enough to capture changes in receptor but 
not ligand expression.  Nevertheless, there is a significant suppression of 
VEGFR2 protein expression following siRNA treatment. These results are in 
fact supported by a recent study that investigated the role of CFB in CNV. By 
using short hairpin RNA (shRNA) to knockdown CFB, they observed a 
significant inhibition in the formation and development of CNV by reducing the 
expression of VEGF252. Another study, although not looking specifically at CFB, 
also showed that VEGF expression was reduced following specific inhibition of 
the alternative pathway276. In spite of the fact that these results implicate a link 
between CFB and VEGF, they are in conflict with a previous report by Sweigard 
et al. After observing reduced neovascularisation in CFB deficient mice exposed 
to OIR they wanted to determine if this increase was a result of VEGF 
expression, and so they proceeded to check the mRNA expression of three 
different VEGF isoforms (including VEGF-A), and VEGFR2 in wildtype and 
CFB-/- mice following exposure to OIR. Surprisingly, they reported no 
differences in the expression levels of either VEGF or VEGFR2. These 
conflicting results could again be attributed to the use of either in vitro or in vivo 
experimental settings to investigate the possible mechanism of CFB. In this 
study the effect of CFB on VEGF expression was analysed in vitro using only a 
single cell type. It is possible that in a controlled, well-defined in vitro 
microenvironment comprising of only a single cell type, CFB promotes VEGF 
expression in HRECs. However, the in vivo microenvironment is complex and is 
comprised of a multitude of cell types. Since VEGF expression was conducted 
on whole retinal tissue (not isolated cell types) it is not possible to rule out the 
possibility that the unchanged VEGF expression reported by Sweigard et al may 
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be because CFB has opposing effects on VEGF expression in other cell types 
which negate the changes in VEGF expression in HRECs alone.  
 
To confirm whether the CFB mediated change in VEGFR2 protein expression 
confers functional changes in VEGF signalling, the effect of exogenous CFB on 
HRECs following inhibition of the VEGF signalling cascade using the small 
molecule tyrosine kinase inhibitor for VEGFR2, Linifanib, was explored using 
the in vitro Matrigel® network formation assay.  Blocking of VEGFR2 with 
Linifanib, attenuated the promoting effect of rhCFB on HREC Matrigel® network 
formation. This suggests that the pro-angiogenic effect of CFB is likely to be 
dependent on the activation of VEGF signalling and that CFB mediates its pro-
angiogenic effect through VEGFR2 signalling.  
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5 Conclusion and Future Work 
 
The complement system, a central constituent of innate immunity, has primarily 
been considered as a rapid and efficient immune surveillance system, however, 
genetic studies, clinical observations, and insights from improved disease 
models have renewed the views of human complement system in disease277,278. 
It is important to appreciate that biological systems are not rigid entities but are 
highly dynamic and interactive networks that influence physiological responses. 
This study aimed to take a more global appreciation of what would traditionally 
be viewed as isolated biological processes, and presented findings that indicate 
a possible cross-talk between the AP component, CFB, and retinal 
angiogenesis associated with DR.  
 
The first aim of this study was to characterise the expression level of CFB in 
rodent models of PDR and human PDR patient samples. Although initial 
characterisation pointed towards an increase in local CFB levels with 
retinopathy, caution must be observed when drawing conclusions from this 
data. Although there was an upregulation of CFB in the aqueous humor of 
patients with retinopathy, this observation was only confirmed in one patient 
sample per group. To obtain a more reliable protein profile, CFB expression 
should be confirmed in more patient samples and in human vitreous samples. 
While the STZ-induced diabetic mice are routinely used as a model for 
mechanistic studies of other diabetic complications, they only develop the early 
vascular changes associated with retinopathy and do not develop the late-stage 
proliferative vascular pathology that is routinely seen in PDR.279. Although 
relevant to diabetes, the STZ-induced diabetic mouse is not the most relevant 
model to study PDR pathology and future in vivo characterisation should be 
carried out using the OIR model. A more detailed characterisation of CFB 
expression is needed to help determine whether it also has a role in retinal 
vascular development. Future studies should compare the retinal vasculature of 
CFB knockout (CFB-/-) with wild-type (WT) mice at different postnatal stages to 
explore whether expression correlates with physiological vascular development, 
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and to determine whether CFB-/- mice have defective retinal vascular 
development. The effect of CFB -/- on pathological neovascularisation has 
already been reported231, but to confirm these observations and follow on from 
this it would be interesting to observe the effect of OIR on neovascularisation 
using mice over-expressing CFB: is neovascularisation strengthened or 
attenuated? Additional characterisation should be carried by immunofluorescent 
staining of mice retinal cross-sections to confirm which cell types are the main 
source of CFB.  
 
The second aim of this study was to investigate the role of CFB in retinal 
vascular endothelial cell behaviour and angiogenesis. In vitro cell based assays 
demonstrated a promoting effect of CFB on HREC behaviour and angiogenic 
potential, suggesting that CFB has a role in driving retinal neovascularisation by 
promoting angiogenesis. However, a significant challenge in the study of 
angiogenesis is selection of the appropriate assay that accurately reflects the 
complexity of the processes that occur in vivo. Using multiple in vitro assays in 
this study helped provide a more comprehensive overview of CFBs function in 
angiogenesis, however they were only carried out using one cell type. 
Angiogenesis is mediated by multiple cell types and besides ECs, pericytes are 
also crucial for angiogenesis. Therefore, future studies should look at the effect 
of CFB on retinal pericytes, both alone and in co-culture with ECs. In addition, 
to better capitulate the diabetic pathology, it would also be insightful to study 
CFB under high glucose conditions. Continuous hyperglycaemia in long-
standing DM majorly perturbs vascular homeostasis and leads to endothelial 
dysfunction, mainly attributable to increased accumulation of oxidative stress 
and advanced glycation end-products (AGEs)6,9. It would therefore be beneficial 
to establish in vitro models of angiogenesis using high glucose or glycated 
collagen. Although the aortic ring and fetal metatarsal assays provide a more 
physiologically relevant platform to study angiogenesis it might not be an 
accurate representation of the process within the eye. Other ex vivo assays 
should be carried out to supplement the aortic ring data including the more 
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pertinent choroid assay. The choroid assay would provide information regarding 
ocular specific microvascular behaviour.  
 
The final aim of this study to elucidate the mechanism through which CFB 
contributes to vascular pathology in DR. Although the data obtained in this 
study gives an indication to a possible mechanism through which CFB may 
exert its pro-angiogenic effect, future work should confirm the results of the 
VEGF and VEGFR2 gene and protein studies, using both rhCFB treatment and 
CFB over-expressing cells. Additionally, it would be interesting to see if the 
promoting effect of CFB is attenuated upon VEGFR2 inhibition in other 
functionality assays such as viability, proliferation and Transwell migration. The 
effect of CFB in the absence and presence of Linifanib, on signalling pathways 
downstream of VEGF/VEGFR2 would also help to supplement this data. 
 
Thus far, these preliminary studies have shown that CFB mediates VEGF gene 
expression, and VEGFR2 gene and protein expression. These studies have 
also demonstrated that the pro-angiogenic function of CFB is upstream of, and 
acts at least partially through the VEGF signalling pathway: the blocking of 
VEGFR2 causes the promoting effect of CFB to be lost. This now raises the 
question, ‘how does CFB induce these changes and regulate VEGF signalling? 
One explanation could be the crosstalk between the complement pathway and 
VEGF. Increased deposition of MAC254, the end-product of complement 
activation has been reported in other ocular neovascular disorders. It has also 
been implicated in the expression of angiogenic growth factors280 including 
VEGF281,282. It is therefore plausible that increased levels of CFB cause over-
activation of the AP, leading to increased formation of MAC. MAC mediated 
VEGF expression could be a pathogenic mechanism through which CFB 
promotes angiogenesis. To investigate this further, the relationship between 
CFB expression and MAC formation should be explored both in vivo using CFB-
/- mice, and in vitro using HRECs. Following this, the effect of MAC inhibition on 
the VEGF signalling pathway and angiogenesis should be explored.  
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The effect of CFB on the VEGF signalling system could also be controlled via 
other mechanisms. Perhaps CFB controls VEGF signalling at the gene 
expression level by activating transcription factors that are involved in the 
regulation of VEGF/VEGFR2 gene transcription. Perhaps CFB is involved in 
regulating VEGF/VEGFR2 protein stability and proteolytic processing, or ligand 
receptor interactions, or receptor endocytosis and trafficking. It is important not 
to over interpret this data and until further work is carried out, we can only 
speculate. A more extensive investigation should be carried out before a 
complete mechanistic framework can emerge. Microarray and proteomics 
studies could help identify genes or proteins that are differentially regulated by 
CFB. Any that are up- or downregulated could then be investigated further to 
see if they are involved in the mediating the relationship between CFB and 
VEGF/VEGFR2.  
 
In conclusion, this study presents a more precise role of CFB in driving retinal 
neovascularisation, providing a framework for a more in-depth exploration of 
CFB-mediated effects on retinal angiogenesis in the future. Given the conflicting 
nature of the results obtained in this study, a more in-depth exploration of CFB’s 
role in driving retinal neovascularisation associated with PDR is needed, 
particularly in regards to mechanism of action studies. However, data taken 
together and examined in the light of other relevant studies and existing 
literature has led to a tentative proposed mechanism of action (please refer to 
Figure 33 for the proposed mechanism of action). 
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Figure 33: A schematic representation of the proposed mechanism of action of CFB in 
retinal neovascularisation in DR. The inflammatory microenvironment in DR induces RPE 
cells to secrete CFB, which acts in a paracrine manner on retinal ECs, inducing the VEGF 
signalling cascade, resulting in enhanced EC survival, proliferation, migration, and network-
formation
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7 Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Transient transfection of HRECs using siRNA results in a downregulation of 
CFB mRNA expression. Primary HRECs were transfected with 66nM siCFB or 66nM siRNA 
control and changes in CFB mRNA levels were analysed at 24, 48 and 72 hours of transfection. 
The changes in gene expression were calculated using fold change (-2(∆∆cT).  RT-qPCR 
analysis of CFB transcript levels is represented by fold change normalised to siControl. Results 
represent the mean ± SD. Statistical significance was determined on raw delta-CT values by 
unpaired two-tailed students’ t-test; n=3, *: p<0.05, **: p< 0.01. 
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Figure 35: Transient transfection of HRECs results in an up-regulation of CFB mRNA 
expression. Primary HRECs were transfected with 1µg pCFB or 1µg pcDNA control and 
changes in CFB mRNA levels were analysed at 24, 48 and 72 hours of transfection. The 
changes in gene expression were calculated using fold change (-2(∆∆cT).  RT-qPCR analysis of 
CFB transcript levels is represented by fold change normalised to pcDNA. Results represent the 
mean ± SD. Statistical significance was determined on raw delta-CT values by unpaired two-
tailed students’ t-test; n=3, ****: p< 0.01. 
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Figure 36: Linifanib treatment reduces HREC network formation in a dose dependent 
manner. Primary HRECs were treated with 1nM, 5nM and 10nM of the VEGFR2 inhibitor, 
Linifanib. Functional changes were measured as changes in EC network formation after 16 
hours incubation A-D, Representative images of Matrigel® network formation. E-F, 
Quantification of HREC Matrigel® network formation reported as the total number of junctions 
and total tubule length. Results represent the mean ± SD of one experiment per treatment 
performed in triplicate (the symbols representing the technical repeats). No statistical 
significance was determined for this data since only one biological repeat was carried out for 
optimisation purposes.    
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8 Appendix 
8.1 General Laboratory Equipment and Consumables  
 
Table 3: List of general laboratory equipment used 
Equipment Model Supplier 
Biological Safety 
Cabinet 1300 Series Class II, Type B2 
Thermo Scientific, USA 
Cell Counter 
BRAND® Counting Chamber 
BLAUBRAND® Neubauer 
Improved 
Merck, Singapore 
Centrifuges 
Sorvall™ ST 40R Thermo Scientific, USA 
Sorvall™ Legend™ Micro 21R Thermo Scientific, USA 
IKA Mini G IKA® Works Asia, Malaysia 
Fridge/Freezers 
-80°C Panasonic MDF-U55V SciMed Asia, Singapore 
-20°C PHCbi MDF-MU539D SciMed Asia, Singapore 
+4°C Thermo Scientific, USA 
Gel Electrophoresis 
Mini Protean® Tetra System 
(Acrylamide Gels) Bio-Rad, USA 
Sub® Cell GT (Agarose Gels) Bio-Rad, USA 
Glucoemter Accu-Chek Performa Roche, Switzerland 
Heating Block MS Major Scienc EL-02 Dual Block Heater 
BioLab, Singapore 
CR Cycler C1000 Touch™ Thermal Cycler Bio-Rad, USA 
Gilson Pipettes 2 µl, 10 µl, 20 µl, 100 µl, 200 
µl, 1000 µl Bio-Rad, USA 
Plate Reader Synergy H1 Hybrid Multi Mode Reader BioTek, Singapore 
Power Supply PowerPac™ Basic Power Supply Bio-Rad, USA 
Rocker Stuart™ SSL4 See-Saw Rocker 
Thermo Scientific, USA 
Serological Pipette BRAND® accu-jet® pro pipette controller Merck, Singapore 
Spectrophotometer NanoDrop™ 2000c Thermo Scientific, USA 
VORTEX VX200 Vortex Mixer BioLab, Singapore 
Water Bath Grant T100-ST38 Heated Circulating Bath 
Insta Bioanalytik, 
Singapore 
Real Time PCR 
System 
Applied Biosystems 
StepOnePlus™ Real Time 
PCR System 
Life Technologies, USA 
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Table 4: List of general laboratory consumables used 
Consumable Supplier 
0.2 mL PCR Strip Tubes Axygen 
8µM Trasnwell® 24-Well Plate Insert Corning, USA 
Amicon® Pro Affinity Column Merck, Singapore 
Cell Scraper SPL Lifesciences  
Cryotubes (1mL) Thermo Scientific, USA 
Dissection Kit Thermo Scientific, USA 
Eppendorf Tubes (1.5mL) Axygen 
Film Carestream 
Filter Pipette Tips Neptune 
Microtitre plates (96-well, 24-well, 12-well, 6-well) Thermo Scientific, USA 
BD Precision Glide Needles (18, 23 and 26G) Sigma Aldrich, USA 
Nitrocellulose Membrane Merck, Singapore 
NUNC Petri Dishes Thermo Scientific, USA 
Pipette Tips Neptune 
Polyvinylidene Fluoride (PVDF) Membrane Merck, Singapore 
Scientific Slide-A-Lyzer MINI Dialysis Device Thermo Scientific, USA 
Serological Pipettes (5mL, 10mL, 25 mL, 50mL) SPL Lifesciences 
Sterile Filters (0.22µM) Merck, Singapore 
Syringes Thermo Scientific, USA 
NUNC Tissue Culture Vessels (25 cm2, 75 cm2) Thermo Scientific, USA 
Universal Tubes (15mL, 50mL) Thermo Scientific, USA 
 
 
Table 5: List of general laboratory chemicals used 
Chemical Supplier 
2-mercaptoethanol Sigma Aldrich, USA 
Acrylamide Invitrogen, Singapore 
Agar Powder 1st Base, Singapore 
Agarose 1st Base, Singapore 
Ammonium Persulfate Invitrogen, Singapore 
Bovine Serum Albumin Sigma Aldrich, USA 
Bradford Reagent Bio-Rad, USA 
Bromophenol Blue Bio-Rad, USA 
Cell Freezing Medium Lonza, USA 
Chloramphenicol Sigma, USA 
Citrate Acid Sigma Aldrich, USA 
Comassie Blue Bio-Rad, USA 
Corning® Matrigel® Matrix Corning, Singapore 
DMSO Sigma, USA 
EDTA (ethylenediaminetetraacetic) Sigma, USA 
Endothelial Basal Media (EBM-2™) Lonza, USA 
Endothelial Growth Supplement Mix Lonza, USA 
Ethanol Chemtech 
Foetal Bovine Serum Gibco, USA 
Freestyle Expression Medium (FEM) Gibco, USA 
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GelPilot® DNA Loading Dye Qiagen, Singapore 
GelRed® Nucleic Acid Gel Stain Thermo Scientific, USA 
GeneRuler 1 kb DNA Ladder Invitrogen, Singapore 
Glycerol Promega 
Glycine 1st Base, Singapore 
Imidazole Sigma, USA 
InstantBlue™ Protein Stain Merck, Singapore 
Lipofectamine 2000 Invitrogen, Singapore 
Lipofectamine 3000 Invitrogen, Singapore 
Luria-Bertani (LB) Media 1st Base, Singapore 
MEM Alpha + GlutaMAXTM-1 GE Healthcare, UK 
Methanol Merck, Singapore 
Milk Powder Anlene 
Mowiol Mounting Medium Merck, Singapore 
MTS Sigma, USA 
Na2HPO4 (dibasic) Sigma, USA 
NaH2PO4 (monobasic) Sigma, USA 
Ni Sepharose High Performance Nickel-Charged 
(IMAC) Resin 
GE Healthcare, Singapore 
NP-40 Sigma Aldrich, USA  
Opti-MEM® Gibco, USA 
p3000 Invitrogen, Singapore 
Paraformaldehyde Sigma Aldrich, USA 
PBS 1st Base, Singapore 
Penicillin Streptomycin Nacalai Tesque, Japan 
Phenyl-methlysulfonyl fluoride Thermo Scientific, USA 
Phosphatase Inhibitor Nacalai Tesque, Japan 
Phosphate Buffered Saline 1st Base, Singapore 
Protease Inhibitor Nacalai Tesque, Japan 
Quick Coating Solution Angio-Proteomie, USA 
RNAse free dH2O Invitrogen, Singapore 
RNAzol®RT Molecular Research Centre, 
Inc 
Sodium Chloride (NaCl) Sigma Aldrich, USA 
Sodium Citrate Sigma Aldrich, USA 
Sodium Dodecyl Sulphate (SDS) 1st Base, Singapore 
Sodium Phosphate (Na2HPO4) Sigma Aldrich, USA 
Streptozocin Powder Sigma Aldrich, USA 
Stripping Buffer Nacalai Tesque, Japan 
SuperSignal ™ West Pico PLUS Substrate Thermo Scientific, USA 
TEMED Invitrogen, Singapore 
Tris Base 1st Base, Singapore 
Trypan Blue Gibco, USA 
Tween-20 Promega, Singapore  
Type I collagen Invitrogen, Singapore 
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8.2  Buffers 
8.2.1 General Laboratory Buffers 
Table 6: List of general buffers and solutions used 
Name Components 
Blocking Buffer - IF (1%) 
0.5% BSA 
1% Tween-20 
3% TritonX-100 
DDH2O 
Blocking Buffer – WB (5%) 2.5 g Milk Powder 50 mL TBST 
Cell Lysis Buffer (pH 8) 
20mM Tris – Base 
420 mM NaCl 
0.1 mM EDTA 
10% Glycerol 
0.5% NP-40 
DDH2O 
Inhibitor Cocktail 
(*Freshly added into RIPA buffer just 
before use) 
*1 X Protease Inhibitor 
*1 X Phosphatase Inhibitor 
*0.2M Dithiothreitol (DTT) 
0.1M Phenyl-methlysulfonyl fluoride 
(PMSF) 
Laemmli Buffer (pH 6.8) (4X) 
8% Sodium Dodecyl Sulphate (SDS) 
20% 2-merceptoethanol 
40% Glycerol 
0.008% Bromophenol Blue 
0.250 M Tris Base 
PBS (1X) Dilute 10X PBS to 1X DDH2O 
RIPA Buffer (pH 8) 
20mM Tris Base 
420 mM NaCl 
0.1 mM EDTA 
10% Gylcerol 
0.5% NP-40 
Running Buffer (1X) 
25 mM Tris Base 
190 mM Glycine 
0.1% SDS 
Transfer Buffer (1X) 
25 mM Tris Base 
190 mM Glycine 
20% Methanol 
Tris Base Buffered Saline with Tween 
(TBST) (1X) 
12.5 mM Tris Base 
137 mM NaCl* 
0.01% Tween-20 
Trypsin EDTA (3X) 0.005% Trypsin 0.35 mm EDTA 
Sodium Citrate Buffer (0.1M) 0.1 M Sodium Citrate 0.1 M Citrate Acid 
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8.2.2 Recombinant CFB Protein Purification Buffers 
Table 7: Sodium phosphate buffer components 
Buffer 
Component 
Molar Mass 
(g/mol) 
Molarity Amount Needed 
for 50 mL (g) 
NaH2PO4 
(monobasic) 
137.99 1 6.9 
Na2HPO4 (dibasic) 177.99 1 8.9 
 
Table 8: Stock buffers for binding and elution buffers 
Buffer Composition 
Stock Buffer 1 (500 mL) 
20 mM sodium phosphate 
300 mM NaCl 
100 mL 0.1M sodium phosphate buffer 
37.5 mL 4M NaCl 
Stock Buffer 2 (500 mL) 
20 mM sodium phosphate 
300 mM NaCl 
500 mM imidazole 
100 mL 0.1M sodium phosphate buffer 
37.5 mL 4M NaCl 
17.02 g imidazole 
Elution Buffer (50 mL) 
20 mM sodium phosphate 
300 mM NaCl 
20 mM imidazole 
48 mL Stock Buffer 1 
2 mL Stock Buffer 2 
Binding Buffer (500 mL) 
20 mM sodium phosphate 
300 mM NaCl 
100 mM imidazole 
40 mL Stock Buffer 1 
10 L Stock Buffer 2 
 
 
8.2.3 Commercially Available Enzymes and Buffers 
Table 9: List of enzymes and commercially available buffers/kits used 
Enzyme/Kit Supplier 
10 mM dNTPs New England Biolabs, USA 
5X Q5 GC Enhancer New England Biolabs, USA 
5X Q5 Reaction Buffer New England Biolabs, USA 
5X qScript® cDNA Supermix Kit New England Biolabs, USA 
AflII Restriction Endonuclease New England Biolabs, USA 
FastDigest Buffer Thermo Scientific, USA 
Q5 DNA Polymerase Qiagen, Singapore 
Q5® High-Fidelity DNA Polymerase New England Biolabs, USA 
QIAprep Spin Miniprep Kit Qiagen, Singapore 
QIAquick Gel Extraction Kit Qiagen, Singapore 
QIAquick PCR Purification Kit Qiagen, Singapore 
Quick Ligation™ Kit New England Biolabs, USA 
SYBR® Green Supermix Bio-Rad, Singapore 
XbaL Restriction Endonuclease New England Biolabs, USA 
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8.3 Primary and Secondary Antibodies 
Table 10: List of primary antibodies. IF - immunoflourescence WB- Western Blot 
Antibody Target Application/Dilutio
n 
Supplier 
Ki67 Proliferating Cells IF 1:500 Abcam, UK 
CD31 Endothelial Cells IF 1:500 Abcam, UK 
Isolectin B4 
(conjugated) 
Endothelial 
Cells IF 1:500 
Vector Laboratories, 
Canada 
CFB - WB 1:1000 Abcam, USA 
VEGF - WB 1:1000 Abcam, USA 
Phospho-
VEGFR2 - WB 1:1000 
Cell Signalling 
Technology, USA 
VEGFR2 - WB 1:1000 Cell Signalling Technology, USA 
GAPDH - WB 1:50,000 Santa Cruz Biotechnology, USA 
 
 
Table 11: List of secondary antibodies. IF - immunofluorescence; WB - Western Blot 
Antibody Supplier Application/Dilution) 
Anti-rabbit HRP conjugated Bethyl Laboratories, USA WB/ 1:5000 
AlexaFluor® 594 anti-rabbit Invitrogen, Singapore IF/ 1:200 
AlexaFluor® 488 anti-rat Invitrogen, Singapore IF/ 1:200 
 
 
8.4 Culture Media 
Table 12: Summary of the composition of HREC EGM-2 media 
Component Volume 
FBS 10 mL 
Hydrocortisone 0.2 mL 
hFGF-β 2 mL 
VEGF 0.5 mL 
Ascorbic Acid 0.5 mL 
R3-IGF-1 0.5 mL 
hEGF 0.5 mL 
GA-1000 0.5 mL 
Heparin 0.5 mL 
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Table 13: Summary of the composition of ex vivo assay media  
Name Component 
Aortic Ring Media  
Metatarsal Dissection Media 
10% FBS 
1% Penecillin/Streptomycin 
1X PBS 
Metatarsal Growth MEdia 
10% FBS 
1% Penicillin Streptomycin 
MEM Alpha + GlutaMAXTM-1 
 
 
8.5 Molecular Biology Techniques 
8.5.1 Ligation 
Table 14: Summary of the Quick Ligation reaction components 
Component 20 µL Reaction 
Quick Ligase Reaction Buffer (2X) 10 µL 
Vector DNA (pcDNA) (4.5 kb) 50 ng 
Insert DNA (pCFB) (2.5 kb) 83.3 ng 
Nuclease-free Water Up tp 20 µL 
Quick Ligase 1 µL 
 
 
8.5.2 Polymerase Chain Reaction 
Table 15: Summary of the PCR mastermix components 
PCR Mastermix 
Component 50 µL Reaction Final Concentration 
5X Q5 Reaction Buffer 10 µL 1X 
Q5 DNA Polymerase 0.5 µL 0.02 U/ µL 
5X Q5 GC Enhancer 10 µL 1X 
10 mM dNTPs 1 µL 200 µM 
10 µM Forward Primer 2.5 µL 0.5 µM 
10 µM Reverse Primer 2.5 µL 0.5 µM 
Template DNA Variable < 1000 ng (Tm – 1-2)°C 
Nuclease Free H2O Top up to 50 µL  
 
 
Table 16: Thermocycling conditions for PCR amplification 
Cycling Condition Temperature Time 
Initial Denaturation 98°C 30 seconds 
25-35 cycles 98°C (Tm – 1-2)°C 
5-10 seconds 
10-30 
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72°C 20-30 seconds/kb 
Final Extension 72°C 2 minutes 
Hold 4°C Infinite 
 
 
8.5.3 First Strand cDNA Synthesis 
Table 17: Components of qScript® cDNA Supermix reaction 
Component Volume 
5X Reaction Mix 4 µl 
Template RNA 1 µg 
Nuclease Free dH2O Up to 20 µl 
 
 
8.5.4 SYBR® Green Real-Time PCR 
Table 18: Mouse primer sequences for RT-qPCR 
Gene  Forward Primer Sequence Reverse Primer Sequence 
Β- Actin GGCACCACACCTTCTACAATG GGGGTGTTGAAGGTCTCAAAC 
CFB GCTTGCCATGGTTGCTTATG AAGGCAGGAGAGAAGCTGG 
 
 
Table 19: Human primer sequences for RT-qPCR 
Gene  Forward Primer Sequence Reverse Primer Sequence 
Β- Actin TGAGAGGGAAATCGTGCGTG TGCTTGCTGATCCACATCTGC 
CFB GGAAGGGAATGTGACCAG AAGGCAGGAGAGAAGCTGG 
VEGF CTACCTCCACCATGCCAAGT GCAGTAGCTGCGCTGATAGA 
VEGFR2 CCAGCAAAAGCAGGGAGTCTGT TGTCTGTGTCATCGGAGTGATATCC 
 
 
Table 20: SYBR® Green reaction volume composition 
 
 
 
 
Component Volume (µl) 
Water 7.2 
SYBR® Green Supermix 10 
Forward Primer 0.9 
Reverse Primer 0.9 
cDNA 1 
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Table 21: RT-qPCR Cycling conditions 
 
 
8.5.5 Sodium Dodecyl Sulphate Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
Tabe 22: Composition of SDS-PAGE gels 
 
Cycle Step Temperature (°C) Time Cycles 
Step 1 95 10 min 1 
Step 2 95 60 
15 s 
1 min 40 
Step 3 
95 
60 
95 
15 s 
15 s 
15 s 
1 
Resolving Gel 10% (5 mL) Stacking Gel (1.5 mL) 
Nuclease Free Water 1.9 mL Nuclease Free Water 680 µL 
30% Acrylamide Mix 1.7 mL 30% Acrylamide Mix 170 µL 
Tris-cl (1.5 M pH 8.8) 1.3 mL Tris-cl (1.5 M pH 8.8) 130 µL 
10% Ammonium Persulfate 50 µL 10% Ammonium Persulfate 10 µL 
TEMED 2 µL TEMED 1 µL 
SDS 10% 50 µL SDS 10% 10 µL 
